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Dengue, the most rapidly spreading mosquito-borne viral infection, is prevalent in 
tropical and subtropical regions of the world and results in diverse clinical outcomes. It 
causes a significant disease burden globally as there is currently neither vaccine nor 
antiviral therapy. Treatment is largely supportive. In order to provide prompt treatment 
management, accurate early prognosis of dengue patients according to risk profiles and 
disease phase is critical. This would also enable more cost-effective resource 
management and future pharmaceutical interventions. Currently, the capability to 
identify adult dengue patients who are at higher risk of progressing into severe disease 
is still lacking, especially during early infection of less than 72-hour post fever. Even 
though the World Health Organization (WHO) have recently recommended using 
clinical warning signs during triage as guidance for strict observation and potential 
clinical interventions in hospital, many challenges remain in the clinical setting. 
 
In the development of early prognostic tools, this thesis explored risk factors from 
three different perspectives of dengue; the genetic, molecular and the clinical profiles. 
In Chapter 3, genetics risk variants of MICB and PLCE1 genes were observed to affect 
the baseline risk of an individual towards developing dengue shock syndrome (DSS). 
The top common variant of MICB gene [rs3132468: meta-odds ratio (OR) =1.34; p-
value=4.41x10-11] was observed to be positively associated with DSS, while the top 
common variant of PLCE1 gene (rs3765524; meta-OR=0.80; p-value=3.08x10-10) was 
likely to have a protective effect against DSS. In Chapter 4, dengue patients with 
diabetes and hypertension were observed to be twice more likely to develop dengue 
haemorrhagic fever (DHF) [adjusted odd ratios (AOR) =2.16; 95% confidence interval 
(CI) =1.18-3.96] as compared to patients without these pre-existing comorbidities. In 
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Chapter 5, RNA biomarkers CCL8, VPS13C with protein biomarkers uPAR or 
platelets count were proposed and independently validated as biomarkers for early 
stratification of patients who are at risk of progressing into severe disease, with 
sensitivity and specificity up to 96% and 54.6% respectively. In Chapter 6, neutrophil 
proportion, alanine aminotransferase and serum urea were proposed as a risk model for 
ICU triage at first presentation with sensitivity and specificity of about 88%. In 
addition, monocyte and lymphocyte proportions, blood pressure, and pulse rate were 
proposed as a risk model for ICU triage 24 hours prior to ICU admission with 
sensitivity and specificity of 88.9% and 78%, respectively. 
 
The application of these early risk models will be beneficial in guiding dengue 
prevention policies, early dengue diagnosis and prognosis in the primary healthcare 
setting, as well as guiding early clinical and therapeutic management in tertiary 
healthcare setting, with the overall objective to reduce disease burden and cost in 












LIST OF TABLES  
Table 1. Significant risk factors of dengue severity with potential clinical prognostic 
impact. ................................................................................................................................ 24 
Table 2. Association analysis between dengue shock syndrome and SNP genotypes at 
MICB and PLCE1 ............................................................................................................. 70 
Table 3. Distribution of demographic characteristics and co-morbidities by cases (DHF) 
and controls (DF) in year 2006 and year 2007-2008 epidemics. ................................... 83 
Table 4. Crude and adjusted odds ratios of the association of DHF with age groups, 
gender and ethnicity in year 2006 and year 2007-2008 epidemics. .............................. 87 
Table 5. Crude and adjusted odds ratios of the association of DHF with co-morbidities in 
year 2006 and year 2007-2008 epidemics. ....................................................................... 87 
Table 6. Crude and adjusted odds ratios of the association of DHF with multiple co-
morbidities in year 2007-2008 epidemic. ......................................................................... 88 
Table 7. Stratified analysis between diabetes mellitus and other comorbidities in year 
2007-2008 epidemic. .......................................................................................................... 88 
Table 8. Demographic descriptions of dengue RT-PCR positive patients classified 
according to designated clinical outcomes. ................................................................... 100 
Table 9. Differential genes between hospitalized patients with warning signs (WS + 
Hosp.), including patients with severe dengue (SD) and non-hospitalized patients 
without warning signs (Non-WS + Non-Hosp.) at less than 72hr post fever. ............ 105 
Table 10. Targeted proteomic expression between Non-WS + Non-Hosp. group and WS + 
Hosp. group. ..................................................................................................................... 107 
Table 11. Targeted proteomic expression between Non-WS + Non-Hosp. groupand severe 
dengue patients among the WS + Hosp. group. ........................................................... 108 
Table 12. Combination of RNA, proteins and laboratory variables as potential 
biomarkers of warning signs and hospitalization. ....................................................... 111 
Table 13. Risk association analyses of RNA and protein biomarker in selected models. 113 
Table 14. Prognostic performance of the top selected models with different probability 
cutoff as positive for falling into WS+Hosp. group in the validation cohort. ............ 118 
Table 15. Demographic and co-morbidities of dengue-infected non-ICU (controls) and 
ICU (cases) patients ........................................................................................................ 131 
Table 16. Severity classification and duration of illness of dengue-infected non-ICU 
(controls) and ICU (cases) patients ................................................................................ 133 
Table 17. Clinical and laboratory variables at first presentation of dengue-infected non-
ICU (controls) and ICU (cases) patients ....................................................................... 136 
Table 18. Significantly associated laboratory variables at 24h prior to ICU admission 
compared to first presentation of dengue-infected ICU (cases) patients ................... 139 
Table 19. Significantly different characteristics between deaths and non-deaths at first 
presentation in the subgroup analysis of ICU Dengue-infected patients. .................. 142 
Table 20.Summary of risk factors as potential early clinical prognosis tools and proposed 






LIST OF FIGURES 
Figure1. Global Dengue Risk. .................................................................................................... 6 
Figure 2. Global Dengue Burden. .............................................................................................. 6 
Figure 3.The WHO 1997 classification system. ..................................................................... 13 
Figure 4. The WHO 2009 classification of severity. .............................................................. 13 
Figure 5. Diagram of the course of dengue disease over time and the application of 
epidemiological, genetic, molecular and clinical risk factors to refine prediction risk 
of developing disease severity, for screening, diagnosis, prognosis and therapeutic 
selection. ............................................................................................................................. 31 
Figure 6. Diagram of the pyramid of dengue severity. .......................................................... 35 
Figure 7. Manhattan plot showing directly genotyped SNPs plotted according to 
chromosomal location (x axis), with –log10 P values (y axis) derived from the 1-
degree-of- freedom score test. .......................................................................................... 69 
Figure 8. Forest plot illustrating the association between MICB rs3132468 and 
susceptibility to dengue. .................................................................................................... 73 
Figure 9. Forest plot illustrating the association between PLCE1 rs3740360 and 
susceptibility to dengue. .................................................................................................... 73 
Figure 10. Selection workflow of dengue patients with warning signs that required 
hospitalization and patients with no warning signs and no hospitalization required. 99 
Figure 11.  Laboratory characteristics (A-Viral copy number at Day 1-3; B-Platelet 
count; C-Lymphocytes count) of hospitalized dengue patients with warning signs 
(WS + Hosp. Group) compared to non-hospitalized patients with no warning signs 
(Non-WS + Non-Hosp. Group). ..................................................................................... 101 
Figure 12. Laboratory characteristics of patients with severe dengue among the 
hospitalized dengue patients with warning signs (WS + Hosp. Group). .................... 102 
Figure 13. Laboratory characteristics of patients with severe dengue compared to non-
hospitalized dengue patients with no warning signs (Non-WS + Non-Hosp. Group).
 ........................................................................................................................................... 103 
Figure 14. Sensitivity and specificity plots of Model 13 (A.) and Model 14 (B.) with the 
varying probability cut-offs. ........................................................................................... 114 
Figure 15. Performance of the optimal model 13 (A.) and model 14 (B.) on the validation 
cohort with different probability cut-off. ...................................................................... 117 
Figure 16. Laboratory characteristics of patients who are likely to require hospitalization 
and develop warning signs. ............................................................................................ 119 
Figure 17. Sensitivity and specificity plots of Model at presentation (A.) and Model for 
24hr Pre-ICU (B.) with the varying probability cut-off. ............................................. 140 
Figure 18. Potential interventions to reduce the public health burden due to dengue at 
different stage of the disease, from pre-infection, pre-clinical (post-infection) to 
clinical stage of the disease. ............................................................................................ 155 
Figure 19. Prognostic performance of using discrete (a) and weighted (b) risk scoring 







LIST OF ABBREVIATIONS  
AST- Aspartate aminotransferase 
ALT- Alanine aminotransferase 
DALYs- Disability-adjusted life years  
DENV- Dengue virus 
DENCO- Dengue and control study  
DF- Dengue fever 
DHF- Dengue haemorrhagic fever 
DSS- Dengue shock syndrome 
HLA- Human leucocyte antigen 
ICU- Intensive care unit 
IL- Interleukin 
LTA- Lymphotoxin-alpha 
MBL- Mannose-binding lectins 
NPV- Negative predictive value 
PPV- Positive predictive value 
SD- Severe dengue 
SNPs- single nucleotide polymorphisms  
TGF- Transforming growth factor 
TNF- Tumor necrosis factor 
VDR- Vitamin D receptor 






CHAPTER 1: BACKGROUND 
 
1.1 OVERALL SUMMARY OF CURRENT CHALLENGES IN 
DENGUE 
Dengue incidence has been increasing over the past decades, which is likely due to the 
increasing trend of globalization, urbanization, and global warming. Although extensive 
studies have been conducted in the past two decades focusing on host-virus interactions, 
the pathogenesis of dengue disease remains unclear. This is likely due to the complex 
interplay between the viral and host factors. Furthermore, the absence of a robust animal 
model of disease made the investigation of dengue pathogenesis even more challenging. 
Currently, there is no licensed vaccine or specific antiviral therapy available for the 
prevention or treatment of dengue. Vector control programmes have been inefficient and 
unsustainable over time. The current strategies applied to reduce burden are mainly close 
observation of patients for signs of bleeding and circulatory compromise, and providing 
early and appropriate supportive fluid management. Therefore, identification of patients 
who are susceptible to developing severe dengue disease or who warrant strict medical 
attention in hospital at the early phases of the disease is critical for proper clinical 
management (WHO, 2009, 2012). However, there were limitations in using the WHO 
1997 and 2009 classifications to triage the increasing proportion of adults who are at risk 
of dengue severity. This is mainly due to the fact that the classifications were derived 
largely from pediatric cases, and have also been shown not be useful in the early phase of 
infection (less than 72 hours). Furthermore, clinical signs and symptoms among adults are 
likely to present late around one day before progression to severe disease, which makes 
any form of intervention very challenging.  
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 Even though there have been reported risk factors that may be effective for 
identifying high risk individuals, these are often not generalizable to all countries of 
interest due to differences in host genetic background, predominant circulating viral 
strains, and geographical areas and public health priorities as well as standard of medical 
services available. Moreover, there have been proposals to look at dengue severity in a 
multi-factorial manner as each risk factor is unlikely to account for all the cases observed 
(Guzman & Kouri, 2008; Guzman et al., 1990). 
 The objectives of this thesis are to explore several complementary approaches to 
identifying susceptibility to severe dengue, namely the use of genetic, molecular, 
epidemiological, clinical risk stratification. We will start with a review of existing 
literature on the topic in Chapter 1, followed by a description of methods used in Chapter 
2. We will then detail individual studies we conducted using the genetic (Chapter 3), 
epidemiological (Chapter 4), molecular (Chapter 5) and clinical approaches (Chapter 6) to 
risk stratification, followed by Chapter 7 which will discuss the applicability of the various 
approaches to different contexts for improving clinical management of dengue disease. 
We will also touch on the implications of our findings for understanding the causes of 









1.2 EPIDEMIOLOGY AND BURDEN OF DENGUE INFECTION 
Dengue, the fastest spreading vector-borne disease, is endemic in the tropical and 
subtropical regions of the world due to the high suitability of its environment for dengue 
transmission (Figure 1) by Aedes mosquitoes, with Aedes aegypti being the more efficient 
vector as compared to Aedes albopictus. Dengue infection is caused by dengue virus 
(DENV), which belongs to the family Flaviviridae and genus flavivirus. There are four 
antigenically distinct serotypes of dengue virus (DENV-1, DENV-2, DENV-3, DENV-4), 
which are usually co-circulating in these endemic regions. Rapid urbanization over the 
past decades has facilitated endemicity as dengue is predominantly found in semi-urban 
and urban areas (Simmons, Farrar, Nguyen v, & Wills, 2012).  
1.2.1 Burden of dengue infection 
The population at risk of dengue infection residing in these endemic regions is 
approximately 2.5 to 3.6 billion people (Murray, Quam, & Wilder-Smith, 2013), with 
about 50 million reported symptomatic dengue infections per year as estimated by the 
World Health Organization (WHO) (WHO, 2009). However, a recent work estimated 390 
million infections per year, of which only 25% was estimated to be symptomatic 
infections (Bhatt et al., 2013). This estimate of symptomatic infections is twice as high as 
the estimate of the WHO, which highlights the increasing trend and the scale of 
underreporting of global burden due to dengue over the past decades. Nevertheless, it was 
also highlighted in the study that the determination of an accurate dengue burden will 
always be a challenge due to inadequate surveillance and reporting systems, as well as 
dengue misdiagnosis. In addition, the rapid expansion of dengue can be due to factors such 
as the dynamic changes of climate, globalization, travel, trade, socioeconomics, settlement 
and also viral evolution (Murray et al., 2013). 
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Approximately, 75% of the global burden (Figure 2) due to dengue was derived from 
the WHO South-East Asia and Western Pacific regions, where more than 70% of the 
population at risk are residing (Bhatt et al., 2013; WHO, 2009). The recent annual 
economic burden due to dengue in South-East Asia, as an example, was estimated to be 
US$950m (cost per capita of US$1.65)  with 372 disability-adjusted life years (DALYs) 
per million inhabitants, which is higher than the burden due to other diseases of public 
health importance such as Japanese encephalitis, upper respiratory infections, and hepatitis 
B (Shepard, Undurraga, & Halasa, 2013). Furthermore, developed countries such as 
Singapore are more affected economically compared to developing countries such as 
Vietnam. Singapore had the highest cost per capita GDP (2010 US$) of US$14.99 
(Shepard et al., 2013) due to dengue with a mean total cost of US$1,500 per dengue 
patient (Carrasco et al., 2011) compared to Vietnam, with the lowest cost per capital GDP 
of US$0.28 (Shepard et al., 2013) with a mean total cost of US$147.77 per dengue patient 
(P. T. Tam et al., 2012). 
1.2.2 Epidemiology of dengue infections 
Dengue infection is predominantly a pediatric disease in most parts of Southeast Asia 
and Western Pacific regions (WHO, 1997), where children less than 15 years of age are at 
higher risk of dengue infection with high DHF/DF ratio compared to adults (Guzman et 
al., 2002). However, over the years, there has been a gradual increase in the reported 
number of dengue infections among older children and young adults age 15 and above in 
Singapore (Goh, 1995; Ooi, Goh, & Chee Wang, 2003; Ooi, Goh, & Gubler, 2006), 
Vietnam (Anders et al., 2011), Thailand (Chareonsook, Foy, Teeraratkul, & Silarug, 1999; 
Pongsumpun, Yoksan, & Tan, 2002; Tantawichien, 2012; Wichmann et al., 2004), South 
China (Guo et al., 2014), Taiwan (M. S. Lee, Hwang, Chen, Lu, & Chen, 2006; C. C. Lin 
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et al., 2010) and Sri Lanka (Kularatne, Gawarammana, & Kumarasiri, 2005). Furthermore, 
this phenomena was also observed outside Southeast Asia in Hawaii (Effler et al., 2005), 
Cuba (Guzman et al., 2000; Pongsumpun et al., 2002) and Brazil (Guilarde et al., 2008; 
Souza et al., 2013). It was hypothesized that the increasing average age of dengue illness 
is due to a shift in the age structure of the population, and its impact on the force of 
infection (Cummings et al., 2009). While most dengue infections, particularly primary 
infections in young children, are mild or silent (Burke, Nisalak, Johnson, & Scott, 1988; 
Endy et al., 2002), infections in adults are more likely to be clinically symptomatic, 
resulting in a higher proportion of DF than DHF/DSS (Egger & Coleman, 2007; Ooi et al., 
2003; Thai et al., 2010).  
1.2.3 Clinical manifestations of dengue infection. 
In addition, there were significant differences in the clinical manifestations between young 
children and adults (Tantawichien, 2012). In comparing adults and children at mean 
duration post fever prior to admission of 4.2 days, headache, nausea, myalgia/arthralgia, 
petechiae, clinical bleeding and severe liver involvement were significantly more common 
in adults, while cough and hepatomegaly were significantly more frequent in children 
(Thai et al., 2010; Wichmann et al., 2004). Moreover, haemoconcentration, 
thrombocytopenia, increased alanine aminotransferase, and longer prothrombin time were 
found to be significantly higher in adults than in children (Kittigul, Pitakarnjanakul, 








Figure1. Global Dengue Risk. 
(Reproduced with permission from Simmons, Farrar et al. NEJM 2012, Copyright 






Figure 2. Global Dengue Burden. 







1.3 DENGUE PREVENTION, TREATMENTS AND THEIR 
CHALLENGES 
 
1.3.1 Challenges of vector control. 
Prevention is always better than cure. Currently, vector control is the main area of 
emphasis for prevention. Vector control measures have been effective in reducing 
populations of the main transmission vector, the mosquito Aedes. aegypti (Kay & Vu, 
2005), but these have largely failed to slow the current dengue pandemic as a cost-
effective and sustainable strategy in an urban endemic setting (Luz, Vanni, Medlock, 
Paltiel, & Galvani, 2011).  
Control of dengue vectors relies on the removal of larval breeding containers, such as 
old tyres or flower vases or on insecticide spraying in homes. This approach has been used 
successfully in some locations, but is not sustainable (Gubler, 1989, 2002; Gubler & 
Clark, 1996; Hemingway, Beaty, Rowland, Scott, & Sharp, 2006; Rigau-Perez et al., 
2002). In addition, continuous insecticide-based larval control with high efficacy has been 
shown to be counterproductive. This is because as resistance against insecticides increases 
while the population herd immunity decreases over time, it is likely to result in an 
increased magnitude of future epidemics (Luz et al., 2011).  
One other potential of vector control is the use of wMel Wolbachia infection, 
introduced into Aedes aegypti from Drosophila melanogaster, which has been recently 
shown to have successfully invaded two natural Aedes aegypti populations in Australia 
and blocked transmission of DENV-2 in caged mosquitoes (Hoffmann et al., 2011; Walker 
et al., 2011). However, data on whether the population replacement has reduced the 
incidence of human dengue cases will take many years to assess and more studies would 
still be required to understand the potential impact on the natural ecology of releasing this 
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Wolbachia-infected mosquitoes on the long term basis as the mechanism behind this 
supercharged host protection remains elusive (LePage & Bordenstein, 2013). 
1.3.2 Challenges of vaccine development 
 
Currently, there is still no licensed vaccine yet as there are many clinical development 
challenges to develop an effective vaccine. Safe vaccination should generate durable 
immune responses to all four dengue serotypes due to the potential implication of 
antibody-dependent enhancement theory such as the phenomena of high immune 
reactogenicity, resulting in severe disease. Other challenges also include the lack of a 
suitable animal model and immunological correlates, the lack of a robust methodology to 
assess efficacy and the necessity to evaluate the vaccine in different populations at risk of 
disease, and to have sufficient dengue cases in the control group to statistically highlight 
efficacy against, ideally, all 4 serotypes (Wallace, Canouet, Garbes, & Wartel, 2013). 
Nevertheless, there were many clinical trials ongoing (Webster, Farrar, & Rowland-
Jones, 2009). However, concerns still remain on the potential reversion of attenuated strain 
to wild type, induction of antibody-dependent enhancement in individuals with pre-
existing immunity, as well as the reduction of serotype-specific response due to over 
proportion of the fusion-loop-specific antibodies compared to the serotype-specific 
antibodies (K. Fink & Shi, 2014).  
Currently, the most promising vaccine candidate is from Sanofi Pasteur, a 
recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV),which is made up 
of recombinant infectious cDNA clones of yellow fever 17D vaccine strain as a backbone, 
substituting membrane precursor protein and envelope protein genes with those of dengue 
viruses (Guy et al., 2011). It has been shown to be immunogenic and safe in population of 
the South-east Asia regions (R. Z. Capeding et al., 2011; Lanata et al., 2012; Leo et al., 
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2012) with efficacy estimates against DENV-1, 3, and 4, but not DENV-2, in a range 
consistent with the assumed overall efficacy of 70% after three injections, and these 
estimates were also significant after at least one vaccination (Sabchareon et al., 2012).  
Similarly, the full evaluation of the phase 3 clinical trial showed consistently high 
efficacy against serotype 1, 3 and 4, but not for serotype 2 with efficacy of about 34.7% 
(M. R. Capeding et al., 2014; Hss et al., 2013), even though serotype 2 is one of the more 
predominant serotype in Asia such as in Singapore. Therefore, further studies would still 
be required to refine the potential vaccine for dengue prevention. As such, there is 
currently a stronger need to focus on the treatment strategies to minimize the burden of 
infection.  
1.3.3 Challenges of anti-viral therapy. 
 
Thus far, there are also no licensed antiviral drugs available against DENV infection 
as a specific treatment for dengue patients. Over the last decades, there were a number of 
antiviral therapies proposed and evaluated in clinical trials on humans. They were 
balapiravir (N. M. Nguyen et al., 2013), chloroquine (Tricou et al., 2010), corticosteroid 
(T. H. Nguyen et al., 2013; D. T. Tam et al., 2012), steroids (Sumarmo, Talogo, Asrin, 
Isnuhandojo, & Sahudi, 1982; Tassniyom, Vasanawathana, Chirawatkul, & Rojanasuphot, 
1993), statins (Whitehorn, Van Vinh Chau, et al., 2012) and Celgosivir (Rathore et al., 
2011).   
1.3.4 Challenges of current clinical interventions. 
Unfortunately, none turned out to be significantly effective in reducing viral load to 
prevent disease at the early phase of infection. Current treatment strategy remains largely 
supportive, which includes careful fluid management, bed rest, antipyretics, and analgesics 
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(Harris et al., 2003; Simmons et al., 2012; WHO, 2009). In addition, constant clinical 
monitoring of patients suspected of severe dengue, together with anticipatory and 
supportive care can help to reduce mortality rate (WHO, 2009). Intensive care is required 
for severely ill patients, including prompt intravenous fluids resuscitation, blood or plasma 
transfusion and medicines. 
Prompt fluid resuscitation, either with isotonic crystalloid solutions or colloids, 
remains the mainstay of treatment to counteract massive plasma leakage (Dung et al., 
1999; Ngo et al., 2001; Wills et al., 2005). Platelet transfusion has been routinely 
performed as part of management of dengue (L. Thomas et al., 2009), but it has been 
observed not to be effective in prevention of severe bleeding or shorten the bleeding 
period recently (Khan Assir et al., 2013). In addition, prophylactic platelet transfusion, 
which is thought to reduce the risk of hemorrhage, has been shown to be unsuccessful so 
far to prevent or to treat severe thrombocytopenia significantly, and to minimize the 
chance of severe disease progression (Kurukularatne, Dimatatac, Teo, Lye, & Leo, 2011; 
Lum, Abdel-Latif Mel, Goh, Chan, & Lam, 2003; Lye, Lee, Sun, & Leo, 2009).  
However, there is still an existing large variation in clinical practice and a lack of 
stronger evidence for prophylactic platelets transfusion from large prospective controlled 












1.4 DENGUE CLASSIFICATIONS AND ITS LIMITATIONS 
 
1.4.1 Dengue classifications 
Dengue infection results in a wide spectrum of clinical manifestations from 
asymptomatic infection, undifferentiated fever, dengue fever (DF) to dengue haemorrhagic 
fever/dengue shock syndrome (DHF/DSS). Recommendations for the classification and 
management of DHF were developed based on key findings of pediatric dengue studies in 
Bangkok in the 1960s (Cohen & Halstead, 1966) and were further used as WHO 
guidelines in 1974, updated in 1986, 1994, and 1997 (WHO, 1997). Dengue fever is 
clinically defined as an acute febrile illness with two or more manifestations (headache, 
retro-orbital pain, myalgia, arthralgia, rash, haemorrhagic manifestations, or leucopenia) 
and occurrence at the same location and time as other confirmed cases of dengue fever 
(Figure 3).  
The hallmark of DHF is the presence of hemorrhagic manifestations and evidence of 
plasma leakage (besides having fever lasting two to seven days and thrombocytopenia), 
which can lead to the loss of intravascular volume and circulatory insufficiency, known as 
hypovolemic shock or DSS and even death, if not treated timely. Early detection and 
management of severe disease are essential to prevent morbidity and mortality (WHO, 
2009).  
Therefore, an ideal dengue classification system should be one which facilitates early 
triage, and prognosis of patients, through early recognition of key warning signs/markers, 
guides clinical management, and is useful as an endpoint evaluation of potential 
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interventions, epidemiological surveillance, reporting and for comparisons among other 





























Figure 3.The WHO 1997 classification system. 
(Reprinted from The Lancet, 368/9530, Deen JL, Harris E, Wills B et al., The WHO 
dengue classification and case definitions: time for a reassessment, 170-173, Copyright 






Figure 4. The WHO 2009 classification of severity. 







1.4.2 Challenges of current classifications 
 
Over the years, there were increasing reports of the challenges and difficulties in 
applying the WHO 1997 classification guidelines (Balmaseda et al., 2005; 
Bandyopadhyay, Lum, & Kroeger, 2006; Deen et al., 2006; Hadinegoro, 2012; Phuong et 
al., 2004; Rigau-Perez, 2006; Setiati et al., 2007; Srikiatkhachorn et al., 2010) and 
proposal was made to review and develop a more evidence-based clinical guideline 
(Horstick et al., 2012; Santamaria et al., 2009). Briefly, this was mainly due to the fact that 
it was developed based on substantial clinical observations of pediatric dengue cases in 
Thailand only, which may not be generalizable or applicable in other countries as dengue 
increasingly spread to new geographical areas and started affecting more adults (aged 
more than 15 years old) in the past decade (Horstick et al., 2012; Rahman et al., 2002).  
In addition, the requirement for repetition of clinical tests impose substantial burden to 
endemic countries with limited resources, and the recommended usage of the tourniquet 
test had limited effectiveness in stratifying DF and DHF (Horstick et al., 2012). 
Furthermore, the emphasis on hemorrhage instead on plasma leakage, and the lack of 
emphasis on organ failure in the WHO 1997 classification had greatly hindered the 
classification of patients with severe dengue, which is also a significant cause of dengue-
related morbidity and fatality (Deen et al., 2006; Horstick et al., 2012; Phuong et al., 2004; 
Rigau-Perez, 2006). These limitations had led to a clinical dilemma of clinicians not being 
able to classify substantial number of severe patients as DHF, particularly in adults as they 
failed to satisfy the four criteria (Balmaseda et al., 2005; Horstick et al., 2012). In view of 
these limitations, the WHO Dengue Scientific Working Group recommended additional 
research into dengue diagnostics and triaging of patients into non-severe and severe 
groups to optimize clinical management in 2006 (Barniol et al., 2011; Horstick et al., 
2012). Subsequently, WHO introduced a new classification system, with guidance from 
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the results of DENCO (Alexander et al., 2011), to guide clinicians in triaging dengue 
severity into two groups to facilitate early and appropriate clinical management. The two 
groups were dengue with/without warning signs and severe dengue. These warning signs 
were proposed as indicators for disease progression towards severe dengue. They were 
mucosal bleeding, abdominal pain, persistent vomiting, lethargy, clinical fluid 
accumulation and rapid decrease in platelet count (WHO, 2009). The WHO recommended 
dengue patients who presented with warning signs should be hospitalized for observation 
so as to provide prompt appropriate clinical management to minimize progression into 
severe disease (WHO, 2009). Evaluation of the revised WHO 2009 dengue classification 
has shown high acceptance and applicability (Barniol et al., 2011), higher sensitivity and 
specificity of classifying pediatric severe dengue cases (Basuki et al., 2010; Narvaez et al., 
2011; Prasad, Kumar, Jain, & Kumar, 2013) and higher sensitivity of classifying adult 
dengue cases with higher proportion of cases requiring hospitalization as compared to that 
using the WHO 1997 classification (Gan et al., 2013; T. L. Thein, Gan, Lye, Yung, & Leo, 
2013; Tsai, Lee, Lee, Yang, & Liu, 2013). 
However, there is a need for more precise definition of warning signs to enable 
optimal triaging for more accurate identification of patients who require hospitalization as 
opposed to those who can be treated as outpatients. It was observed that adult dengue 
patients without any warning signs can be treated as outpatients, and no single warning 
sign can independently predict disease progression (Leo et al., 2013; T. L. Thein, Gan, et 
al., 2013; Tsai et al., 2013). Furthermore, most of these warning signs appeared at median 
4th day of illness and only up to 50% of the severe patients had warning signs preceding 
occurrence of DHF or severe dengue (T. L. Thein, Gan, et al., 2013), or one day prior to 
the development of severe illness/ requirement of intervention (Alexander et al., 2011), 
and this narrow window makes any form of intervention challenging, particularly when 
16 
 
appropriate healthcare facilities are not accessible or available near their place of 
residences. Alternative means of stratifying high risk patients during triage into the various 
dengue severity levels for prevention and prompt clinical management would be to 
explore epidemiological, genetic, molecular and clinical risk factors as potential early 
























1.5. RISK FACTORS OF DENGUE SEVERITY 
 
1.5.1. Epidemiological risk factors of dengue severity among children 
Unravelling of risk factors is challenging but important for screening and prevention as 
well as for implementation of vaccines and therapeutics when they are available. General 
epidemiological risk factors of DHF/DSS among children were dengue-serotype 2 
(Guzman et al., 1990; S. Thein et al., 1997; Vaughn et al., 2000), dengue-serotype  3 
(Guilarde et al., 2008; Harris et al., 2000), Asian genotype (Watts et al., 1999), prior 
dengue infections (Bravo, Guzman, & Kouri, 1987; Burke et al., 1988; Guzman et al., 
1984; Vaughn et al., 2000), age less than 15 years old (Anders et al., 2011; Guzman et al., 
2002; Ooi et al., 2003), white females (Anders et al., 2011; Guzman et al., 1984), and 
obesity (S. Kalayanarooj & Nimmannitya, 2005; Pichainarong, Mongkalangoon, 
Kalayanarooj, & Chaveepojnkamjorn, 2006). Epidemiological risk factors of mortality 
among children were age under five (Anders et al., 2011), female (Anders et al., 2011), 
rural residents (Anders et al., 2011).  
1.5.2 Epidemiological risk factors of dengue severity among adults. 
Even though there have been efforts in unravelling the risk factors among adults, 
usually defined as age greater than 15 years old, the findings were still limited for use in 
early prevention, triage and clinical management. The risk factors among adults were age 
greater than 65 years (M. S. Lee et al., 2006), low income (Blanton et al., 2008) and 
having co-morbidities. Co-morbidities were reported as risk factors for DHF in a number 
of studies from dengue endemic countries. These co-morbidities included sickle cell 
anaemia(Bravo et al., 1987), asthma (Bravo et al., 1987; Cunha et al., 1999; D. Gonzalez 
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et al., 2005), hypertension (Cunha et al., 1999; Figueiredo et al., 2010; M. S. Lee et al., 
2006), uremia (M. S. Lee et al., 2006), allergies treated with corticosteroid (Figueiredo et 
al., 2010) and diabetes mellitus (Bravo et al., 1987; Cunha et al., 1999; Figueiredo et al., 
2010; M. S. Lee et al., 2006).  
However, these co-morbidities may not be generalized to all populations and 
epidemics of all dengue serotypes. Furthermore, most of these risk factors were identified 
from univariate analysis (Bravo et al., 1987; Cunha et al., 1999; D. Gonzalez et al., 2005) 
instead of multivariate analysis whichtake into account of potential confounders 
(Figueiredo et al., 2010; M. S. Lee et al., 2006). Increasingly, there were more evidence of 
substantial risk of death among adults whose age is greater than 55 years old (Leo et al., 
2011; C. H. Lin et al., 2012; Ong, Sandar, Chen, & Sin, 2007). These may be due to the 
fact that elderly dengue patients were at higher risk of DHF, SD and hospital-acquired 
infections (Low et al., 2011; Rowe et al., 2014).  
Furthermore, there are several challenges in reducing the dengue burden in the elderly. 
First, there is a lack of evidence-based clinical management protocols for managing 
elderly patients. It is especially important if fluid replacement therapy, which was mainly 
used on paediatric patients to prevent shock, is not monitored carefully, it could result in 
fluid overload and death. The situation would be more complicated particularly for those 
who have pre-existing or undiagnosed cardiovascular disease (Low & Ooi, 2013). Second, 
it is clinically challenging to diagnose dengue-infected elderly as they may present 
atypically as compared to younger dengue infected adults, with the elderly being more 
likely to have hepatomegaly and malaise/lethargy (C. C. Lee, Hsu, Chang, Hong, & Ko, 
2013; Low et al., 2011; Rowe et al., 2014). Nevertheless, it has been proposed that elderly 
with fever and leukopenia be tested for dengue, even in the absence of other symptoms as 
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this combination can achieve a sensitivity of 82% and specificity of 87% (Low et al., 
2011).   
1.5.3 Genetic risk factors of dengue severity 
Genetic risk factors include single nucleotide polymorphisms (SNPs), gene copy 
number variants and genetic deletions. These subtle changes might have important 
consequences for susceptibility to disease (Casanova & Abel, 2007). Indirect evidence 
implicating host genetic background in predisposing to DHF/DSS has been reported in 
Cuban dengue epidemics whereby a reduced risk for DHF/DSS was observed in those 
with an African ancestry compared to those with European ancestry (Blanton et al., 2008; 
Bravo et al., 1987; D. Gonzalez et al., 2005; Guzman, 2005; Guzman et al., 1999; Guzman 
& Kouri, 2008; Guzman et al., 2002; Sierra et al., 2007). These Cuban observations are of 
significant epidemiological interest, as the differences in susceptibility to DHF among 
racial groups in Cuba coincide with the low susceptibility reported in African and Black 
Caribbean populations (Halstead et al., 2001; Saluzzo, Cornet, Adam, Eyraud, & Digoutte, 
1986).  
Genetic studies in Thailand, Cuba, Mexico, Sri Lanka, Malaysia and Vietnam have 
also reported associations between certain Class I HLA alleles and DHF (Appanna, 
Ponnampalavanar, Lum Chai See, & Sekaran, 2010; Chiewsilp, Scott, & Bhamarapravati, 
1981; LaFleur et al., 2002; Loke et al., 2001; Malavige et al., 2011; Nguyen et al., 2008; 
Stephens et al., 2002). Cuban studies showed that HLA-B14 and A-29 are negatively 
correlated with DHF risk and HLA-A1 and B-blank were positively associated with severe 
disease. Mexican studies showed that HLA-DRB1*04 is an important resistance allele to 
DHF and its high frequency in Mexican population could explain at least partly the 
atypical course of DHF in that country (LaFleur et al., 2002). In Vietnam, HLA-
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DRB1*0901 (HLA Class II) was generally found to be a protective allele against the 
severe form of dengue, while HLA-A*24 (HLA Class I) was found to be an enhancing 
allele (Nguyen et al., 2008). Furthermore, a recent study suggested that HLA-
DRB1*07/*15 genotype in combination with TNF polymorphisms influence progression 
to DHF (Alagarasu et al., 2013).  
Studies carried out in different populations have shown the association of genetic 
variations in the CD209 (Sakuntabhai et al., 2005), vitamin D receptor (VDR) (Alagarasu 
et al., 2012; Loke et al., 2002), tumor necrosis factor (TNF) (Fernandez-Mestre, 
Gendzekhadze, Rivas-Vetencourt, & Layrisse, 2004; Perez et al., 2010; Vejbaesya et al., 
2009), transforming growth factor-beta1 (TGF-β1) (Perez et al., 2010), interleukin-10 
(IL10) (Perez et al., 2010), lymphotoxin-alpha (LTA) (Vejbaesya et al., 2009) and 
FCGR2A (Loke et al., 2002) genes with DHF. Interestingly, wild type AA mannose-
binding lectin 2 (MBL2) genotype was observed to augment susceptibility for the risk of 
manifesting dengue thrombocytopenia (Acioli-Santos et al., 2008).  
Though there may be a fair amount of research on the implication of host genetics on 
dengue severity, it is still very limited as most of these studies were based on candidate-
gene approach with small numbers of subjects (less than a thousand of patients) involved, 
and mostly it is hard to replicate the findings. Furthermore, this approach is strategically-
biased as it does not explore other genetic regions of the whole human genome due to their 
very limited efficiency and statistical power. An assessment of the whole human genome 
for these susceptibility or resistance polymorphisms in different populations at risk 
(Chaturvedi, Nagar, & Shrivastava, 2006; Coffey et al., 2009; Stephens, 2010)using whole 
genome chip would minimize selection biases and is highly established and favorable for a 
more comprehensive understanding of the role of host genetics on dengue severity of a 
specific population at risk(Khor & Hibberd, 2012).  
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1.5.4 Clinical risk factors of dengue severity 
Clinical risk factors for death in children were severe bleeding (hemoptysis), epistaxis 
and persistent vomiting during hospitalization (Branco et al., 2014). Whereas, in adults, 
clinical risk factors observed were hematemesis and melena during the acute phase in 
Mexico (Navarrete-Espinosa, Gomez-Dantes, Celis-Quintal, & Vazquez-Martinez, 2005), 
pre-fatal (48 hour before fatality) profound thrombocytopenia and leukocytosis in Taiwan 
(I. K. Lee, Liu, & Yang, 2012), absence of myalgia, leukocytosis (T. L. Thein, Leo, et al., 
2013) and tachycardia on admission in Singapore (Ong et al., 2007). In addition, cases of 
gastrointestinal bleeding, ascites, pericardial and/or pleural effusion, hepatomegaly, 
hypotension and shock were proposed to have higher risk of progression to death in Brazil 
(Cavalcanti et al., 2010), and Acute Physiology and Chronic Health Evaluation 
(APACHE) II may predict higher risk for death among dengue patients admitted to 
intensive care unit (ICU) in India (Juneja et al., 2011).  
Clinical risk factors of DHF/DSS of children were thrombocytopenia and bleeding 
(Srikiatkhachorn et al., 2010), spontaneous bleeding, hepatomegaly, signs of capillary 
leakage like ascites and pleural effusion (Gupta et al., 2011), and hemoconcentration of 
more than 22% from baseline hematocrit (Tantracheewathorn & Tantracheewathorn, 
2007), whereas for adults the factors were bleeding, particularly mucosal bleeding (M. S. 
Lee et al., 2006; V. J. Lee et al., 2008; Rowe et al., 2014; Vasanwala et al., 2014), 
abdominal pain and persistent vomiting (T. L. Thein, Gan, et al., 2013).  
1.5.5 Laboratory and molecular risk factors of dengue severity. 
Laboratory and molecular risk factors for DHF/DSS of children were higher viral load 
than DF children (Endy et al., 2004; Vaughn et al., 2000), lower platelet count and higher 
AST level than DF patients (S. Kalayanarooj et al., 1997), lower WBC count, percent 
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monocytes, platelet count, and hematocrit level, but higher neutrophil and AST level than 
non-DSS children (Potts et al., 2010), sTNRr80, IFN-γ, sCD8, and sIL2R (Green, Vaughn, 
Kalayanarooj, Nimmannitya, Suntayakorn, Nisalak, Lew, et al., 1999), sTNRr75 (Bethell 
et al., 1998), free sNS1 (Libraty, Young, et al., 2002), sVCAM-1 (Murgue, Cassar, & 
Deparis, 2001) and IL-10 (Green, Vaughn, Kalayanarooj, Nimmannitya, Suntayakorn, 
Nisalak, Rothman, et al., 1999).  
Whereas, laboratory and molecular risk factors for DHF/DSS relevant to dengue-
infected adults were higher urine protein creatinine ratio (UPCR), platelet count, serum 
hematocrit, serum protein (Vasanwala et al., 2011; Vasanwala et al., 2014), interferon-
gamma, interleukin-17, fibroblast growth factor, RANTES, IP-10, serum amyloid A2 
(SAA) and haptoglobin (HPT) (Y. Kumar et al., 2012), lower lymphocyte proportion and 
total protein and higher urea (V. J. Lee et al., 2008), CD3, 4, 5, 8 (Fadilah et al., 1999), 
AST and ALT (Guilarde et al., 2008; L. K. Lee et al., 2012; W. K. Wang et al., 2006), 
platelet-associated IgM (Saito et al., 2004), C5a, sIL-2R and viral load (W. K. Wang et al., 
2006), soluble thrombomodulin and VEGF (Butthep et al., 2006; Del Moral-Hernandez et 
al., 2014; Seet, Chow, Quek, Chan, & Lim, 2009; Wills et al., 2002). Furthermore, a study 
which defined severity as death and intensive care admission proposed using four 
laboratory criteria [creatinine (>140 mmol/L), free bilirubin (>18 umol/L), amylase 
(>220IU/L) and platelets (<45,000/mm3)] to triage adult dengue patients for closer 
monitoring and hospitalization requirement (Bouldouyre, Baumann, Berlioz-Arthaud, 
Chungue, & Lacassin, 2006).  
In addition, laboratory and molecular risk factors of hospitalization due to 
thrombocytopenia at early febrile phase of dengue infection of less than 72hr were higher 
viral load, lower platelet counts, white blood cells, lymphocyte count and neutrophil 
counts (Low et al., 2011; Tanner et al., 2008), presence of IgG (Tanner et al., 2008), 
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higher proportion of chemokines CCL2 (MCP-1), CCL8 (MCP-2), CXCL10 (IP-10) and 
CCL3 (MIP-1α), antimicrobial peptide β-defensin 1 (DEFB1), desmosome/intermediate 
junction component plakoglobin (JUP) and a microRNA 147 (NMES1) (Tolfvenstam et 
al., 2011).  
Lastly, it is important to note that some of these laboratory and molecular factors were 
measured at the point of severity, and hence, were not prognostic biomarkers. Laboratory 
and molecular factors which were assessed at the point of admission or before the 
development of severe dengue conditions were evaluated for their prognostic performance 





Table 1. Significant risk factors of dengue severity with potential clinical prognostic impact. 











sTNFR80b cut-off 1.6 ng/mL  DHF Children 2 days before 
fever abates 




Nisalak, Lew, et 
al., 1999) 
sTNF75 > 55pg/ml DSS Children: 
Median 6 yrs 
old 
4 days post 
symptom 
onset 
Vietnam 93 34 27 95 (Bethell et al., 
1998) 
sNS1 level ≥600 ng/mL DHF Children: 
Median 9.5 yrs 
old 
1-3 days post 
symptom 
onset 
Thailand 72 79 - - (Libraty, Young, 
et al., 2002) 
WBC count (≤8500), percent 
monocytes (≤9%), platelet count 
(≤160,200), and hematocrit achieved 
(≤40) 
DSS Children: 





Thailand 97 48   (Potts et al., 2010) 
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WBC count (<13700), percent 
neutrophils (>68%), AST (>50), 





99 44   
sTM (8.8-21.1ng/ml) DHF Adult: Median 
25 yrs old 
4 days post 
illness 
Mexico 94.1 98.6 - - (Del Moral-
Hernandez et al., 
2014) 
VEGF (281.4-1047pg/mL) 55.8 80 - - 
Dengue viral load ≥7.5 log RNA 
copies/ml 
DHF Adult: Median 
51 yrs old 
1 day before 
fever abates 
Taiwan - - 71 94 (W. K. Wang et 
al., 2006) 






Philippines 48.6 92.1 - - (Saito et al., 2004) 
UPCR cutoff 29mg/mmol DHF Adults: 




fever onset  
Singapore 76 77 - - (Vasanwala et al., 
2014) UPCR, WBC & platelet count, serum 
hematocrit and protein, bleeding 
92 80 - - 
Bleeding, lymphopenia, serum protein 
and urea (Cutoff P=-2.9) 
DHF Adults: 





Singapore 83 83.5 18 99 (V. J. Lee et al., 
2008) 
Cutoff P=-5.1 97.6 60.2 10 >99 
Independent Validation DHF Adults: Median 6 Singapore 94 17 16 94 (T. L. Thein, Leo, 
26 
 
Bleeding, lymphopenia, serum protein 
and urea (Cutoff P=-5.1) 




Lee, Sun, & Lye, 
2011) 
Bleeding, serum protein and urea 
(decision tree) 
DHF Adults: 





Singapore 100 46 7.5 100 (V. J. Lee, Lye, 
Sun, & Leo, 2009) 
Independent Validation 
Bleeding, serum protein and urea 
(decision tree) 
DHF Adults: 





Singapore 99 12 16 99 (T. L. Thein et al., 
2011) 
AST/ ALT DHF Adults: 





Singapore 50% 40% - - (L. K. Lee et al., 
2012) 











Singapore 78.2 80.2   (Tanner et al., 
2008) 
Any number of seven warning signs DHF Adults: 





Singapore 87 18 30 77 (T. L. Thein, Gan, 
et al., 2013) 
Validation in (Leo 
et al., 2013) 
Abdominal pain/ tenderness  29 73 17 85 
Persistent vomiting 6 93 16 82 
Hepatomegaly 1 99 20 81 
27 
 
Hematocrit rise and rapid platelet 
count drop 
9 92 17 83 
Clinical fluid accumulation 2 98 18 83 
Mucosal bleeding 42 88 31 93 
Lethargy 33 55 28 61 
Any number of seven warning signs Severe 
Dengue 
96 18 15 96 
Abdominal pain/ tenderness  21 72 9 87 
Persistent vomiting 8 93 18 85 
Hepatomegaly 0 99 6 84 
Hematocrit rise and rapid platelet 
count drop 
5 94 9 89 
Clinical fluid accumulation 2 98 16 87 
Mucosal bleeding 17 82 10 89 
Lethargy 34 56 17 76 
Creatinine (>140 mmol/L), free 
bilirubin (>18 umol/L), amylase 
(>220IU/L) and platelets 
(<45,000/mm3) 
Death/ ICU Adults: Mean 















1.6. SIGNIFICANCE OF THESIS 
 
         Based on the paradigm of disease progression as illustrated in Figure 5, there is a 
significant increase in disease burden and cost as the disease progresses from pre-clinical 
to the late clinical phase. This reinforces the importance of prevention, screening and early 
triage as the way forward to reduce disease burden due to dengue severity. Dengue 
severity can be defined as a spectrum of clinical manifestations from non-severe (i.e. DF, 
Dengue with or without warning signs) to severe classifications (i.e. DHF/DSS/Severe 
Dengue). Dengue severity can also be defined based on clinical interventions such as the 
requirement for strict observation in hospital based on the WHO 2009 recommendation 
and the requirement for intensive care unit admission. Much focus has been on looking at 
the risk factors of dengue severity among children in the past two decades as dengue was 
primarily a pediatric disease at the time.  
          As the epidemiology of dengue changes, there is an increasing trend of adults being 
affected by dengue, and there have been limited studies on the risk factors of dengue 
severity in adults, hence, the lack of simple but effective early predictors that can reliably 
predict dengue severity in adults at early phase of infection. In addition, these current risk 
factors may not be generalizable to all unique populations, and epidemics. Furthermore, 
most of the current studies were likely to be case series studies or univariate analyses, 
which provide less convincing evidence for causal inference. As a result, these may either 
lead to over-hospitalization, or under-prognosis, particularly in resource-limited settings.  
Both scenarios increase the public health burden and cost, which would be detrimental to 
the country’s economy overtime. Therefore, the discovery of risk factors may provide 
meaningful policies and guidance on dengue prevention, early screening and triaging of 
high risk patients who require appropriate clinical interventions. These findings may also 
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further provide insights into the development and management of clinical trial protocols, 
as well as distribution and usage strategy and recommendations of vaccine and anti-viral 






























Figure 5. Diagram of the course of dengue disease over time and the application 
of epidemiological, genetic, molecular and clinical risk factors to refine 
prediction risk of developing disease severity, for screening, diagnosis, prognosis 
and therapeutic selection. 
(Adapted from Translational Research 154/6, Ginsburg GS and Willard, Genomic and 
personalized medicine: foundations and applications, 277-286, Copyright 2009, with 

































































1.7. AIMS OF THESIS 
With the recent changing epidemiology of dengue disease, with increasingly more 
adults infected by dengue compared to a decade ago, it would be critical to understand the 
risk factors involved in the progression of dengue severity to guide prevention and control 
strategies, and to have effective triage tools to stratify these potentially, high risk patients 
at the early phase of infection. Triaging of dengue disease severity early and effectively 
allows the appropriate level of medical care and interventions such as resuscitative 
measures, fluid management, anti-viral (when available) and vaccine (when available, in 
the pre-infection phase to individuals susceptible to severe dengue) to be administered at 
an appropriate time point so as to reduce dengue progression. As such, the aims of the 
thesis are to explore clinical, genetic and molecular risk factors/biomarkers of dengue 
disease severity and to propose early prognostic models of adult dengue disease 
severity, ideally, simultaneously with dengue diagnosis for early and appropriate clinical 
management of adult patients.  
A total of four studies were performed to address the aims of the thesis, covering 
relevant risk factors from pre-infection, post-infection to pre-ICU admission (Figure 6). 
Study I is focused on unraveling the human genetic risk factors of dengue disease 
severity that predispose dengue patients to severe dengue disease. Study II is focused on 
unraveling the epidemiological risk factors that are associated with higher risk of severe 
dengue disease. As such, Study I and II aim to explore the baseline risk factors before 
dengue infection as well as at the primary care level to guide prevention and control 
measures against progression to severe disease (Figure 6). Study III is focused on 
unraveling molecular risk factors at early post-infection as potential early warning signs 
of severe disease progression. Study IV is focused on unraveling clinical and laboratory 
risk factors of dengue disease severity at earliest presentation to the hospital. Both Study 
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III and IV hence aim to explore early prognostic tools to guide clinicians in primary care 
(study III) and tertiary care (study IV) on stratifying patients who are likely to develop 
severe dengue disease for closer monitoring in hospital and appropriate clinical 






























































CHAPTER 2: METHODOLOGY 
 
2.1. THE INTEGRATIVE APPROACH WITH GENOMIC 
MEDICINE 
Disease progression and severity are mainly outcomes of the dysfunctional regulation 
and expression of genomic molecules, via complex and dynamic interactions, resulting in 
disruption of the steady-state of a host system. (Ginsburg & Willard, 2009). Genomic 
medicine, which is the use of information from genomes and their derivatives (RNA and 
proteins) to guide medical decision making—is a key component of stratified medicine, 
which is a rapidly advancing field of health care that is informed by each person’s unique 
family history, clinical, genetic, molecular, and environmental information. The 
fundamentals of genomic and stratified medicine will require the development, 
standardization, and integration of this important information into health systems and 
clinical workflows. With the advent of the next generation technologies, more novel 
genomic information could be derived, to enable a paradigm shift to a comprehensive 
approach that will redefine individual risks and guide clinical management and decision 
making. All of these could form the basis for a more informed and effective approach to 
patient care. Therefore, current research studies involving the integration of genetic, 
epidemiological, clinical, and molecular perspectives of dengue disease, could serve as the 








2.2. DENGUE DIAGNOSIS 
Dengue diagnosis was established by expert clinicians, following the World Health 
Organization (WHO) 1997 (WHO, 1997), 2009 (WHO, 2009) criteria or both, depending 
on the hypothesis of each study, unless stated otherwise in the specific study. Based on the 
WHO 1997 criteria, the diagnosis for dengue fever includes fever, laboratory diagnosis 
and any two of the following signs and symptoms: headache, retro-orbital pain, myalgia 
(muscle pain), arthralgia (bone or joint pain), rash, leukopenia, and haemorrhagic 
manifestations. Based on the WHO 2009 criteria, the diagnosis for dengue fever includes 
living in or travelling to dengue endemic areas, having fever and two of the following 
signs and symptoms: nausea or vomiting, rash, aches and pains, and leukopenia with 
laboratory- confirmed dengue test. The tourniquet test was not performed. Laboratory 
diagnosis of dengue virus infection was defined as either polymerase chain reaction (PCR) 
assay and/ or Dengue Duo IgM & IgG Rapid Strip Test (Panbio Diagnostic), unless 
specified otherwise in the respective studies. Different genetic backgrounds and exposures 
such as demographics, pre-existing clinical conditions and different dominant circulating 
virus serotypes may have different implications on disease severity of the host. As such, 










2.3. THE WHO 1997 AND 2009 CLASSIFICATIONS OF DENGUE 
INFECTION 
Based on the WHO 1997 classification, diagnosis of dengue haemorrhagic fever 
(DHF) was made on the basis of the four following characteristics: (i) high continuous 
fever lasting two to seven days, (ii) haemorrhagic manifestations, (iii) thrombocytopenia 
(<100×109/L) and (iv) evidence of plasma leakage (haematocrit change ≥20%, 
hypoproteinemia [serum protein <63 g/dL] or if signs of clinical fluid accumulation were 
present). For dengue shock syndrome (DSS), DHF cases required either (i) tachycardia 
(pulse >100/minute) with narrow pulse pressure (<20 mmHg) or (ii) hypotension for age 
(systolic blood pressure <90 mmHg).  
Based on the WHO 2009 classification, patients classified as dengue with warning 
signs had to have laboratory-confirmed dengue infection with one of the following: (i) 
abdominal pain/tenderness, (ii) persistent vomiting (≥2 consecutive days), (iii) clinical 
fluid accumulation (pleural effusion or ascites on examination or radiography), (iv) 
mucosal bleed, (v) liver enlargement, and (vi) increase in haematocrit concurrent with 
rapid decrease in platelet count (interpreted as any haematocrit ≥20% over baseline with 
platelet <50000/mm3). For severe dengue, the criteria were: for severe plasma leakage, 
either clinical fluid accumulation or evidence of plasma leakage (haematocrit change of 
≥20%) with at least one of tachycardia (pulse >100/minute), hypotension (systolic blood 
pressure <90 mmHg), or narrow pulse pressure (<20 mmHg);severe bleeding was defined 
as WHO Grade 2 or above: hematemesis, melena, menorrhagia or clinical drop in 
haemoglobin requiring whole blood or packed red cell transfusion; severe organ 
involvement comprised hepatic injury (aspartate [AST] or alanine transaminase [ALT] 
levels >1000 unit/L), renal impairment (Stage 2 Acute Kidney Injury (Mehta et al., 2007) 
40 
 
defined as serum creatinine increase of 100% over baseline or calculated norm for 


























2.4. METHODS FOR HUMAN GENETIC RISK FACTORS STUDY 
(CHAPTER 3) 
Patient enrollment and diagnosis. Blood samples for genotyping were collected from 
patients enrolled into either of two research studies of children with dengue. In both 
studies, children were eligible if ≤15 years of age and had clinical signs, symptoms and 
hematological findings that led to a clinical diagnosis of incipient or established DSS, as 
defined by WHO criteria. All patients were resuscitated with bolus intravenous fluid 
therapy (≥15 ml per kg body weight in the first hour). Summary laboratory and clinical 
findings were recorded into case record forms during the inpatient period until the patient 
was discharged from hospital, died or was transferred to another hospital. Blood samples 
for research and diagnostic tests were collected at the time of enrollment and again before 
patient discharge from hospital. The first study enrolled patients in the pediatric intensive 
care unit of the Hospital for Tropical Diseases (Ho Chi Minh City, Vietnam) between 
2001 and 2009. The second study enrolled patients in high dependency rooms or the 
intensive care departments of Children’s Hospital No. 1 and Children’s Hospital No. 2 (Ho 
Chi Minh City, Vietnam), Tien Giang Provincial Hospital (My Tho City, Vietnam), Dong 
Thap Provincial Hospital (Cao Lanh City, Vietnam) and Sa Dec Hospital (Sa Dec Town, 
Vietnam) between 2008 and 2010.  
 
The GWAS was performed on DNA samples (n = 1,039) from patients enrolled 
between 2001 and 2009 at the Hospital for Tropical Diseases and from patients (n = 969) 
enrolled at the other five participating hospitals during 2008 only. The replication study 
was performed in patients (n = 1,737) enrolled between 2009 and 2010 at Children’s 
Hospital No. 1, Children’s Hospital No. 2, Tien Giang Provincial Hospital, Dong Thap 
Provincial Hospital and Sa Dec Hospital. All patients represented in the GWAS and 
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replication phases had laboratory evidence of dengue, as shown by reverse transcription 
PCR detection of viral RNA in plasma collected at the time of enrollment and/or by 
serological detection of dengue-virus–reactive IgM or IgG in single or paired plasma 
specimens.  
 
Cord blood DNA samples. Blood from the cord of newborn infants was collected in 
one of two prospective studies. The first study was conducted at Hung Vuong Hospital 
(Ho Chi Minh City, Vietnam) between 2004 and 2006. The second study was conducted at 
Hung Vuong Hospital and Dong Thap Hospital between 2009 and 2010. All participants 
gave written informed consent to participate. The Scientific and Ethical Committees of 
each study site approved the study protocols, as did the Oxford University Tropical 
Research Ethical Committee. DNA was extracted from cord blood using Nucleon BACC 
Genomic DNA Extraction Kits (GE Healthcare, USA).  
 
The use of population controls. The number of potentially misclassified cord blood 
controls in the GWAS and replication stages was estimated to be 11 (out of 2,018) in the 
GWAS stage, and 15 (out of 2,394) in the replication stage, based on the following three 
assumptions that: a) all individuals in a given birth cohort will experience two sequential 
infections by different serotypes during their lifetime(Chau et al., 2009) b) that only up to 
25% of these infections are clinically apparent (Balmaseda et al., 2010; Endy et al., 2011; 
Endy et al., 2002; Porter et al., 2005; Tien et al., 2010), c) 2% of clinically apparent 
secondary infections develop DSS. These assumptions estimate a life-time population risk 
of DSS to be 0.5%. This is consistent with estimates of the prevalence of DSS cases 
expected over the first 15 years in a given birth cohort under the assumption that the 
incidence of DSS is constant (DSS incidence in Southern Viet Nam in 2009 was 
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26.59/100,000; based on statistics obtained from the Dengue Control program, Ministry of 
Health Viet Nam, 2010). Under this assumption we would expect 0.4% of a birth cohort to 
experience DSS before the age of 15yrs. 
 
Genotyping. Cases and controls were randomized on plates and were genotyped with 
Illumina Human 660W Quad BeadChips following manufacturer instructions. For the 
replication stage, 72 of the selected SNPs that were not on the broad MHC region were 
genotyped with the Sequenom MassArray primer extension iPLEX system. MICB 
rs3132468 and rs3134899 were genotyped using the Applied Biosystems TaqMan 
platform.  
 
Statistical analysis. Stringent quality control filters were applied to remove poorly 
performing SNPs and samples using tools implemented in PLINK (version 1.7) (Purcell et 
al., 2007). The quality control criteria were as follows: SNPs that had genotypes with more 
than 5% missing, showed gross departure from Hardy–Weinberg equilibrium (a departure 
of P < 10−7) or had a minor allele frequency below 1% were excluded from downstream 
analysis. For sample quality control, samples with an overall genotyping call rate of <95% 
were excluded from analysis. The remaining samples were then subjected to biological 
relationship verification by using the principle of variability in allele sharing according to 
the degree of relationship. Identity-by-state information was derived using PLINK (Purcell 
et al., 2007). For those pairs of individuals who showed evidence of cryptic relatedness 
(possibly owing to duplicated or biologically related samples), we removed the sample 
with the lower call rate before performing principal component analysis. Principal 
component analysis was undertaken to account for spurious associations resulting from 
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ancestral differences of individual SNPs (Price et al., 2006), and principal component plots 
were performed using the R statistical program package. 
 
For both the GWAS and replication stages, analysis of association with DSS was 
carried out using a 1 degree of freedom score-based test. This test models for a trend per 
copy of the minor allele on disease risk and has been extensively described (Purdue et al., 
2011; G. Thomas et al., 2009). It has the best statistical power to detect association for 
complex traits across a wide range of alternative hypotheses, with the exception of those 
involving rare recessive variants (Lettre, Lange, & Hirschhorn, 2007). The threshold for 
significant independent replication was set at P < 0.05 in the combined replication data 
sets.  
 
Meta-analysis was conducted using inverse variance weights for each cohort, which 
calculates an overall Z statistic, corresponding P value and accompanying ORs for each 
SNP analyzed (Asano et al., 2009; McGovern et al., 2010).Genotyping clusters were 
directly visualized for the 85 SNPs exceeding P < 10-4 and confirmed to be of good quality 
before inclusion for statistical analysis. Analysis of linkage disequilibrium was performed 
using Haploview (Barrett, Fry, Maller, & Daly, 2005). 
 
Statistical findings after routine GWAS analysis. Analysis of genetic ancestry 
using principal components revealed no significant population substructure between the 
DSS cases and controls. As the individual principal components were non-significant 
(Bonferroni corrected P > 0.05) when tested as continuous covariates using logistic 
regression, we did not adjust for them in subsequent association analysis. Single SNP 
analysis was performed using logistic regression assuming additive genetic effects relating 
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genotype dosage (scoring for 0, 1 or 2 copies of the minor allele) to DSS. A quantile–
quantile plot of the single SNP analysis showed a clear excess of extreme P values 
compared to the null distribution. As this excess was observed against a background of 
minimal genome-wide inflation of test statistics (λgc = 1.024), it excludes the possibility 
of substantial population substructure and differential genotyping call rate between cases 
and controls as a reason for the excess. Instead, this suggests that at least some of these 
extreme P values (P < 1 × 10−4) may represent true genetic associations with DSS.  
 
Overall, we genotyped 2,118 DNA samples from Vietnamese children with 
established or incipient DSS and 2,089 cord blood controls in a genome-wide association 
study (GWAS). After exclusion of samples for discrepancies between clinical and 
genetically inferred gender, relatedness or for per-sample call rates of less than 95 percent, 
there were 2,008 DSS cases and 2,018 controls available for analysis. The clinical and 
virological characteristics of the case population were also described. A total of 657,366 
SNPs were initially included within the Illumina 660W Beadchip used for genome-wide 
genotyping. After various stringent QC exclusions, which include removal of CNV SNPs, 
SNPs with minor allele frequency (MAF) less than 1%, call rate less than 95%, non-
autosomal SNPs, SNPs with intensity only, a total of 481,342 SNPs were retained for 
downstream association analysis. We were able to design assays for 72 out of these 85 
SNPs using the Sequenom Mass-Array platform. The remaining 13 SNPs in the broad 
MHC region were refractory to assay design, thus necessitating ABI Taqman assays to be 
designed for the sentinel SNP at MICB (rs3132468) and rs3134899 (also within MICB; 
GWAS P = 1.03 x 10-4, OR = 1.31). We then genotyped these 74 SNPs (72 non-MHC 
SNPs and two SNPs within MICB) in a replication sample of 1,824 DSS cases and 3,019 
controls. We applied the same GWAS QC filters for the replication set: five SNPs had 
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poor genotyping clusters and were excluded from analysis, and 132 samples (87 cases and 
85 controls) had per-sample call-rates of less than 95 percent; these were excluded from 
























2.5. METHODS FOR EPIDEMIOLOGICAL RISK FACTORS 
STUDY (CHAPTER 4) 
 
Patient source and diagnosis. A retrospective case-control study was conducted 
using data collected from all adult dengue patients admitted from 1 January 2006 to 31 
December 2008 to the Department of Infectious Diseases at Tan Tock Seng Hospital 
(TTSH). In this hospital, which treats the most dengue patients in Singapore, dengue 
patients are managed using a standardized dengue care path. The extracted data was de-
identified in analysis. Probable dengue patients had positive acute dengue serology, as 
measured by Dengue Duo IgM & IgG Rapid Strip Test (Panbio Diagnostic, Queensland, 
Australia) (Blacksell et al., 2006; Cuzzubbo et al., 2001), and clinical diagnostic criteria of 
dengue fever by WHO 1997. The IgG test line for this Rapid Strip Test is set to detect the 
high levels of IgG characteristic of secondary virus infection, and has been validated to 
detect acute secondary infection (Cuzzubbo et al., 2001). Confirmed dengue patients had 
positive dengue polymerase chain reaction (PCR) assay (Barkham, Chung, Tang, & Ooi, 
2006) and clinical diagnostic criteria according to WHO 1997.  
 
Case-control groups and data extracted. Patients with outcome diagnosed as 
DHF and DF were classified as the case group and control group respectively. In order to 
compare the demographic and co-morbidity profiles between DHF and DF patients, data 
were extracted from chart review. Demographic data extracted were age, gender and 
ethnicity. Co-morbidities data extracted were diabetes mellitus, hypertension, asthma, 
hyperlipidaemia, stroke, chronic obstructive pulmonary disease, corticosteroid use and 
HIV/AIDS. However, stroke, chronic obstructive pulmonary disease, corticosteroid use 
and HIV/AIDS were not included in the analysis because these co-morbidities were either 
48 
 
not reported or reported by very few cases (DHF) or controls (DF). Patients with diabetes 
mellitus tend to have other co-morbidities, and the risk effect of diabetes mellitus with an 
additional co-morbidity on DHF outcome was also investigated.   
 
Statistical analysis. For descriptive analysis, Pearson’s chi-square and Fisher’s 
exact tests were used to compare categorical variables, and Mann-Whitney U test was 
used to compare continuous variables with non-normal distribution. Univariate and 
multivariate logistic regression were used to calculate crude and adjusted odds ratios 
(COR, AOR), respectively, and their 95% confidence intervals (CI) were used to assess 
the association of the variables with DHF. Confounding effects were minimized by 
performing multivariate logistic regression adjusting for potential confounders identified 
in the descriptive analysis. These potential confounders are exposures that were found to 
be statistically different (p<0.05) between DHF and DF patients and the model that fits 
best in the multivariate regression was then identified using the likelihood-ratio test. In 
Singapore, dengue infections were predominantly due to dengue serotype 1 (detected in 
75% to 100% of dengue samples collected each month) during the epidemic in the year 
2006, and dengue serotype 2 (detected in up to 91% of dengue samples) during the 
epidemic in the year 2007 and 2008 (K. S. Lee et al., 2010). Given that different dengue 
serotypes may cause different disease severity (Fried et al., 2010), the data from year 2006 
and the data from year 2007 to 2008 were analyzed separately to minimize any possible 
confounding effect due to different predominant dengue serotypes, since information on 
the dengue serotype was not available for individual infections. Stratified analyses using 
logistic regression were performed to evaluate the presence of effect modification between 
diabetes mellitus and other co-morbidities on the risk of DHF outcome. There is at least 
70% power of detecting a significant (P<0.05) odds ratio of 1.3 with a sample size of 400 
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DHF and 400 DF. Correction for multiple comparisons was not performed as each of the 
variables of interest was tested independently, instead of simultaneously. There was no a 
priori analytical plan to adjust for risk factors associated with DHF in previous studies, 
unless it was also shown to be significantly different in the univariate analysis in this 
study. All statistical analyses were performed using Stata 10.0 (Stata Corp., College 
Station, TX, 2005). All tests were conducted at the 5% level of significance, with OR, P-










































2.6. METHODS FOR MOLECULAR RISK FACTORS STUDY 
(CHAPTER 5) 
 
Patient enrolment and sample collection. The early dengue infection and control 
study (EDEN) was launched in April 2005 and has been described in previously published 
articles (Low et al., 2006; Tanner et al., 2008; Tolfvenstam et al., 2011). Patients fulfilling 
the inclusion criteria (18 years of age or older; within 72 hrs from acute onset of fever of 
38oC or above and; no clinically obvious alternative diagnosis to fever) presenting at any 
of the participating primary care polyclinics were eligible for enrolment. Enrolment of 
study participants was conditional on appropriate informed consent administered by a 
study research nurse. A standardized case report form (CRF) was used for collecting 
clinical data. Additionally, venous blood for hematological and molecular analyses was 
collected. Clinical data and samples were obtained at time of inclusion (within 72 hrs post 
fever onset), at time of defervescence (4-7 days post fever onset) and finally at time of 
convalescence (3-4 weeks post fever onset).  The clinical data for hospitalized patients 
were obtained from the electronic medical records. No study criteria for hospitalization 
were specified with the decision to admit left to the discretion of the attending physician. 
The training cohort consists of samples collected from patients enrolled from year 2005 to 
2008 while the validation cohort consists of samples collected from patients enrolled from 
year 2009 to 2012. 
 
Patient classification criteria. In 2009, WHO published new guidelines for the 
management of patients with acute dengue infection. These are based on clinical signs and 
symptoms, and divides patients into “probably dengue”, “dengue with warning signs” and 
“severe dengue”. The warning signs stated in the guidelines are; abdominal pain or 
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tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleed, lethargy, 
restlessness, persistent vomiting, liver enlargement >2cm and increase in HCT concurrent 
with rapid decrease in platelet account. Severe dengue was defined by severe plasma 
leakage, internal bleeding and/or severe organ impairment (WHO, 2009). In the EDEN 
study, only three warning signs were recorded during the study period and hence, can only 
be evaluated in our study setting. They are abdominal pain, mucosal bleeding and 
persistent vomiting. Patients were classified as having “persistent vomiting” either when 
they report vomiting at both the first and second study clinic visit, or at the second visit 
and at time of hospitalization. Patients who had at least one of these warning signs were 
classified with a more marked dengue disease and referred to as “patients with warning 
signs”, whereas, patients who did not present any of these warning signs in all three study 
clinic visits are referred to as “patients without warning signs”.   
  
Hospital admission criteria. The decision to hospitalize a patient was left to the 
discretion of the treating physician. However, national guidelines on dengue management 
are available and are adopted by the healthcare institutions in Singapore. Hospitalization 
criteria in these guidelines include: significant bleeding, fall in blood pressure, dehydration 
and postural hypotension, rise in haematocrit of 20% or greater compared to the baseline, 
platelet count <80,000 cells/mm3, severe vomiting or diarrhoea, severe abdominal pain, 
and elderly patients with co-morbidities who are unwell. 
 
Hematology. A full blood count was performed on anticoagulated whole blood 
collected at all three time points. A bench-top, FDA-approved hematocytometer was used 
for this application (iPoch-100, Sysmex, Japan). Calibration by internal and external QC 




RNA extraction. RNA was extracted using QIAamp Viral RNA mini kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s protocol.   
 
Viral detection and quantification. Dengue virus RNA detection was carried out by 
PCR using a set of generic pan-dengue primers that targeted the 3’ non-coding region of 
dengue viruses as previously described (Lai et al., 2007). Results were analyzed with the 
LightCycler software version 3.5. Reactions with high crossover threshold (Ct) value or 
ambiguous melting curve results were further analyzed by electrophoresis on a 2% agarose 
gel, to confirm the presence of the correctly sized amplicon. Quantification of viremia was 
performed by a Taqman based PCR using earlier published primers and probes detecting 
DENV 1-4 (Ito et al., 2004). Standard ABI conditions were used, incorporating primers at 
900nM and probes at 50nM.  
 
Serology. IgM and IgG antibodies against dengue virus were detected using 
commercially available ELISAs (PanBio, Brisbane, Australia) according to 
manufacturer’s instructions.   
 
Microarray. Total RNA (500ng) was amplified in a single-round of IVT amplification 
that allowed incorporation of Biotin-labeled nucleotides using the Illumina® TotalPrep™ 
RNA Amplification Kit (Ambion, Inc., Austin, TX) according to the manufacturer’s 
instructions. cRNA (850ng) of each sample was hybridized to an Illumina HumanRef-8 
V3.0 BeadChip (containing probes to approximately 24,500 transcripts) at 55 °C for 18 
hrs following the manufacturer’s instructions (Illumina, Inc., San Diego, CA). This was 
followed by washing, blocking, and streptavadin-Cy3 staining steps and finally by 
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scanning with a high resolution Illumina Bead Array Reader confocal scanner, all carried 
out following manufacturer’s instructions (Illumina, Inc., San Diego, CA).  Data 
extraction was performed using Illumina Bead Studio software.  
 
Microarray normalization and gene selection. The detection p-value was calculated 
by Beadstudio software (Illumina). Standard normalization procedures (GenespringGX 
software; version10.0; Silicon Genetics) for one color array data were used. In brief, array 
(mean) normalization accounted for chip variability was performed by dividing all of the 
measurements on each chip by a 75th percentile value. After normalization, the data was 
filtered according to flags present there at least 75% of the samples in any 1 of the 2 
conditions had flags present leaving 6844 genes for further analyzes. Significance 
Analysis of Microarray (SAM) was used to detect transcripts that were relatively more or 
less abundant in one group of samples. SAM also corrected significance values for 
multiple testing using a false discovery rate threshold of 5%. False discovery rate of less 
than 5 percent and fold difference of at least 1.5 fold were used to identify the significant 
genes. Pathway analysis was done using Ingenuity Pathway Analysis software (version 
7.5; Ingenuity Systems).  
 
Measurement of RNA expression using Fluidigm technology. In order to develop a 
potential point-of-care device, a simple PCR based technology should be applied instead 
of using a microarray based technology to reduce cost and processing time. Fluidigm 
platform was used. The required amount of RNA is 500ng/10ul per reaction. The protocols 
were according to the manufacturer’s recommended instructions. Briefly, cDNA is 
synthesized through reverse transcription using MultiScribe reverse transcriptase with the 
following program: 25 ◦C for 10 min, 37 ◦C for 120 min, 85◦C for 5 min and 4◦C for 
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30min. This is followed by pooling of Taqman assays and preamplification reaction with 
the following program: 95 for 10min, and 14 ◦C cycles of 95◦C for 15sec and 60◦C for 4 
min. Lastly, this is followed on with final amplification using the BioMark and the 48.48 
dynamic array as instructed in the manufacturer’s instructions. The signal of the gene 
expression was normalised by 18S rRNA expression. The expression level and quality 
control checks were determined using the BioMark Real-Time PCR Analysis Software. 
 
Statistical analyses of demographics and haematological parameters.Group 
comparisons were performed by a Mann Whitney U test, for viremia, lymphocyte counts, 
platelet levels, age and a Chi-square test for gender. Two tailed tests were used and a P-
value of < 0.05 was considered as statistically significant. All statistical analyses were 
performed using Stata 10.0 (Stata Corp., College Station, TX, 2005).  
 
Protein measurements.Serum samples collected at three time points (within 72 hours 
post fever onset, day 4-7 and three to four weeks post fever onset) were assayed for 22 
cytokines and chemokines related to inflammation and immune response based on 
published and unpublished data using a luminex bead array approach (Bioplex) (BioRad 
Carlsbad, CA) according to the manufacturer’s protocol. Quantitative sandwich enzyme-
linked immunosorbent assays (ELISA) were used to measure fibrinogen (Immunology 
Consultants Laboratory Inc, Newberg, OR), urokinase plasminogen activator receptor 
(uPAR) as well as IP-10 (R&D Systems, Minneapolis, MN). The assay from R&D 
Systems was needed as a significant number of serum samples from dengue patients had 
concentration of IP-10 above the detection range of the Bioplex system. All assays were 




Statistical analysis of protein expression. Two-sample t test for independent samples 
were used to compare the means of protein levels in the serum between the patient groups. 
For proteins expression with unequal variance, two-sample t test for independent samples 
with unequal variance was used. Two-tailed P value of <0.05 were considered statistically 
significant.  
 
Biomarkers Selection and Prognostic Model Development. RNA and proteins that 
were statistically significant (P<0.05) between the two groups within 72 hrs (Day1-3) 
were chosen for the model development. Each RNA and protein was assessed as a 
potential single biomarker model based on the area under the curve (AUC) from the 
receiver operating characteristic curve (ROC) analysis. In addition, Hosmer-Lemeshow 
Goodness-Of-Fit (GOF) test was used to assess whether the model provides a good fit to 
the training data. These single biomarker models were then ranked according to their 
stratification performance based on the AUC analysis and the GOF test. Forward stepwise 
and backward elimination estimation using multiple logistic regressions, AUC analyses 
and GOF test were performed using the top 10 RNA and protein single biomarker models 
to determine the optimal multi-biomarkers (RNA only, proteins only and combination of 
RNA and proteins) model for stratification of patients with warning signs that require 
hospitalization from patients without warning signs and do not require hospitalization. 
Likelihood ratio test was performed to evaluate if a model with N variables is as good fit 
as a model with N+1 variables to achieve a more parsimonious model, and to compare the 
AUC of RNA-Protein model against that of the viral load AUC, lymphocyte AUC and 





2.7. METHODS FOR CLINICAL AND LABORATORY RISK 
FACTORS STUDY (CHAPTER 6) 
 
Patient source and study design. A retrospective matched case-control study was 
conducted using anonymized data collected from all adult dengue patients admitted into 
intensive care unit (ICU) from 1 January 2004 to 31 December 2008 to the Department of 
Infectious Diseases at Tan Tock Seng Hospital (TTSH), where dengue patients were 
managed using a standardized dengue care path. In Singapore, dengue infections were 
predominantly due to dengue serotype 1 (detected in 75% to 100% of dengue samples 
collected each month) during the epidemics in the year 2004 to 2006, and dengue serotype 
2 (detected in up to 91% of dengue samples) during the epidemic in the year 2007 and 
2008 (K. S. Lee et al., 2010). Each case who was admitted into ICU was randomly 
matched to four patients who did not require intensive care by the year of dengue 
presentation as controls. Dengue-confirmed patients with positive dengue polymerase 
chain reaction (PCR) assay, and probable dengue patients with positive dengue 
immunoglobulin-M (IgM) or immunoglobulin-G (IgG) (Dengue Duo IgM & IgG Rapid 
Strip, Panbio Diagnostic, Queensland, Australia) and fulfilling either the WHO 1997 or 
2009 probable dengue criteria, were included in this study.  
 
 Data extraction. The following data at first presentation in hospital and 24 hours 
prior to ICU admission were obtained from medical records: demographic, 
epidemiological, co-morbidity, clinical, laboratory, treatment and outcome data. The 
severity of the patients as evaluated by the WHO 1997 and 2009 classifications was 
determined at first presentation and during hospitalisation. The duration of progression to 
‘DHF’ or ‘severe dengue’ was determined only for patients who were either classified as 
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‘DF’ or ‘probable dengue with/without warning signs’ at first presentation. The number of 
days post presentation (DPP) was used to define the period since the first presentation in 
hospital. The number of days post fever (DPF) was used to define the period since the day 
of fever onset. 
 
 Statistical analysis. Univariate and multivariate conditional logistic regression 
were performed to assess the association between the variables and dengue severity as 
defined by ICU admission. Conditional logistic regression was used to account for the 
matching factor selected in the analyses (Sedgwick, 2012). Matching was performed based 
on the year of presentation to control for potential confounding by the predominant 
serotype in each year. Any potential confounding effects were further minimized by 
performing multivariate conditional logistic regression adjusting for significant 
demographic & co-morbidity factors associated with ICU admission only. This 
parsimonious approach would minimize overloading the multivariable model to achieve 
higher statistical power to detect true association as the sample size available was small 
(Sedgwick, 2010, 2013). The laboratory variables were analyzed in the continuous format 
to maximize all the data available, and to minimize reporting bias when the variables were 
categorized into the expected normal or hypothetical range. For analysis of risk factors 24 
hour prior to ICU admission, four ICU patients were excluded as they were admitted into 
ICU less than 24 hour post presentation to hospital. The most optimal predictive model 
was derived using the stepwise forward and backward elimination method, with the top 10 
most significantly associated variables based on the P-value of the univariate conditional 
regression analyses. Only variables with P-value <0.05 would remain in the optimal model 
during the model development. Hosmer–Lemeshow Goodness of fit test was used to check 
if the model fit the observed dataset with P >0.05. Likelihood ratio test was used to assess 
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if a model is more efficient than the other similar model with more significant variables. 
Fisher’s exact test and Wilcoxon rank-sum test were used for categorical and continuous 
variables, respectively, for the subgroup analysis of death cases in ICU group. All 
statistical analyses were performed using Stata 10.0 (Stata Corp., College Station, TX, 
2005). All tests were conducted at the 5% level of significance, with conditional odds ratio 

















































2.8. METHODS FOR THE POTENTIAL PUBLIC HEALTH 
IMPACT OF RISK FACTORS ASSOCIATED WITH ADULT 
DENGUE SEVERITY (CHAPTER 7) 
Epidemiological risk factors. Using the epidemiological risk factors identified in 
Chapter 4, which includes age range from 30-49, Chinese, female and having diabetes as 
individual risk factors of DHF, a discrete and weighted screening/triage risk score was 
computed for about 2600 laboratory confirmed dengue patients upon first presentation to 
the clinicians in Singapore. A discrete score was computed based on whether each of the 
four risk factors is present for each dengue patient upon presentation, up to a total score of 
four. The sensitivity, specificity, negative predictive value (NPV) and positive predictive 
value (PPV) was calculated for each risk score of one, two and three of predicting whether 
the patient is at high risk of developing DHF. The weighted risk score was computed using 
the logistic regression coefficients of each these epidemiological risk factors, and the score 
can range from 0 to 21.The score cut-offs used for assessing the sensitivity, specificity, 
NPV and PPV for predicting DHF outcome were greater than zero, greater than three, 
greater than six, greater than nine and greater than 12, with dengue patients having scores 
greater than the respective cut-offs were predicted at higher risk of DHF outcome. 
𝐷𝐻𝐹 𝑂𝑢𝑡𝑐𝑜𝑚𝑒
= 0.6(𝐷𝑖𝑎𝑏𝑒𝑡𝑒𝑠) + 0.45(𝐹𝑒𝑚𝑎𝑙𝑒) + 0.34(𝐴𝑔𝑒30 − 39)
+ 0.3(𝐴𝑔𝑒40 − 49) − 0.09(𝐴𝑔𝑒50 − 59) + 0.16(𝐴𝑔𝑒 > 60)




Genetic risk factors. The top genetic locus at MICB (rs3132468) that is associated 
with DSS (Khor et al., 2011) and non-DSS cases (Whitehorn et al., 2013) in Vietnam were 
used to assess its sensitivity, specificity, PPV and NPV using a Singapore cohort of about 
1017 Chinese dengue adult cases to evaluate the prognostic performance of the genetic 
loci rs3132468 to predict DHF outcome. The genetic marker of rs3132468 was genotyped 
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CHAPTER 3: HUMAN GENETIC RISK FACTORS OF 
DENGUE DISEASE SEVERITY 
 
3.1. INTRODUCTION. 
As highlighted in Chapter 1, dengue disease results in a wide spectrum of disease 
manifestations ranging from subclinical infection to severe and fatal disease. Severe 
dengue, most commonly found in children, is characterized by an increase in vascular 
permeability that leads to life-threatening hypovolemic shock (dengue shock syndrome-
DSS). This is often accompanied by thrombocytopenia and haemostatic dysfunction, 
which may result in severe bleeding. Although children are at greatest risk of developing 
DSS, with careful supportive care the case fatality rate is less than 1% (Anders et al., 
2011). In southern Vietnam, serological studies have estimated the population based 
exposure to dengue virus infection to reach 85% by the end of childhood (15 years old) 
(Thai et al., 2005),  while the incidence of DSS is estimated to occur at less than 1% of 
exposed individuals (Anders et al., 2011)(see “The use of population controls” in the 
Methods section). A host genetic basis to susceptibility to severe dengue has been alluded 
to in epidemiological studies, and various candidate gene studies of modest sample sizes 
have only been performed(Loke et al., 2002; Loke et al., 2001; Sakuntabhai et al., 2005; 
Stephens et al., 2002; Vejbaesya et al., 2009). Therefore, there is a critical lack of a well-
powered assessment of the whole genome that aims to determine the genetic risk factors 


































(Publication 1: Khor CC, Chau TN, Pang J, Davila S. et. al. Genome-wide association 
study identifies susceptibility loci for dengue shock syndrome at MICB and 
PLCE1.Nat. Genet. 2011. 43(11):1139-1141.) 
(Publication 2: Whitehorn J, Chau TNB, Nguyet NM, Kien DTH, Quyen NTH, Trung DT, 
Pang J et al. Genetic variants of MICB and PLCE1 and association with non-severe 
dengue.PLoS ONE 2013 8(3):e59067.) 
 
Susceptibility loci for dengue shock syndrome at MICB and PLCE1  
 
Upon conducting the routine GWAS statistical tests (see Statistical findings in the 
Methods section), detailed examination of the overall scan results revealed strong 
evidence of disease association at two distinct loci; (Figure 7) MICB on Chromosome 6 
and PLCE1 on Chromosome 10, both represented by SNPs which were close to the formal 
threshold for genome-wide significance (PGWAS = 5.38 x 10
-8 for MICB rs3132468 and 
PGWAS = 5.84 x 10
-8 for PLCE1 rs3740360) (Table 2). Together with the SNPs at MICB 
and PLCE1, a total of 85 SNPs exceeded PGWAS< 10
-4 on single SNP analysis and were 
extended for replication phase with an independent cohort. In keeping with the GWAS 
observations, the strongest evidence of association in the replication phase was observed 
with SNPs at MICB (rs3132468, Prepl = 9.32 x 10
-5 and rs3134899, Prepl= 0.0082) and 
PLCE1 (3 SNPs with Prepl ranging from 5.23 x 10
-4 to 1.6 x 10-4, Table 1). Using inverse-
variance weights, data from both the GWAS and replication cohorts (N = 3,745 DSS cases 
and N = 4,952 controls) were combined in formal meta-analysis, and this revealed strong 
evidence of association with rs3132468 at MICB (Pmeta = 4.41 x 10
-11; per-allele odds ratio 
(OR) = 1.34, [1.23 - 1.46]) and 7 SNPs at PLCE1 (4.18 x 10-9 ≤ Pmeta ≤ 3.08 x 10-10; 0.75 ≤ 
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OR ≤ 0.87, Table 2). To aid in refining the original signal of association, we performed 
imputation analysis at regions flanking both loci (Chr. 6: 30 - 32 Mb, and Chr. 10: 95.5 - 
96.5 Mb). This did not reveal signals of association over and above that of the directly 
genotyped SNPs. The associations observed at MICB and PLCE1 were not specific to any 
Dengue virus serotype on subgroup analysis of viral serotype, nor were they associated 






























Figure 7. Manhattan plot showing directly genotyped SNPs plotted according to 
chromosomal location (x axis), with –log10 P values (y axis) derived from the 1-
degree-of- freedom score test. 















Gene/Marker  Chromosome Stage MAF MAF OR P ORmeta Pmeta 
(Alleles) (Position)    Cases  Controls     (95% CI)   
MICB/rs3132468 6 GWAS 0.176 0.132 1.41 5.39 x 10-8   
(C/T) 31583465 Replication 0.163 0.134 1.27 9.32 x 10-5 1.34 (1.23 - 1.46) 4.41 x 10-11 
MICB/rs3134899 6 GWAS 0.130 0.102 1.31 1.09 x 10-4   
(G/A) 31581265 Replication 0.114 0.096 1.20 0.0082 1.26 (1.14 - 1.38) 4.08 x 10-6 
PLCE1/rs3765524 10 GWAS 0.249 0.300 0.77 2.68 x 10-7   
(T/C) 96048288 Replication 0.265 0.302 0.83 1.60 x 10-4 0.80 (0.75 - 0.86) 3.08 x 10-10 
PLCE1/rs2274223 10 GWAS 0.250 0.303 0.77 1.19 x 10-7   
(G/A) 96056331 Replication 0.267 0.300 0.85 5.23 x 10-4 0.81 (0.75 - 0.86) 6.89 x 10-10 
PLCE1/rs3740360 10 GWAS 0.219 0.271 0.75 5.84 x 10-8   
(C/A) 96015481 Replication 0.242 0.273 0.85 0.0012 0.80 (0.75 - 0.86) 1.15 x 10-9 
PLCE1/rs12263737 10 GWAS 0.250 0.301 0.77 3.73 x 10-7   
(A/G) 96034903 Replication 0.266 0.300 0.84 3.95 x 10-4 0.81 (0.75 - 0.87) 1.22 x 10-9 
PLCE1/rs11187842 10 GWAS 0.219 0.269 0.76 1.19 x 10-7   
(T/C) 96042501 Replication 0.240 0.271 0.85 0.0011 0.80 (0.75 - 0.86) 1.78 x 10-9 
PLCE1/rs753724 10 GWAS 0.219 0.269 0.76 1.28 x 10-7   
(T/G) 96041407 Replication 0.242 0.272 0.85 0.0012 0.81 (0.75 - 0.86) 2.27 x 10-9 
PLCE1/rs3781264 10 GWAS 0.229 0.278 0.77 3.43 x 10-7   
(G/A) 96060365 Replication 0.250 0.280 0.85 0.0011 0.81 (0.76 - 0.87) 4.18 x 10-9 
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Found within the broad Major Histocompatibility (MHC) locus, MICB lies just outside 
both the type I and type II HLA regions, ~140,000 base-pairs centromeric to the nearest 
Class I gene (HLA-B) and more than 1 million base-pairs away from the nearest Class II 
gene (HLA-DR). Apart from the peak signal at rs3132468 which was observed directly 
within MICB, twelve other SNPs in this region also showed association signals exceeding 
P < 10-4 on single-SNP analysis. We thus performed conditional analysis to assess the 
independence of the association observed at MICB rs3132468 from that of the nearby 
genes.  
Although the most significant SNP from the GWAS (rs3132468) could account for the 
majority of the association signal across the locus, we observed residual signals of 
association (0.0003 < P < 0.05) with SNPs near the vicinity of HLA-B and HLA-C as well 
as other neighboring genes. These residual associations indicate that definitive 
identification of MICB as a gene associated with DSS could be complicated by its location 
within the broad MHC region, which is known for its extensive linkage disequilibrium 
(LD) spanning multiple genes. This precludes definitive identification of the causative 
gene without extensive further fine-mapping and re-sequencing.  
With regards to PLCE1 on Chromosome 10, association analysis conditioning for the 
lead SNP (rs3743060, directly genotyped) did not reveal any secondary signals of 
association, which suggests that the lead SNP -or any of its close correlates in complete 
LD with it and confined within their distinct genomic region- best explains the association 
signal at the locus. We did not observe any evidence of epistasis between SNPs at MICB 








Genetic variants of MICB and PLCE1 and associations with non-severe dengue. 
 
Pooled analysis of genotype data from the pediatric patient cohorts revealed that 
non-DSS dengue cases were significantly more likely to carry the MICB risk allele 
rs3132468 than controls (per-allele odds ratio (OR) = 1.16; 95%CI: 1.07 – 1.25). Pooled 
analysis of cohorts of adult non-DSS dengue cases revealed a similar pattern of effect with 
the MICB risk allele, but this did not reach statistical significance (OR = 1.10, P = 0.11; 
Figure 8). However, a pooled analysis of all pediatric and adult patient cohorts indicated a 
significant association (OR = 1.15, P = 0.0014; Figure 8) compared to controls, with no 
heterogeneity between children and adults (Phet = 0.19). In the relatively small number of 
adult and pediatric DSS cases (N = 297), we were able to confirm the association and 
effect size reported in our previous GWAS (OR = 1.42, P = 0.0014; Figure 8). We 
observed significant association between PLCE1 risk allele rs3740360 with non-DSS 
cases upon pooled analysis of all adults and children (OR = 0.92, P = 0.018; Figure 8). 
Amongst DSS cases, the association at PLCE1 revealed by the previous GWAS was also 
confirmed (OR = 0.77: P = 0.0094). 
 
Since each of the infant cohorts was relatively small in their own right, a meta-
analysis was performed. Consistent with the findings in older children, this pooled 
analysis revealed a significant association between dengue in infants and MICB rs3132468 
(OR = 1.48; P = 0.0075), as well as PLCE1 rs3740360. (OR = 0.75, P = 0.041) (Figures 8 
and 9). Although the infant cohorts included 16 cases of DSS, removal of these samples 






Figure 8. Forest plot illustrating the association between MICB rs3132468 and 




Figure 9. Forest plot illustrating the association between PLCE1 rs3740360 and 





































3.3. DISCUSSION AND CONCLUSION 
MICB appears to be a promising candidate based on the present strength of the 
statistical associations observed in the Chromosome 6 hit region. MICB encodes for MHC 
class I polypeptide-related sequence B, an inducible activating ligand for the NKG2D type 
II receptor on natural killer (NK) and CD8+ T cells (S. Gonzalez, Lopez-Soto, Suarez-
Alvarez, Lopez-Vazquez, & Lopez-Larrea, 2008; Steinle et al., 2001). Ligation of NKG2D 
by MICB stimulates anti-viral effector functions in NK cells including cytokine expression 
and the cytolytic response (Garrity, Call, Feng, & Wucherpfennig, 2005).  We have 
previously reported that MICB, together with other genes associated with NK cell 
activation, are highly expressed in the leukocytes of acute dengue patients (Hoang et al., 
2010). We therefore propose the association between the MICB rs3132468 genotype and 
susceptibility to severe dengue might reflect altered or dysfunctional NK and/or CD8+ T 
cell activation early in infection that results in a higher viral burden in vivo, a recognized 
factor in clinical outcome (Libraty, Endy, et al., 2002; Vaughn et al., 2000). The recent 
finding that a SNP near the closely related MICA gene (rs2596542) is associated with 
Hepatitis C virus induced hepatocellular carcinoma is suggestive of a pivotal role for MIC 
proteins in the pathogenesis of these Flaviviridae infections (V. Kumar et al., 2011). 
 
Mutations within PLCE1 are associated with nephrotic syndrome(Hinkes et al., 2006). 
Nephrotic syndrome is a kidney disorder in which dysfunction of the glomeruli basement 
membrane results in proteinuria and hypoproteinemia that when severe leads to reduced 
vascular oncotic pressure and edema. These elements of nephrotic syndrome have striking 
similarities with severe dengue and suggest an important role for PLCE1 in maintaining 
normal vascular endothelial cell barrier function. In addition, mutations within PLCE1 are 
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associated with cancer such as colorectal (Duan et al., 2014), esophageal (Cui et al., 2013), 
and gastrointestinal cancer (Hao et al., 2013), which suggested that the progression of DSS 
may involve similar mechanism as the progression of cancers. However, future studies 
would be required to determine the association between DSS and cancer.  
 
Significant associations were observed between MICB rs3132468 and PLCE1 
rs3740360 and both clinical phenotypes of non-DSS and DSS. In addition, we observed 
association between both SNP genotypes and infants with non-DSS dengue at effect sizes 
comparable to that seen with children DSS in the GWAS study. Finally, amongst children 
and adults with DSS in a separate cohort, we were able to confirm association of MICB 
rs3132468 and PLCE1 rs3740360 that was first observed in the previous GWAS. The 
association of the MICB rs3132468 genotype with DSS and non-DSS indicates a role for 
this variant in susceptibility to overall clinically apparent dengue and not just severe 
disease. The effect size between the PLCE1 rs3740360 risk genotype and non-DSS was 
less pronounced than that observed for DSS cases. In light of the observed association 
with PLCE1 and nephrotic syndrome it is interesting that the degree of proteinuria has 
been proposed as a potential predictor in determining which dengue patients are at risk of 
developing more severe disease (Vasanwala et al., 2011; Vasanwala et al., 2014). 
Recently, the association of these SNPs was also replicated in children dengue patients in 
Thailand (Dang et al., 2014) . 
 
The association between MICB rs3132468 and dengue in infants, with effect sizes in 
keeping with that observed in DSS patients reflects a prominent role for innate immunity 
and particularly NK cells in controlling early viral infection in infants; impaired control of 
viral replication could be a risk factor for clinically apparent dengue in this age group. 
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This is further supported by the elevation of soluble MICB during acute primary DENV 
infections in infants, as a potential immune evasion strategy that may have contributed to 
the severity of the acute illness (Libraty, Zhang, Obcena, Brion, & Capeding, 2014). The 
effect size observed at PLCE1 rs3740360 in infants was also similar to that observed in 
DSS patients. It has been noted that hospitalized infants with dengue represent a group 
with the highest risk of death, and it is thought that this is partly related to an intrinsically 
more permeable vascular endothelium in this age group (Anders et al., 2011). In infants 
with dengue, carriage of either risk alleles thus represent an additional risk variable 
alongside the presence of maternally-derived non-neutralizing antibodies and poor 
compensatory reserve (Chau et al., 2010; Kliks, Nimmanitya, Nisalak, & Burke, 1988). 
 
Our study has several limitations. Misclassified control samples will be more common 
in non-severe dengue study than in the original GWAS of DSS cases because dengue 
without shock is a more common clinical outcome for a given cohort of children in an 
endemic area. Reassuringly, the fact that consistent associations were observed despite this 
limitation lends credence to our observations. In addition, as the functional basis of these 
mutations is yet to be clearly defined, our conclusions are to an extent speculative. As 
dengue without shock includes a diverse range of clinical manifestations, our ability to 
determine this functional basis is more limited. 
 
We have shown that the MICB rs3132468 and PLCE1 rs3740360 genotypes are 
associated with clinically apparent dengue in both adults and children, including infants, 
which is a significant extension from the earlier GWAS on children DSS cases alone. As 
expected, the effect sizes of these variants is small and underscores that susceptibility to 
symptomatic dengue is multifactorial and includes epidemiological risk factors (e.g. age). 
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However, we have not performed multivariate analysis in this study as the majority of risk 
factors for symptomatic (non-severe) dengue are not clearly defined. The challenge now is 
also to define the functional basis for these observed genetic associations at MICB and 
PLCE1 and thus increase our understanding of disease pathogenesis. Future studies would 
also include targeted resequencing of these two genes (MICB and PLCE1) to determine 


































CHAPTER 4: EPIDEMIOLOGICAL RISK FACTORS OF 
DENGUE DISEASE SEVERITY 
 
4.1. INTRODUCTION 
In several Asian countries, dengue is one of the leading causes of hospitalization and 
death among children (WHO, 1997, 2009, 2010a). However, in Singapore, there has beena 
decreasing trend of children (aged <15 years) and an increasing trend of adults (aged ≥25 
years) being infected with dengue since 1982 (Ooi et al., 2006). Molecular determinants of 
DHF such as virus variation, viral load, antibody-dependent enhancement (ADE), ‘original 
antigenic sin’, ‘cytokine storm’ and plasma factors were proposed in the pathophysiology 
of DHF (Rothman, 2003, 2011; Srikiatkhachorn & Green, 2010). However, predicting or 
preventing the occurrence of DHF remains a challenge. Identifying epidemiological risk 
factors for DHF can facilitate prevention, clinical, and healthcare resource management. 
Epidemiological risk factors for DHF that have been identified include dengue-serotype 2 
(Guzman et al., 1990; S. Thein et al., 1997), Asian genotype (Watts et al., 1999), prior 
dengue infections (Burke et al., 1988; Guzman et al., 1984), children (Guzman et al., 
2002; Ooi et al., 2003), age >65 years (M. S. Lee et al., 2006), and white females 
(Figueiredo et al., 2010; Guzman et al., 1984) 
 
Co-morbidities were reported as risk factors for DHF in a number of studies from 
dengue endemic countries. These co-morbidities included sickle cell anemia (Bravo et al., 
1987), asthma (Bravo et al., 1987; Cunha et al., 1999; D. Gonzalez et al., 2005), 
hypertension (Cunha et al., 1999; Figueiredo et al., 2010; M. S. Lee et al., 2006), uremia 
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(M. S. Lee et al., 2006), allergies treated with corticosteroid (Figueiredo et al., 2010) and 
diabetes mellitus (Bravo et al., 1987; Cunha et al., 1999; Figueiredo et al., 2010; M. S. Lee 
et al., 2006). However, these co-morbidities may not be generalized to all populations and 
epidemics of all dengue serotypes. Furthermore, most of these risk factors were identified 
from univariate analysis (Bravo et al., 1987; Cunha et al., 1999; D. Gonzalez et al., 2005; 
M. S. Lee et al., 2006) instead of multivariate analysis to adjust for potential confounders 
(Figueiredo et al., 2010). In this study, we explored demographic and co-morbidity risk 
factors for DHF in Singapore in the year 2006 (where dengue serotype 1 predominated) 



















(Publication 3: Pang J, Salim A, Lee VJ, et al. Diabetes with hypertension as risk 
factors for adult dengue hemorrhagic fever in a predominantly Dengue serotype 2 
epidemic: A case control study. PLoS NTD. 6(5): e1641.) 
 
Demographic and co-morbidity profiles of DHF & DF patients during the two 
epidemics 
In year 2006 epidemic, there were 149 DHF and 326 DF patients. Among these 
patients, there were 131 (27.6%) patients who were PCR positive and 344 (72.4%) 
patients who were serology positive but PCR negative. The mean age was 37.3 (±12.8) 
years and 34.0 (±11.0) years for DHF patients and DF patients respectively. Among DHF 
patients, there were 67.8% male and 77.2% Chinese. Of the 326 DF patients, 71.5% were 
male and 62.9% were Chinese (Table 3). In year 2007 and 2008 epidemic, there were 669 
DHF and 1,141 DF patients. Among these patients, there were 590 (32.6%) patients who 
were PCR positive and 1220 (67.4%) patients who were serology positive but PCR 
negative. The mean age was 38.4 (±13.4) years and 36.2 (±12.9) years for DHF patients 
and DF patients respectively. Among the DHF patients, there were 58.7% male and 77.1% 
Chinese. Of the 1,141 DF patients, 70.9% were male and 62.8% were Chinese (Table 3).  
 
Of the demographic variables, statistically significant differences (P<0.05) were 
found between DHF and DF with respect to mean age (P=0.008), age groups (P=0.017) 
and ethnicity (P=0.021) in year 2006, and mean age (P<0.001), age groups (P=0.002), 
gender (P<0.001) and ethnicity (P<0.001) in year 2007 and 2008 (Table 3). Using the 
number of fever days before hospital presentation as a surrogate index of health-seeking 
behavior between DHF and DF patients, no significant difference was observed in both 
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year 2006 (P=0.941) as well as year 2007-2008 (P=0.308) (Table 3). Notably, statistically 
significant differences were found between DHF and DF with respect to hypertension 




Table 3. Distribution of demographic characteristics and co-morbidities by cases (DHF) and controls (DF) in 
year 2006 and year 2007-2008 epidemics. 















 N % N %  P-value∆ N % N %  P-value∆ 
Age (Years)             
Mean (SD) 37.3 (12.8) 34.0 (11.0)  0.008^ 38.4 (13.4) 36.2 (12.9)  <0.001^ 
<30 43 28.9 115 35.3 1 : 2.67  180 26.9 405 35.5 1 : 2.25  
30-39 46 30.9 127 39.0 1 : 2.76  209 31.2 328 28.8 1 : 1.57  
40-49 39 26.2 58 17.8 1 : 1.49  152 22.7 213 18.7 1 : 1.40  
50-59 12 8.1 19 5.8 1 : 1.58  76 11.4 132 11.6 1 : 1.74  
≥ 60 9 6.0 7 2.2 1 : 0.78 0.017 52 7.8 63 5.5 1 : 1.21 0.002 
Gender             
Male 101 67.8 233 71.5 1 : 2.31  393 58.7 809 70.9 1 : 2.06  
Female 48 32.2 93 28.5 1 : 1.94 0.414 276 41.3 332 29.1 1 : 1.20 <0.001 
Ethnicity             
Others 15 10.1 60 18.4 1 : 4.00  79 11.8 188 16.5 1 : 2.38  
Chinese 115 77.2 205 62.9 1 : 1.78  516 77.1 717 62.8 1 : 1.39  
Malay 4 2.7 12 3.7 1 : 3.00  38 5.7 62 5.4 1 : 1.63  
Indian 15 10.1 49 15.0 1 : 3.27 0.021 36 5.4 174 15.3 1 : 4.83 <0.001 
Fever DBP             
Mean (SD) 4.9 (1.5) 4.9 (1.6)  0.941^ 4.9 (1.7) 5.0 (1.8)  0.308^ 
Hypertension             
No 140 94.0 315 96.6 1 : 2.25  594 88.8 1047 91.8 1 : 1.76  
Yes 9 6.0 11 3.4 1 : 1.22 0.179 75 11.2 94 8.2 1 : 1.25 0.036 
Diabetes             
No 147 98.7 319 97.9 1 : 2.17  626 93.6 1101 96.5 1 : 1.76  
Yes 2 1.3 7 2.2 1 : 3.50 0.726# 43 6.4 40 3.5 1 : 0.93 0.004 
Hyperlipidemi
a 
            
No 145 97.3 317 97.2 1 : 2.19  612 91.5 1061 93.0 1 : 1.73  
Yes 4 2.7 9 2.8 1 : 2.25 1.000# 57 8.5 80 7.0 1 : 1.40 0.241 
Asthma             
No 145 97.3 311 95.4 1 : 2.15  637 95.2 1082 94.8 1 : 1.70  
Yes 4 2.7 15 4.6 1 : 3.75 0.323 32 4.8 59 5.2 1 : 1.84 0.740 
∆Person’s Chi-square, unless otherwise annotated; ^ Mann-Whitney U test; # Fisher’s Exact test; 
DHF-Dengue hemorrhagic fever; DF- Dengue fever; DBP- Days before presentation in hospital 
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Independent risk factors for DHF 
Chinese ethnicity was the only significant risk factor independently associated with 
DHF in year 2006, after adjustment for statistically significant univariate risk factors 
(Table 4). Although marginally significant, the likelihood (AOR) of a Chinese patient 
developing DHF was 1.90 (95% CI: 1.01-3.56) times higher than that of other ethnicity 
(not Chinese, Malay or Indian). In year 2007 and 2008, age groups, gender and ethnicity 
were observed to be independently associated with DHF, following adjustment for 
statistically significant univariate risk factors (Table 4). The likelihood (AOR) of an 
individual who were 30 to 39 years of age and 40 to 49 years of age developing DHF was 
1.41 (95% CI:1.09-1.81) and 1.34 (95% CI:1.09-1.81) times higher than that of an 
individual below 30 years old respectively. Females had 1.57 (95% CI: 1.28-1.94) times 
higher risk developing DHF than males. In addition, the likelihood (AOR) of a Chinese 
patient developing DHF was 3.15 (95% CI: 2.34-4.23) and 1.67 (95% CI: 1.24-2.24) times 
higher than that of Indian and other ethnicity respectively (Table 4). 
 
For co-morbidities, after adjustment for statistically significant univariate risk 
factors, only diabetes mellitus remained an independent risk factor for DHF outcome 
(AOR=1.78; 95% CI:1.06-2.97) in year 2007 and 2008 (Table 5). Diabetic patients tend to 
have other co-morbidities. We investigated the risk effect of DHF outcome on patients 
having diabetes mellitus with hypertension, hyperlipidemia or asthma. Diabetes mellitus 
with hypertension (COR=2.43; 95% CI: 1.42-4.15), diabetes mellitus with hyperlipidemia 
(COR=1.82; 95% CI: 1.06-3.12) and diabetes mellitus with no asthma (COR=1.74; 95% 
CI: 1.10-2.76) were observed to be significantly associated with DHF outcome (Table 5). 
However, only diabetes mellitus with hypertension (AOR=2.16; 95% CI: 1.18-3.96) and 
diabetes with no asthma (AOR=1.68; 95% CI: 1.02-2.76) were observed to be 
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independently associated with DHF outcome after adjustment for statistically significant 
univariate risk factors (Table 5). Interestingly, the likelihood (AOR) of an individual 
having diabetes mellitus with asthma developing DHF was 4.38 (95% CI: 0.80-23.85) 
times higher than that of an individual having no diabetes with no asthma. However, there 
is a lack of statistical significance and it is most likely due to the small sample size with 
only 7 subjects having diabetes mellitus with asthma (Table 5). In order to confirm this 
observed phenomenon, further studies with larger sample size are required. In addition, 
among patients with hypertension, the likelihood (AOR) of developing DHF due to 
diabetes mellitus was higher (AOR=2.39; 95% CI: 1.21-4.71) compared to that of patients 
without hypertension (AOR=1.28; 95% CI: 0.56-2.93; Table 6). This provided preliminary 
evidence of effect modification between diabetes mellitus and hypertension on the risk of 
DHF outcome. Moreover, it was observed that the mean hospitalization days was longer 
for diabetic patients (4.99±3.34 days) compared to non-diabetic patients (4.04±1.62 days; 
P=0.001). A significant difference was also observed in the mean hospitalization days 
between diabetic DHF patients and non-diabetic DHF patients (diabetic DHF: 5.21±3.12 
days; non-diabetic DHF: 4.33±1.75 days; P=0.046) (data not shown). 
 
Subgroup analyses of patients with dengue IgG data and of Chinese patients were 
carried out. In the subgroup analysis of 1,220 (67.4%) patients hospitalized during the year 
2007-2008 that had dengue IgG data, we further showed that diabetes (AOR: 1.92; 95% 
CI: 1.02-3.61) as well as diabetes with hypertension (AOR: 4.41; 95% CI: 1.16-16.82) 
remained as a risk factor of DHF. Furthermore, in a subgroup analysis of cases (DHF) and 
controls (DF) identified as Chinese in year 2007 and 2008, diabetes mellitus (AOR=2.23; 
95% CI:1.21-4.11), diabetes mellitus with hypertension (AOR=2.1; 95% CI:1.07-4.12), 
diabetes mellitus with no hyperlipidemia (AOR=3.75; 95% CI:1.27-11.02) and diabetes 
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mellitus with no asthma (AOR=1.96; 95% CI:1.09-3.52) were independently associated 


























Table 4. Crude and adjusted odds ratios of the association of DHF with age groups, 
gender and ethnicity in year 2006 and year 2007-2008 epidemics. 
Year 2006 2007-2008 
Exposure COR 95% CI AOR* 95% CI COR 95% CI AOR** 95% CI 
Age (Years)         
<30 1  1  1  1  
30-39 0.97 0.60 - 1.58 0.92 0.56 - 1.50 1.43 1.12 - 1.84 1.41 1.09 - 1.81 
40-49 1.80 1.05 - 3.07 1.53 0.88 - 2.67 1.61 1.22 - 2.11 1.34 1.09 - 1.81 
50-59 1.69 0.76 - 3.77 1.47 0.65 - 3.31 1.30 0.93 - 1.81 0.91 0.63 - 1.30 
≥ 60 3.44 1.20 - 9.81 2.71 0.94 - 7.88 1.86 1.24 - 2.79 1.14 0.70 - 1.85 
Gender         
Male  1  1  1  1  
Female 1.19 0.78 – 1.81 1.14 0.74 – 1.78 1.71 1.40 – 2.09 1.57 1.28 – 1.94 
Ethnicity         
Others 1  1  1  1  
Chinese  2.24 1.22 – 4.13 1.90 1.01 – 3.56 1.71 1.29 – 2.28 1.67 1.24 – 2.24 
Malay 1.33 0.38 – 4.72 1.15 0.32 – 4.13 1.46 0.90 – 2.36 1.30 0.79 – 2.13 
Indian 1.22 0.55 – 2.75 1.19 0.53 – 2.68 0.49 0.32 – 0.77 0.53 0.34 – 0.83 
 
* Adjusted odds ratio was obtained from a multivariate logistic regression being adjusted by age groups and ethnicity. 
** Adjusted odds ratio was obtained from a multivariate logistic regression being adjusted by age groups, gender, 
ethnicity, diabetes mellitus and hypertension. 
DHF- Dengue Hemorrhagic Fever 
COR- Crude odds ratio 
AOR- Adjusted odds ratio 







Table 5. Crude and adjusted odds ratios of the association of DHF with co-
morbidities in year 2006 and year 2007-2008 epidemics. 
Year 2006 2007-2008 
Exposure COR 95% CI AOR* 95% CI COR 95% CI AOR** 95% CI 
Hypertension         
No  1  1  1  1  
Yes 1.84 0.74 - 4.54 0.97 0.31 - 3.00 1.41 1.02 - 1.94 1.06 0.70 - 1.60 
Diabetes          
No 1  1  1  1  
Yes 0.62 0.13 - 3.02 0.34 0.06 - 1.89 1.89 1.21 - 2.94 1.78 1.06 - 2.97 
Hyperlipidemia         
No 1  1  1  1  
Yes 0.97 0.29 - 3.20 0.54 0.15 - 1.96 1.24 0.87 - 1.76 0.79 0.50 - 1.26 
Asthma         
No 1  1  1  1  
Yes 0.57 0.19 - 1.75 0.51 0.16 - 1.62 0.92 0.59 - 1.43 0.86 0.55 - 1.35 
 
*Adjusted Odds Ratio was obtained from a multivariate logistic regression being adjusted by age groups and ethnicity. 
** Adjusted odds ratio was obtained from a multivariate logistic regression being adjusted by age groups, gender, 
ethnicity, diabetes mellitus and hypertension. 
DHF- Dengue Hemorrhagic Fever 
COR- Crude odds ratio 
AOR- Adjusted odds ratio 








Table 6. Crude and adjusted odds ratios of the association of DHF with multiple co-
morbidities in year 2007-2008 epidemic. 
Exposures Cases Controls      
 N N COR 95% CI AOR* 95% CI 
Diabetes       
No 626 1101 1  1  
Yes 43 40 1.89 1.21 - 2.94 1.78 1.06 - 2.97 
Diabetes, Hypertension       
No diabetes with no hypertension 584 1031 1  1  
No diabetes with hypertension 42 70 1.06 0.71 - 1.57 0.97 0.62 - 1.52 
Diabetes with no hypertension 10 16 1.1 0.50 - 2.45 1.26 0.55 - 2.87 
Diabetes with hypertension 33 24 2.43 1.42 - 4.15 2.16 1.18 - 3.96 
Diabetes, Hyperlipidemia       
No diabetes with no hyperlipidemia 597 1048 1  1  
No diabetes with hyperlipidemia 29 53 0.96 0.60 - 1.53 0.82 0.50 - 1.37 
Diabetes with no hyperlipidemia 15 13 2.03 0.96 - 4.29 2.03 0.93 - 4.47 
Diabetes with hyperlipidemia 28 27 1.82 1.06 - 3.12 1.62 0.90 - 2.92 
Diabetes, Asthma       
No diabetes with no asthma  599 1044 1  1  
No diabetes with asthma 27 57 0.83 0.52 - 1.32 0.79 0.49 - 1.27 
Diabetes with no asthma 38 38 1.74 1.10 - 2.76 1.68 1.02 - 2.76 
Diabetes with asthma 5 2 4.36 0.84 - 22.53 4.38 0.80 - 23.85 
*Adjusted odds ratio was obtained from a multivariate logistic regression being adjusted by age groups, 
gender, ethnicity, diabetes mellitus and hypertension; DHF- Dengue Hemorrhagic Fever 




Table 7. Stratified analysis between diabetes mellitus and other comorbidities in year 
2007-2008 epidemic. 
Exposures Cases Controls      
 N N COR 95% CI AOR* 95% CI 
Diabetes        
No 626 1101 1  1  
Yes 43 40 1.89 1.21 - 2.94 1.78 1.06 - 2.97 
No hypertension       
No diabetes  584 1031 1  1  
Diabetes  10 16 1.10 0.50 – 2.45 1.28 0.56 – 2.93 
Hypertension       
No diabetes  42 70 1  1  
Diabetes  33 24 2.29 1.20 – 4.39 2.39 1.21 – 4.71 
No hyperlipidemia       
No diabetes  597 1048 1  1  
Diabetes  15 13 2.03 0.96 – 4.29 1.95 0.88 – 4.36 
Hyperlipidemia       
No diabetes  29 53 1  1  
Diabetes  28 27 1.90 0.94 – 3.80 2.03 0.93 – 4.41 
No asthma       
No diabetes  599 1044 1  1  
Diabetes  38 38 1.74 1.10 – 2.76 1.77 1.03 – 3.00 
Asthma       
No diabetes  27 57 1  1  
Diabetes  5 2 5.28 0.96 – 29.0 1.01 0.04 – 25.15 
*Adjusted odds ratio was obtained from a multivariate logistic regression being adjusted by age groups, 
gender, ethnicity, diabetes mellitus and hypertension; DHF- Dengue Hemorrhagic Fever 





4.3. DISCUSSION AND CONCLUSION 
The results of this study showed that female, Chinese, age group between 30 to 49 
years, pre-existing diabetes mellitus or diabetes mellitus with hypertension were risk 
factors of developing DHF during the year 2007 and 2008 epidemic when dengue serotype 
2 was predominant. In contrast, Chinese ethnicity was the only risk factor observed during 
the year 2006 epidemic when dengue serotype 1 was predominant. This might be due to 
the different predominant circulating dengue serotypes during the two epidemics (K. S. 
Lee et al., 2010). Notably, dengue serotype 2 was known to be associated with more 
severe dengue disease than serotype 1 (Fried et al., 2010; Guzman et al., 1990; S. Thein et 
al., 1997). In a combined analysis of year 2006, 2007 and 2008 epidemic, all the risk 
factors identified in the year 2007-2008 epidemic remained as independent risk factors 
except for diabetes mellitus. This may suggest potential confounding effect of different 
serotypes. Furthermore, it was observed that age, gender and co-morbidities were not 
independently associated with DHF outcome in a previous study of 1,973 adult dengue 
patients in the year 2004 epidemic when dengue serotype 1 was also predominant (V. J. 
Lee et al., 2008). However, it is not possible to conclusively demonstrate serotype 
difference during epidemics as the main factor that accounted for the differences in risk 
factors in this study. This was because we do not routinely serotype all individual 
infections and this was hence not available for analyses. Instead, the differences in risk 
factors may be due to the small sample size of patients admitted in year 2006, and the 
significant differences in mean age, number of patients with co-morbidities and DHF 
outcome admitted during the two epidemics. It is beyond the scope of this study to 
highlight other potential factors, such as climate change, viral genotype change as well as 




It is not surprising that female and Chinese ethnicity were independent risk factors of 
DHF as gender (Anders et al., 2011; Guzman et al., 1984) and ethnicity (Figueiredo et al., 
2010; Guzman et al., 1984) were shown to be risk factors for DHF in Cuba and Brazil 
studies as well as in Vietnam for dengue shock syndrome (DSS). Age groups between 30 
and 39 and between 40 and 49 were independent risk factors of DHF in our adult dengue 
cohort. This observation is different from previous studies in Cuba (Guzman et al., 2002) 
and in Singapore (Ooi et al., 2003) where children <14 years of age had higher risk of 
developing DHF compared to young adults aged 15 years or greater. The rationale behind 
this difference could be due to lowered herd immunity and change in transmission patterns 
(Ooi et al., 2003; Ooi, Hart, Tan, & Chan, 2001). The elderly (>65 years of age) in Taiwan 
(M. S. Lee et al., 2006) had a higher risk of developing DHF. However, the age group ≥60 
year was not an independent risk factor of DHF outcome (Table 3) in our current study 
which is also consistent with our previous study on dengue in older adults (Lye, Lee, Sun, 
& Leo, 2010). It is still not well understood how these risk factors contribute to the 
pathophysiology of DHF, and understanding the underlying mechanism may facilitate 
clinical management.  
 
Co-morbidities such as hypertension, diabetes mellitus, hyperlipidemia and asthma are 
among the few leading causes of mortality and morbidity in Asia (WHO, 2005) and 
globally (Geneau et al., 2010; WHO, 2010b). Co-morbidities were shown to be associated 
with severe clinical manifestations of several infectious disease such as SARS (Booth et 
al., 2003; Lau et al., 2010), pandemic influenza H1N1 (Jain et al., 2009), tuberculosis 
(Dooley & Chaisson, 2009; Dooley, Tang, Golub, Dorman, & Cronin, 2009), hepatitis C 
(Charlton, Pockros, & Harrison, 2006) and community-acquired infections (Jackson, 2005; 
Muller et al., 2005). Many studies found association between various co-morbidities and 
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DHF outcome (Bravo et al., 1987; Cunha et al., 1999; Figueiredo et al., 2010; D. Gonzalez 
et al., 2005; M. S. Lee et al., 2006) but only one study was carried out with multivariate 
analysis to adjust for potential confounders (Figueiredo et al., 2010). Furthermore, none 
has evaluated the risk effect of two existing co-morbidities and the effect modification 
between two co-morbidities on DHF outcome. In this study, we showed that diabetes 
mellitus was associated with DHF outcome as observed by other studies (Bravo et al., 
1987; Cunha et al., 1999; Figueiredo et al., 2010). In addition, we observed that 
individuals reported as having diabetes mellitus with hypertension had higher risk of 
developing DHF compared with individuals with no diabetes mellitus and no 
hypertension. Our study may be the first that provide the preliminary evidence of synergy 
of risk effects between diabetes mellitus and hypertension on DHF outcome (Tables 5 & 
6). Our study showed concomitant diabetes mellitus with hypertension as an independent 
risk factor for DHF in a large number of adult DHF cases in Singapore, and supported the 
initial evidence of association between hospitalization with a diagnosis of DHF and 
diabetes mellitus in Brazil(Figueiredo et al., 2010). However, the pathophysiology behind 
diabetes leading to DHF outcome is not well understood yet, even though numerous 
studies had suggested that diabetes mellitus can result in immune and endothelial 
dysfunction (Dandona, Aljada, Chaudhuri, & Mohanty, 2004; Geerlings & Hoepelman, 
1999; Gonzalez-Curiel et al., 2011; Hsueh, Lyon, & Quinones, 2004; Kaye et al., 1986). 
 
Identifying risk factors for DHF can guide clinicians to triage dengue patients for the 
right site of care for closer monitoring and early intervention with fluid resuscitation. In an 
epidemic where healthcare resources may be stretched, risk factors for DHF can be used to 
prioritize hospitalization of dengue patients. In our study, we observed that diabetic 
patients with DHF outcome required longer stay and, presumably, required more medical 
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attention in the hospital compared to non-diabetic patients with DHF. Additionally, policy 
makers can prioritize population groups at high risk of developing DHF such as female 
patients, patients in age group 30-49, and patients having diabetes or diabetes with 
hypertension for vaccination when dengue vaccines are available. Demographic and co-
morbidity risk factors may help public health clinicians raise awareness among high-risk 
individuals to take preventive measures against dengue infections.  
 
As this is a retrospective study, the quality of the study was dependent on the quality 
of the data available and collected. Information bias was minimized by the use of the 
standardized dengue care path for consistent clinical documentation. Reporting bias was 
minimized by the fact that patients with comorbidities tend to know their existing 
condition and are likely to be on constant medication. However, it is challenging to 
exclude the fact that there are no undiagnosed existing comorbidities among some of these 
patients as this study is performed retrospectively. In addition, there may be selection bias 
because the subjects were all hospitalized and hence were likely to have active health care-
seeking behaviour, and the controls were hospitalized DF patients who may not truly 
represent the general population. In the general population, less active health care-seeking, 
asymptomatic or mild DF patients may not visit a doctor or hospital and may also have 
diabetes mellitus or other co-morbidities assessed in this study. However, it is technically 
challenging to identify these less active health care-seeking, asymptomatic or mild DF 
patients for inclusion in the study. We also did not have patient-specific dengue serotype 
data and could only extrapolate our observations from a previous population level study in 
Singapore (K. S. Lee et al., 2010). Lastly, we acknowledge the importance of accounting 
for prior infection as it is a main risk factor for DHF. The result of IgG test carried out 
within seven days of fever onset can be used to classify patients with or without prior 
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infection (Cuzzubbo et al., 2001; Thomas et al., 2008). However, we only had IgG results 
of 67.4% of all patients during the year 2007-2008. In the subgroup analysis, we showed 
that prior infection was not significantly associated with DHF in adult patients. It has been 
shown that prior infection was strongly associated with DHF, but this was in children 
under the age of 15 years (Fried et al., 2010; Gubler, 1998). Our study instead suggests 
that diabetes as well as diabetes with hypertension may be one of the key risk factors of 
DHF in adults, regardless of prior dengue infections. Further studies involving larger 
number of patients with acute secondary infections are required to confirm this hypothesis. 
Lastly, there is a lack of Body Mass Index (BMI) or obesity data which could be a 
potential confounder for the relationship between diabetes, hypertension and dengue 
severity. 
 
In conclusion, we found age between 30 and 49 years, female gender, Chinese 
ethnicity, diabetes mellitus and diabetes mellitus with hypertension to be independent risk 
factors for DHF in an adult dengue epidemic with predominantly dengue serotype 2. The 
two co-morbidities appeared to have effect modification on the risk of DHF outcome. 
More studies, particularly prospective studies are required to confirm these findings. Our 
finding raised the likely association between the pathophysiology of diabetes mellitus, 
hypertension and dengue severity. An ongoing genome-wide association study in 
Singapore may help elucidate genetic predisposition to severe dengue disease including 






























CHAPTER 5: MOLECULAR RISK FACTORS OF DENGUE 
DISEASE SEVERITY 
5.1. INTRODUCTION 
Based on the WHO 2009 new classification of dengue disease, patients with 
symptomatic infection may be classified as having dengue without warning signs, dengue 
with warning signs or severe dengue as possible outcomes of infection, in order of 
increasing severity. Severe dengue infection is characterized by severe plasma leakage, 
severe bleeding, and severe organ involvement which can proceed to shock if left 
untreated, that usually occurs at time of defervescence, four to seven days after fever 
onset. Specific antiviral therapy is currently not available and case management is entirely 
supportive. The standard-of-care for dengue disease is not specific, but rather directed 
towards constantly monitoring patients for early warning signs, with the aim of providing 
appropriate and timely fluid support, to prevent the development of hypovolemic shock (S 
Kalayanarooj, 1999). As such, the WHO 2009 classification advocates clinicians to look 
out for specific presentation of warning signs, as indicators of possible severe dengue 
manifestations (WHO, 2009).  
 
However, there are a number of challenges encountered when applying the warning 
signs-guided revised WHO dengue classification. Firstly, it has been found to be too 
highly sensitive and less specific in identifying severe illness, potentially resulting in 
significant increase in hospitalization, workload to medical personnel and burden to 
resource-limited endemic regions (Barniol et al., 2011; S. Kalayanarooj, 2011; Narvaez et 
al., 2011). Secondly, warning signs generally occurred one day prior to the development of 
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severe illness/ requirement of intervention or 4-7 days post illness, and this narrow 
window makes any form of intervention challenging, particularly when appropriate 
healthcare facilities are remote from their place of residence. On the other hand, it was 
observed that patients with no warning signs, which typically occurred on median 4-5 days 
post fever were generally less likely to develop severe dengue and these patients, and it 
has been proposed that these can be monitored and managed as outpatients(T. L. Thein, 
Gan, et al., 2013). As such, further refinement of the triage process of patients with 
warning signs and required hospitalization in the early phase of infection would be 
particularly useful in the healthcare setting to reduce over-hospitalization(Barniol et al., 
2011; Srikiatkhachorn et al., 2011).  
 
As the expression of RNA and proteins are dynamic and sensitive to stimulus from 
environmental, diet and metabolic changes, as well as pathogen infection, these molecular 
features when assessed systematically at early infection may provide potential signals of 
the emerging warning signs, and more importantly, severe clinical outcomes. In 2005, a 
prospective study was set up in Singapore with the major aim to characterize adults with 
acute dengue infection at the early stage of illness when a specific intervention could be 
introduced effectively (Low et al., 2006). In this study, we aim to investigate the 
molecular features associated with warning signs and the requirement for hospitalization at 
early infection that could be applied as a point-of-care tool to complement the triage 
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Between May 2005 and December 2008, a total of 1,315 dengue patients were 
enrolled. Among the 212 (16%) patients who had RT-PCR confirmed dengue infection, 47 
patients with WS were subsequently hospitalized (WS+Hosp. Group; Figure 10). These 
patients were representative of those that should be prioritized for strict monitoring and 
interventions at early infection. In addition, 14 (30%) of these patients were classified as 
severe dengue as the disease progressed (Table 8). Furthermore, 45 patients with no WS 
and were not hospitalized (Non-WS+Non-Hosp. Group; Figure 10) represented a group 
of mild dengue patients who were safely managed as outpatients and did not develop 
severe dengue. 
 
Clinical and Laboratory Characteristics of Discovery Cohort. 
Among the WS+Hosp. group, 44 (94%), 10 (21%) and 5 (11%) reported mucosal 
bleeding, persistent vomiting and abdominal pain respectively. Six (14%) patients had 
signs of mucosal bleeding at Day 1-3 post fever onset (p.f.), 14 (32%) at Day 4-7 p.f., 27 
(61%) at time of hospitalization. Moreover, 32 (73%) showed signs of bleeding during 
hospitalization. Gum bleeding was the most common (n=18) followed by skin (n=12), 
menstrual bleeding (n=8), nose bleeding (n=5), hematuria (n=3) and per rectal bleeding 
(n=2). Six of the 10 patients reported persistent vomiting at Day 1-3 p.f. and Day 4-7 p.f., 
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and nine of 10 reported it at Day 4-7 p.f. and during hospitalization. Two patients had 
abdominal pain at Day 1-3 p.f. while 3 patients had abdominal pain at Day 4-7 p.f. The 
patients in the WS+Hosp. group were admitted in a median of 4 days (range 1-7) p.f. and 
hospitalized for a median of 3 days (range 1-7) (Table 8). Among patients with severe 
dengue, 6 had severe plasma leakage, 5 had severe bleeding (2 hematuria, 3 rectal 
bleeding) and 3 had severe organ involvement (transaminase >1000 U/L). During 
hospitalization, 44 out of 47 (94%) patients received intravenous fluid replacement.   
 
There were significant differences (P<0.05) in viral, platelet and lymphocyte levels 
between the WS+Hosp. and Non-WS+Non-Hosp. groups (Figure 10). Within the 
WS+Hosp. group, there was no significant differences in viral, platelet and lymphocyte 
levels at Day 1-3 p.f. between the 14 patients who progressed to severe dengue and the 
remaining 33 patients with no progression to severe dengue (Figure 12). However, severe 
dengue patients had significantly higher viral, lower platelet and lymphocyte levels than 



































Figure 10. Selection workflow of dengue patients with warning signs that required 
hospitalization and patients with no warning signs and no hospitalization required. 
1,315 patients enrolled between 
May 2005 and Dec 2008 
212 RT-PCR Dengue positive 
patients 
1,103 RT-PCR Dengue 
negative patients 
158 patients with all clinical data 
and samples collected at three time 
points 
54 patients with missing 
clinical data and/or samples 
29 patients were 
not hospitalized. 
(None with severe 
dengue) 
76 (48%) patients had at least one 
of the three warning signs 
(abdominal pain, mucosal bleeding 
and persistent vomiting)  
82 (52%) patients had 
no warning signs.  
47 (62%) patients had warning 
signs & required hospitalization.            
(WS + Hosp.) 
45 (55%) patients had no 
warning signs and did not 
required hospitalization. (Non-
WS + Non-Hosp.) 
14 (30%) severe dengue 
37 patients were 
hospitalized due to 
other comorbid 
conditions/social/ 
caretaking issues (None 
with severe dengue) 




Table 8. Demographic descriptions of dengue RT-PCR positive patients classified 








Non-Hosp WS + Hosp 
 
Non-WS + Non-
Hosp WS + Hosp  
 























     





     
Chinese 32 71.1 39 83.0 
 
31 56.4 16 64.0  
Malay 1 2.2 4 8.5 
 
5 9.1 6 24.0  
Indian 7 15.6 3 6.4 
 
8 14.5 1 4.0  






     





     
1 16 35.6 25 53.2 
 
3 5.5 3 12  
2 13 28.9 14 29.8 
 
35 63.6 19 76  
3 16 35.6 8 17.0 
 
0 0 2 8  
4 0 0 0 0 0.098 6 10.9 1 4 0.011 
Unknown 0 0 0 0 
 
11 20 0 0  





     












4 (1-7)  
 
n.a.  5 (1-8)              
Length of 
stay (Range) n.a. 
 
3 (1-7)  
 






     
Yes 0 0 14 30.0 <0.001^ 0 0 1 4 0.312^ 
# Mann-Whitney Test  
^ Fisher’s Exact Test 
p.f. - post fever onset 





Figure 11.  Laboratory characteristics (A-Viral copy number at Day 1-3; B-Platelet 
count; C-Lymphocytes count) of hospitalized dengue patients with warning signs 
(WS + Hosp. Group) compared to non-hospitalized patients with no warning signs 
(Non-WS + Non-Hosp. Group). 






Figure 12. Laboratory characteristics of patients with severe dengue among the 
hospitalized dengue patients with warning signs (WS + Hosp. Group). 





Figure 13. Laboratory characteristics of patients with severe dengue compared to 
non-hospitalized dengue patients with no warning signs (Non-WS + Non-Hosp. 
Group). 




Differential transcriptome between WS + Hosp. group and Non-WS + Non-Hosp. 
group.at less than 72hrs post fever. 
To identify the genomic background behind the clinical and laboratory characteristics 
of the patients with and without warning signs, we compared gene transcript abundance in 
whole blood from the first sampling point between two groups of patients. After analysis 
by SAM, 23 genes were found to be significantly differentially expressed. 17 genes were 
over expressed and six were under expressed in the group of patients with warning signs 
when compared to the group without warning signs (Table 9). Eight of these genes are 
known to be related to innate immune activation and in particular CCL2 and CCL8, which 
have previously been described as key responses to dengue infection (Tolfvenstam et al., 
2011). Interestingly, when comparing the 14 patients with severe dengue against the non-
hospitalized patients without warning signs, IL-8 was also significantly differentially 
expressed, besides CCL2 and CCL8 (Table 9). The expression level of these RNA 
responses may be informative of the strength of the innate response during the early 












Table 9. Differential genes between hospitalized patients with warning signs (WS + 
Hosp.), including patients with severe dengue (SD) and non-hospitalized patients 
without warning signs (Non-WS + Non-Hosp.) at less than 72hr post fever. 
 
WS + Hosp. VS   
Non-WS + Non-
Hosp. 












IL-8 - 3.2 N.S. N.S. 
PKD2L1 2.9 2.4 Up reg. Up reg. 
CCL8 2.7 2.5 Up reg. Up reg. 
HESX1 2.6 - Up reg. Up reg. 
BRDG1 2.5 - Up reg. Up reg. 
OLFM4 2.4 - N.S. N.S. 
CCL2 2.3 2.3 Up reg. Up reg. 
SERPINE2 - 2.3 N.S. N.S. 
CD69 2.2 - N.S. N.S. 
C15orf48 2.0 2.4 N.S. N.S. 
ARL5B 2.0 - N.S. N.S. 
RIN2 1.8 - Up reg. Up reg. 
HIST1H4E 1.8 - N.S. N.S. 
NCOA7 1.6 - Up reg. Up reg. 
LOC440093 1.6 - N.S. N.S. 
KCTD14 1.6 - Up reg. Up reg. 
CCL3 1.6 2.2 Up reg. Up reg. 
RGL1 1.6 - Up reg. Up reg. 
NFIL3 1.5 - Up reg. N.S. 
ESPN -1.5 - Down reg. N.S. 
VPS13C -1.6 - N.S. N.S. 
CYP27A1 -1.6 - Down reg. Down reg. 
CDKN1C -1.6 - Up reg. Up reg. 
SH3KBP1 -1.8 - N.S. N.S. 
FECH - -2.2 N.S. N.S. 
PI3 -2.5 - Down reg. Down reg. 
aData from 32 patients generated by comparing samples from day 1-3 after fever onset 
with convalescent samples from day 21-28 after fever onset (Tolfvenstam et al., 2011).  
bData generated by comparing samples from dengue positive patients sampled day 1-3 
after fever onset with samples from dengue negative febrile patients sampled day 1-3 after 
fever onset (Tolfvenstam et al., 2011).  
Reg.- regulated; N.S.-not significant 
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Differential targeted proteomic between WS + Hosp. group and Non-WS + Non-
Hosp. group. 
Targeted differential protein expressions between hospitalized patients with warning 
signs and non-hospitalized patients without warning signs were analyzed. Out of the 22 
proteins analyzed, four proteins (IP-10, IL-1ra, FGA, uPAR) were significantly higher in 
abundance at Day 1-3in hospitalized patients with warning signs compared to non-
hospitalized patients without warning signs. The four proteins were IP-10 (p-
value=0.0001), IL-1ra (p-value=0.0094), FGA (p-value=0.0423) and uPAR (p-
value=0.0047) (Table 10). RANTES was the only protein observed to be significantly 
lower (p-value=0.0207) in abundance in hospitalized patients with warning signs 
compared to patients without warning signs at Day 1-3. Interestingly, CCL-4, IP-10 and 
uPAR protein expression were differentially expressed when comparing patient who 
developed severe dengue with patients with no warning signs and non-hospitalized at Day 





Table 10. Targeted proteomic expression between Non-WS + Non-Hosp. group and 
WS + Hosp. group. 
  DAY 1- 3  
Proteins  Non-WS + Non-Hosp WS + Hosp   
  N Mean SD N Mean SD p-value  
Chemokines          
MCP-1 (CCL2)  45 351.29 382.65 47 537.16 701.50 0.117  
MCP-2 (CCL8)  45 693.78 354.13 47 896.23 821.28 0.127  
MIP1a (CCL3)  45 6.63 8.74 47 10.15 14.75 0.1661  
MIP1b (CCL4)  45 252.48 151.46 47 325.81 225.47 0.0697  
RANTES (CCL5)  26 16877 9103.60 27 11593 6900.10 0.0207  
IP-10 (CXCL10)  45 10167 19784 46 23010 18217 0.0001  
Interleukins          
IL-1b  45 1.49 2.99 39 1.70 1.08 0.6662  
IL-1ra (IL1RN)  45 1362.40 1524.60 47 3707.60 5757.80 0.0094  
IL-2  45 6.32 17.60 47 7.73 12.83 0.6617  
IL-4  45 0.68 2.28 47 0.62 0.40 0.8731  
IL-8  45 18.55 9.38 47 26.94 34.81 0.1171  
IL-10  45 44.04 85.91 47 53.63 94.40 0.6118  
IL-12  45 9.48 11.50 47 7.41 5.98 0.286  
IL-18  35 228.41 113.43 43 281.46 157.41 0.0988  
Interferons          
IFN-a2  45 112.91 74.97 47 121.91 61.27 0.529  
IFN-g  45 60.49 95.61 47 76.70 89.56 0.4034  
Tumor Necrosis 
Factor  
              
 
TNF-a (TNF)  45 24.83 18.48 47 32.32 26.03 0.114  
TRAIL(TNFSF10)  45 994.08 525.45 47 1060.30 538.45 0.5525  
Others                 
Fibrinogen (FGA)  35 4820.70 3476.70 35 7672.30 7304.20 0.0423  
ICAM-1  26 231917 64163 27 260042 97853 0.2207  
VCAM-1  26 409475 227158 27 528265 252640 0.0781  










Table 11. Targeted proteomic expression between Non-WS + Non-Hosp. groupand 
severe dengue patients among the WS + Hosp. group. 
  DAY 1- 3  
Proteins  Non-WS + Non-Hosp Severe Dengue  
  N Mean SD N Mean SD p-value  
Chemokines          
MCP-1 (CCL2)  45 351.29 382.65 14 822.98 1119.20 0.159  
MCP-2 (CCL8)  45 693.78 354.13 14 1015.52 761.18 0.162  
MIP1a (CCL3)  45 6.63 8.74 14 12.23 16.49 0.258  
MIP1b (CCL4)  45 252.48 151.46 14 433.63 289.68 0.048  
RANTES (CCL5)  26 16876.54 9103.57 7 11405.57 7966.89 0.147  
IP-10 (CXCL10)  45 10166.67 10784.03 14 32301.95 22130.61 0.004  
Interleukins          
IL-1b  45 1.49 2.99 10 1.92 1.44 0.507  
IL-1ra (IL1RN)  45 1362.43 1524.61 14 5787.56 8647.18 0.091  
IL-2  45 6.32 17.60 14 6.17 8.56 0.968  
IL-4  45 0.68 2.28 14 0.74 0.55 0.858  
IL-8  45 18.55 9.38 14 41.55 63.10 0.116  
IL-10  45 44.04 85.91 14 38.92 30.23 0.739  
IL-12  45 9.48 11.50 14 7.48 3.11 0.301  
IL-18  35 228.41 113.43 14 338.87 227.58 0.116  
Interferons          
IFN-a2  45 112.91 74.97 14 133.62 57.89 0.300  
IFN-g  45 60.49 95.61 14 71.24 43.59 0.568  
Tumor Necrosis 
Factor 
         
TNF-a (TNF)  45 24.83 18.477 14 31.05 16.86 0.265  
TRAIL(TNFSF10)  45 994.08 525.96 14 1233.53 587.51 0.202  
Others          
Fibrinogen (FGA)  35 4820.73 3476.66 10 10825.44 10865.57 0.117  
ICAM-1  26 231916.5 64162.6 7 257704.26 104522.33 0.553  
VCAM-1  26 409475 227158.3 7 510908.98 264411.17 0.379  
uPAR (PLAUR)  35 5870.54 1990.26 10 8522.53 3022.12 0.023  
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Prognostic Performance of RNA and Protein Biomarker Models to discriminate 
patients between WS+Hosp. group and Non-WS+Non-Hosp. group at Day 1-3 p.f. 
We next investigated if these molecular markers were significantly associated with 
hospitalization and warning signs, and whether they could be utilized as early prognostic 
biomarkers models. The top single RNA biomarker model, is CCL8 with an AUC of 0.73 
(Hosmer-Lemeshow GOF p-value=0.14) for differentiating the patients into either 
hospitalized with warning signs group, or without warning signs and no hospitalization 
group. Whereas, the top single protein biomarker is IP-10 with an AUC of 0.74 (Hosmer-
Lemeshow GOF p-value: 0.57) (Table 12). Combining the RNA and protein 
measurements together, the top RNA-protein biomarker model, includes CCL8, VPS13C 
and uPAR with an AUC of 0.90 (Hosmer-Lemeshow GOF p-value=0.24; Table 12). 
Furthermore, these biomarkers were shown to be significantly associated with hospitalized 
patients with warning signs (Table 13). Using the default cut-off of P = 0.5, the model 13 
had sensitivity of 82.9% sensitivity, 80.0% specificity, positive predictive value (PPV) of 
80.6% and negative predictive value (NPV) of 82.4%. Using Fluidigm technology to 
replace microarray technology for assessment of RNA expression level of CCL8 and 
VPS13C provides comparable AUC of 0.84 (GOF p-value=0.34). Hence, the predicted 
probability of warning signs and hospitalization ( ip ) within 72 hour post fever onset was 














For each individual i, 1x  to 3x  are indicator variables taking on respective values, where 
1x represents CCL8, 2x  represents VPS13C and 3x represents uPAR (pg/ml). 1x and 2x  are 
obtained from Fluidigm delta Ct, while 3x is obtained from ELISA. Optimizing the 
sensitivity and specificity may be achieved through the varying probability cut-offs as 
shown in Figure 14A. 
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We next investigated if these models are more efficient than just using laboratory 
indicators. Viral Ct, lymphocytes as well as platelets level were used in the modeling 
development to assess the overall performance of stratification between the two groups of 
patients. The results suggested that the RNA-protein biomarker model has better 
predictive power with AUC of 0.90, compared to that of viral load (AUC=0.71; GOF p-
value=0.56), lymphocytes (AUC=0.68; GOF p-value=0.0.1) and platelets level 
(AUC=0.74; GOF p-value=0.84) to differentiate hospitalized patients with warning signs 
from non-hospitalized patients without warning signs (Table 12). Furthermore, combining 
the biomarkers with the laboratory features, the top model which comprised of CCL8 and 
VPS13C, together with platelets level produced an AUC of 0.88 (Table 12). Furthermore, 
these biomarkers were shown to be significantly associated with hospitalized patients with 
warning signs (Table 13). Using the default cut-off of P = 0.5, the model 14 had 
sensitivity of 80.9% sensitivity, 84.4% specificity, positive predictive value of 80.6% and 
negative predictive value of 82.4%. Using Fluidigm technology to replace microarray 
technology for assessment of RNA expression level of CCL8 andVPS13C also provides 
comparable AUC of 0.87 (GOF p-value=0.74). Hence, the predicted probability of 















For each individual i, 1x  to 3x are indicator variables taking on respective values, 
where 1x represents CCL8, 2x  represents VPS13C and 3x represents platelet (x10 3/ul). 1x
and 2x  are obtained from Fluidigm delta Ct, while 3x is obtained from ELISA. Optimizing 




Table 12. Combination of RNA, proteins and laboratory variables as potential biomarkers of warning signs and hospitalization. 




Models without Laboratory Features 
      
1 IP-10 0.7353 54.35 77.78 71.43 62.50 0.57 
2 IL-1ra 0.7348 55.32 84.44 78.79 64.41 0.29 
3 CCL8 0.7277 72.34 66.67 69.39 69.77 0.14 
4 HIST1H4E 0.7229 76.60 55.56 64.29 69.44 0.06 
5 PKD2L1 0.7047 72.34 53.33 61.82 64.86 0.68 
6 CCL3 0.6979 63.83 64.44 65.22 63.04 0.57 
7 uPAR 0.6955 60.00 74.29 70.00 65.00 0.77 
8 VPS13C 0.6950 61.70 53.33 58.00 57.14 0.05 
9 RGL1 0.6946 68.09 53.33 60.38 61.54 0.70 
10 NCOA7 0.6927 70.21 60.00 64.71 65.85 0.13 
11 IP-10, CCL8 0.7942 71.74 73.33 73.33 71.74 0.48 
12 HIST14HE, VPS13C, IL-1RAuPAR* 0.9045 82.86 77.14 78.38 81.82 0.62 
13 CCL8, VPS13C, uPAR^§ 0.8988 82.86 80.00 80.56 82.35 0.24 
 
Models with Laboratory Features 
      
14 CCL8, VPS13C, Platelets Level^* 0.8757 80.85 84.44 84.44 80.85 0.32 
15 Platelets Level 0.7390 72.34 68.89 70.83 70.45 0.84 
16 Viral Ct Level 0.7058 73.91 56.82 64.15 67.57 0.56 
17 Lymphocytes Level 0.6792 76.60 48.89 61.02 66.67 0.01# 
18 Platelets and Viral Ct Level 0.8370 73.91 79.55 79.07 74.47 0.20 
19 Platelets ,Viral Ct Level, IP10 0.8520 77.78 81.82 81.40 78.26 0.08 
20 Platelets Level, IP10 0.8097 76.09 77.78 76.09 77.78 0.33 
21 Platelets ,Viral Ct Level, CCL8 0.8696 84.78 79.55 81.25 83.33 0.02# 
 Models with Warning Signs       
22 Abdominal Pain 0.5102 100.0 0 51.09 - N.A 
23 Persistent Vomiting  0.5615 23.40 88.89 68.75 52.63 N.A 
24 Mucosal Bleeding 0.5000 0 100 - 52.33 N.A 
 Internal Validation using Fluidigm for CCL8, VPS13C       
13 CCL8, VPS13C, uPAR 0.8420 77.27 61.90 68.00 72.22 0.34 
14 CCL8, VPS13C, PLT 0.8682 69.57 83.87 76.19 78.79 0.74 
11 IP10, CCL8 0.7451 41.18 88.89 70 70.59 0.83 
112 
 
Continued from Table 12 
 
^ Forward Stepwise Estimation from top 10 single RNA and protein molecules based on AUC;  
* Backward Elimination Estimation from top 10 single RNA and protein molecules based on AUC; 
§ Likelihood-Ratio test shows model 12 provides the same fit as model 11 (p-value=0.1688); 
#Model has significant lack of fit for the data;  
GOF- Goodness-of-fit test showed significant “lack-of-fit” when p<0.05 
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A. Biomarkers in 
Model  
Data Sources 
Variable Coefficient OR p-value 95% CI 
CCL8, VPS13C, 
uPAR 







VPS13C -2.4363 0.09 0.002 0.02-0.40 
uPAR 0.0004 1.01 0.003 1.00-1.02 
cons -4.8011    
CCL8, VPS13C, 
Platelets (PLT) 
CCL8 0.6855 1.98 <0.001 1.41-2.79 
VPS13C -1.3869 0.25 0.02 0.08-0.80 
PLT -0.0200 0.98 <0.001 0.97-0.99 
cons 0.9761    
CCL8, Viral Ct, 
IP-10, uPAR 
CCL8 0.6501 1.00 0.014 1.14-3.21 
Viral Ct -0.0065 0.99 0.944 0.83-1.19 
IP-10 0.000003 1.00 0.890 0.99-1.01 
uPAR 0.0003 1.00 0.010 1.00-1.01 
cons -4.9307    
CCL8,  IP-10 CCL8 0.37449 1.45 0.013 1.08-1.95 
IP-10 0.00005 1.00 0.006 1.00-1.01 
cons -2.3953    
IP-10  IP-10 0.00064 1.00 0.001 1.00-1.01 
  cons -0.9495    
CCL8  CCL8 0.47861 1.61 0.001 1.22-2.14 
  cons     
B. Biomarkers in 
Model 
Data Sources 






value );  
Protein from 
ELISA 
CCL8 -0.4418 0.64 0.034 0.43-0.97 
VPS13C 0.9915 2.70 0.041 1.00-7.59 
uPAR 0.0004 1.00 0.019 1.00-1.01 
cons -5.4221    
CCL8, VPS13C, 
Platelets (PLT) 
CCL8 -0.3606 0.70 0.035 0.50-0.98 
VPS13C 0.9421 2.57 0.014 1.21-5.43 
PLT -0.0197 0.98 0.013 0.967-0.99 
cons 0.2971    
CCL8, Viral Ct, IP-
10, uPAR 
CCL8 -0.20534 0.81 0.461 0.47-1.41 
Viral Ct -0.20766 0.81 0.136 0.62-1.07 
IP-10 0.00001 1.00 0.742 0.99-1.01 
uPAR 0.00033 1.00 0.075 0.99-1.01 
 cons 2.0693    
CCL8, IP-10 CCL8 -0.1513 0.86 0.394 0.61-1.22 
IP-10 0.00007 1.00 0.029 1.00-101 
 cons -1.0832    
CCL8 CCL8 -0.30604 0.74 0.026 0.56-0.96 







Figure 14. Sensitivity and specificity plots of Model 13 (A.) and Model 14 (B.) with 









































































Validation of top two prognostic models 
For validation of our two optimal models, we utilized samples collected from patients 
enrolled between January 2009 and December 2012. There were 1,895 patients enrolled 
and only 117 patients were dengue RT-PCR positive. Of these, 2 were excluded due to 
lack of data and the remaining were 115 patients. Using the same classification criteria as 
described in Methods, there were 55 patients who had no warning signs and do not need 
hospitalization, and 25 patients who had warning signs and hospitalization. Patient 
characteristics are outlined in Table 8. Model 13 consisting of CCL8, VPS13C and uPAR 
were used to stratify the patients at the first visit (≤72H post fever onset) and achieved 
64% sensitivity, 76% specificity, positive predictive value of 55% and negative predictive 
value of 82% with the default cutoff of 0.5(Figure 15andTable 14). Model 14 consisting 
of CCL8, VPS13C and platelets were also used to stratify the patients at the first visit 
(≤72H post fever onset) and achieved 60% sensitivity, 78% specificity, positive predictive 
value of 56% and negative predictive value of 81%with the default cutoff of 0.5 (Figure 
15 and Table 14). Only one patient was defined as having severe dengue in this validation 
cohort, and both models classified this patient into the hospitalized with warning signs 
group. Viral levels were significantly higher in the predicted warning signs and 
hospitalization group within 72 hour post fever onset compared to the predicted no 
warning signs and non-hospitalization group using both optimal models (). Platelet level 
was only significantly different at time point Day 4-7 using model 13 between the two 
predicted groups, but it was significantly lower at both time points Day 1-3 and Day 4-7 
using Model 14 (Figure 16). The lymphocyte level was only significantly lower in the 
predicted warning signs and hospitalization group at time point Day 1-3 compared to the 
predicted no warning signs and non-hospitalization group using both models (Figure 16). 
The optimal model 14, which consisted of platelet as one of variables also act as a positive 
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control, where it is expected for the model to be more sensitive to pick up patients with 
































Figure 15. Performance of the optimal model 13 (A.) and model 14 (B.) on the 
validation cohort with different probability cut-off. 
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Table 14. Prognostic performance of the top selected models with different 




Model 13: CCL8, VPS13C, uPAR    
Probability Cutoff Sensitivity Specificity PPV NPV 
0.2 96.0 49.1 46.2 96.4 
0.5 64.0 76.4 55.2 82.4 
0.8 40.0 90.9 66.7 76.9 
 
B.  
Model 14: CCL8, VPS13C, Platelets   
Probability Cutoff Sensitivity Specificity PPV NPV 
0.2 96.0 54.6 49.0 96.8 
0.5 60.0 78.2 55.6 81.1 
0.8 32.0 94.6 72.7 75.4 
 
C.  
Model 1: IP-10     
Probability 
Cutoff 
Sensitivity Specificity PPV NPV 
0.2 100.0 0 31.3 - 
0.5 80.0 50.9 42.6 84.9 
0.8 32.0 96.4 80.0 75.7 
 
D.  
Model 3: CCL8     
Probability 
Cutoff 
Sensitivity Specificity PPV NPV 
0.2 96.0 16.4 34.3 90.0 
0.5 48.0 67.3 40.0 74.0 












Figure 16. Laboratory characteristics of patients who are likely to require 
hospitalization and develop warning signs. 
Viral (A, D), platelet (B, E) and lymphocyte (C, F) levels of the patients predicted into 
either the “Non-WS + Non-Hosp” group or “WS + Hosp” group. The predicted groups of 
A, B and C are based on Model 13, while D, E and F are based on Model 14. WS- 


































5.3. DISCUSSION AND CONCLUSION 
The diverse clinical spectrum of dengue disease is still a challenge for health care 
workers in dengue endemic regions, especially to identify patients early that will later 
require clinical interventions to prevent progression of severe illness, particularly in adults. 
WS were found to be associated with severe illness, but they typically occurred only one 
day prior to the development of severe illness (Alexander et al., 2011; Leo et al., 2013; T. 
L. Thein, Gan, et al., 2013; Tsai et al., 2013), which would be a challenging window for 
any effective intervention. In this study, we aimed to identify and validate distinct 
pathophysiological and molecular features associated with adult dengue patients who 
presented WS and required hospitalization within 72 hours of fever.  
 
The WHO 2009 WS guidelines and clinical judgment were applied to identify patients 
who did and did not require clinical observation, dividing the patients into those 
hospitalized with WS of abdominal pain, bleeding and/or persistent vomiting (WS+Hosp. 
group); and those without WS and did not require hospitalization (Non-WS+Non-Hosp. 
group). We found that the WS+Hosp. group had significantly higher viral, lower platelet 
and lymphocyte levels compared with Non-WS+Non-Hosp. group at early infection (Day 
1-3). These novel observations clearly illustrated that viral (AUC=0.71), platelet 
(AUC=0.74) and lymphocyte (AUC=0.68) levels as potential biomarkers to triage patients 
into the two groups at early infection, probably at an earlier time point than the 
presentation of WS, typically on Day 4-7 p.f. (Alexander et al., 2011; Leo et al., 2013). At 
Day 4-7, when hospitalization typically occurred, the platelet level was lower in the 
WS+Hosp. group suggesting hospitalization due to low platelet levels was common in our 
cohort. The lack of statistical differences in viral, platelet or lymphocyte levels between 
the severe dengue group and the remaining patients from the WS+Hosp. group highlighted 
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the difficulties in recognizing these severe dengue patients at early infection as they are 
likely to be indistinguishable from other hospitalized patients with WS, even on Day 4-7 
p.f. This reflects the similar observations in children with severe illness and hospitalized 
non-severe illness published previously (Hoang et al., 2010). However, in spite of the 
small number of severe dengue patients, they remained significantly different in 
pathophysiology from the Non-WS+Non-Hosp. group at early infection. High viremia was 
associated with severe dengue outcomes (Low et al., 2011; Tanner et al., 2008; Vaughn et 
al., 2000). Similarly, our findings showed that viremia was significantly associated with 
WS and close monitoring at early infection; this is similar for platelet and lymphocyte 
level, suggesting the important role of these parameters in dengue disease severity. 
 
Biomarkers associated with WS+Hosp. group were involved in innate immunity 
(CCL2, CCL3, CCL8, CD69, RANTES, IL1RA), type II interferon (IP-10) and 
coagulation (uPAR, FGA) pathways which were associated with dengue severity 
(Becquart et al., 2010; J. Fink et al., 2007; Green, Pichyangkul, et al., 1999; Hsieh et al., 
2006; Y. R. Lee et al., 2006; Tolfvenstam et al., 2011). The high expression level of these 
biomarkers except RANTES at Day 1-3 may be informative of the strength of the innate 
response during early infection, which may be related to the progression of disease 
severity after Day 1-3. CCL8 (MCP-2), the top RNA biomarker is a chemokine that had 
been previously associated as a biomarker for tuberculosis diagnosis (Ruhwald et al., 
2008) and outcome of hepatitis C virus infection (Hellier et al., 2003). IP-10 (CXCL-10), 
the top protein biomarker is a pro-inflammatory chemokine (Luster, 1998), which had 
been highly associated as a biomarker to predict severity of inflammatory diseases 
including infectious diseases, immune dysfunction and tumor development (Liu et al., 
2011). Soluble uPAR is a versatile signaling proteinase receptor (Blasi & Carmeliet, 
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2002)that was associated as a biomarker to predict survival of HIV-1 infection (Sidenius et 
al., 2000) and to discriminate primary focal segmental glomerulosclerosis (Huang et al., 
2014), which may be related to the protective PLCE1 loci associated with DSS (Khor et 
al., 2011). Furthermore, VPS13C is a vascular protein was previously associated with the 
pathophysiology of type-2 diabetes (Strawbridge et al., 2011), which may support the 
association of diabetes with dengue severity (Pang et al., 2012). These biomarkers showed 
high biological relevance to dengue pathophysiology but they may not fully explain the 
development of severe disease, as it may also be influenced by other mechanisms such as 
the host genetic susceptibility (Khor et al., 2011). 
 
Many of the WS stated by the WHO 2009 classification are seen typically Day 4-7 p.f. 
in the clinical course (Leo et al., 2013; T. L. Thein, Gan, et al., 2013; Tsai et al., 2013). 
Mucosal bleeding was a common WS in our cohort and in others (Leo et al., 2013; T. L. 
Thein, Gan, et al., 2013), and a majority of the patients showed WS mainly during 
admission into hospital at Day 4-7 p.f. and during hospitalization, which was also 
observed in other studies (Binh, Matheus, Huong, Deparis, & Marechal, 2009; Leo et al., 
2013). Similarly, in other studies (Leo et al., 2013; T. L. Thein, Gan, et al., 2013), WS 
namely abdominal pain (AUC=0.51), persistent vomiting (AUC=0.56) and mucosal 
bleeding (AUC=0.50) had less optimal prognostic performance in this cohort, 
reemphasizing the importance to assess the molecular biomarker as a potential prognostic 
tool.  
 
Ideally, in primary healthcare facilities, the clinician should have a reliable test that 
can diagnose and predict at Day 1-3 p.f. if a patient may progress to severe disease which 
requires close monitoring and hospitalization. Our findings showed that by combining 
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RNA and protein biomarkers, a model (CCL8, VPS13C, and uPAR) was established with 
82.9% sensitivity, 80.0% specificity using the discovery cohort. Furthermore, by adding 
platelet counts to the biomarkers, a model (CCL8, VPS13C and Platelets) with 81% 
sensitivity and 84% specificity could be established. When validating in an independent 
cohort, the top two models achieved high sensitivity of up to 96% with a corresponding 
specificity of 49.1% (CCL8, VPS13C, and uPAR), and 56% (CCL8, VPS13C and 
Platelets), where sensitivity is more critical during triage as compared to specificity. 
Moreover, these models may be tested simultaneously with the dengue virus PCR assay as 
diagnosis, particularly in dengue endemic regions with high prevalence, to reduce the turn-
around time required to guide prompt clinical management. Furthermore, we showed that 
the predicted WS+Hosp. group using the top two models displayed significant differences 
in pathophysiology compared with the predicted Non-WS+Non-Hosp. group, illustrating 
the optimistic performance of the optimal models. In addition, we showed that both 
models were able to pick up patients who do not present with thrombocytopenia at Day 1-
3 p.f., but only present at Day 4-7 p.f.  
 
The generalizability of these optimal models may be limited until validation is 
performed in larger cohorts of adult dengue patients. The different predominant serotype 
in the discovery and validation cohorts may have also affected the results to some extent. 
However, the results suggested that the optimal models may still be applicable during 
epidemics of both serotype 1 and 2, which are the two most common serotypes that cause 
significant disease burden in Singapore and South-East Asia. Nevertheless, it is also 
important to emphasize that this study had presented other potential models such as IP-10 
protein and CCL8 RNA for prognosis, even though they may not be most optimal in this 
population (Table 2 and Supplementary Table 5). They may be more useful in other 
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population when validated with large number of patients. The small number of severe 
dengue patients is due to the low prevalence of severe dengue in adults in Singapore (Leo 
et al., 2013). Therefore, it was statistically challenging to develop optimal models in 
stratifying patients of high risk of severe dengue. Nevertheless, with the low prevalence of 
severe dengue patients, it highlighted the need to focus more on patients with warning 
signs to prevent them from severe disease progression. Furthermore, the clinical 
management may vary in the two different periods of the discovery and validation cohorts, 
which may account for the variation in the performance of the models. Lastly, innovation 
will be needed to reduce the cost and complexity of the current methods used to detect 
multiple RNA transcripts and protein simultaneously with a blood test based application, 
particularly for application in a developing countries. 
 
In summary, this is the first study, to our best knowledge, that showed hospitalized 
adult dengue patients with WS at Day1-3 p.f. have differential pathophysiological features 
from non-hospitalized patients with no WS. Selected laboratory and molecular features 
were potential biomarkers for triage at early infection. With future independent larger 
cohorts for validation, these optimal models may be refined for stratification of adult 
patients at early infection who are more likely to progress in disease severity that require 
close monitoring and potential interventions. These biomarkers can be integrated with 
viral detection assays as a potential point-of care tool for diagnosis and prognosis, 
simultaneously, to guide clinical management and potentially treatment, when antivirals 






















CHAPTER 6: CLINICAL AND LABORTORY RISK 
FACTORS OF DENGUE DISEASE SEVERITY 
 
6.1. INTRODUCTION 
Dengue results in a wide spectrum of non-specific clinical manifestations with 
unpredictable clinical course and outcome. Patients can be clinically classified as ‘dengue 
fever’ (DF), ‘dengue hemorrhagic fever’ (DHF) or ‘dengue shock syndrome’ (DSS) 
according to the 1997 WHO dengue classification system (WHO, 1997). More recently, 
based on the WHO classification system (WHO, 2009), patients can be clinically 
classified as ‘probable dengue’, ‘dengue with warning signs’ or ‘severe dengue’ according 
to the 2009. Although a large proportion of patients recover after a mild self-limiting 
disease, a small proportion may progress to develop severe dengue clinical manifestations, 
some of which require interventions in the intensive care unit (ICU). The progression to 
severe clinical manifestations is usually unpredictable. Without prompt and appropriate 
therapy, case fatality rate may exceed 20%(WHO, 2009).   
 
There are currently no systematic studies, but only case series reported (Bouldouyre et 
al., 2006; Juneja et al., 2011) focusing on epidemiological, clinical and laboratory risk 
factors at first presentation in hospital that are predictive of clinical severity, as defined by 
the requirement for ICU admission, instead of the WHO classification criteria. These 
studies and classifications may not be generalizable to all populations at risk as well as in 
different clinical settings and healthcare systems. Furthermore, with the recommendation 
of close monitoring of patients with warning signs in hospital (WHO, 2009), there is a 
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greater need to identify these high risk dengue patients 24 hours prior to ICU admission, 
and information on this is also currently lacking. Therefore, it is important to identify and 
evaluate the clinical and laboratory risk factors of ICU admission at first presentation in 
hospital as well as 24 hours prior to ICU admission, particularly in the predominantly 
dengue serotype 1 and 2 epidemics which are most commonly found and responsible for 























(Junxiong Pang, Tun-Linn Thein, Yee-Sin Leo, David C Lye. Clinical and 
Laboratory Risk Factors of Dengue Patients Requiring Admission into Intensive 
Care Unit during 2004-2008 Dengue Epidemics: A Matched Case-Control Study- 
BMC Infect Dis. 2014 Dec 5;14(1):649.) 
 
A total of 8,123 dengue-infected patients were admitted into Tan Tock Seng Hospital 
during the dengue epidemics between January 2004 and December 2008. Among these 
admissions, there were a total of 27 dengue-infected cases that required intensive care 
interventions in the intensive care unit (ICU). Out of these 27 ICU cases, 22 cases had 
shock, four cases had severe organ involvement, two cases had severe bleeding, two cases 
had acute respiratory disease syndrome (ARDS), one case had encephalopathy and one 
case had intracranial hemorrhage. Each ICU case was matched to four non-ICU dengue 
cases by year of presentation, with a total of 108 dengue-infected matched controls that 
did not require intensive care interventions randomly selected. The median age of the 
cases was 44 years (25th-75th percentiles [pctl]: 36-53 years), with 30% female and 78% 
Chinese. The median age of the controls was 34 years (25th-75th pctl: 25-44 years), with 
36% female and 71% Chinese (Table 15). Among the cases, 48% were positive for 
dengue polymerase chain reaction assay (PCR) and 52% were positive by serology. 
Among the controls, 29% were positive for dengue PCR, and 71% were positive by 
serology. The median DPF at presentation was 3 (25th-75th pctl: 3-5 days) and 5 days 
(25th-75th pctl: 4-5 days) for cases and controls, respectively. This may suggest that the 
ICU patients were sicker, requiring earlier admission to hospital. However, there was no 
significant association observed in gender, ethnic groups, IgG status and median days post 
fever (DPF) at first presentation with ICU admissions. 
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Demographic and Co-morbidity Risk Factors of ICU 
 Age groups 50-59 years old [conditional odds ratio (COR) =8.51; 95% confidence 
interval (CI) =1.38-52.6] and equal to or greater than 60 years old (COR=21.98; 95% 
CI=1.97-245) had significantly higher risk of ICU admission compared with age group 14 
to 30 years old. However, after adjusting for diabetes mellitus, only age group 50-59 years 
old was observed to be a significant risk factor (adjusted COR (ACOR)=6.9; 95% 
CI=1.25-38.23) for ICU admission (Table 15). Among the co-morbidities analyzed, 
patients with diabetes mellitus were found to have significantly higher risk (COR=11.57; 
95% CI=1.25-1077) of ICU admission compared with patients with no diabetes. After 
adjusting for age, the risk remained high with ACOR of 5.53 (95% CI=0.56-54.15), but it 
was statistically insignificant, probably due to the small sample size of cases (Table 15). 
In addition, patients with a cardiac disorder (dysfunction) were observed to be at higher 
risk (ACOR=3.18; 95% CI=0.21-47.52) compared with patients without. This may also be 
a potential risk factor that requires further investigation, even though it was statistically 













Table 15. Demographic and co-morbidities of dengue-infected non-ICU (controls) 
and ICU (cases) patients 
DPF- Days Post Fever; COR- Conditional Odds Ratio 
*Adjusted Conditional Odds Ratio (ACOR) was obtained from a multivariate conditional logistic 































 1.07 0.003 1.02-1.11 1.05 0.014 1.01-1.10 
Age groups           
14-30 36 33 4 15 1      
30-39 32 30 7 26 3.64 0.138 0.66-20.0 2.48 0.244 0.54-11.41 
40-49 24 22 7 26 5.9 0.061 0.92-37.9 4.1 0.126 0.67-25.04 
50-59 13 12 6 22 8.51 0.021 1.38-52.6 6.9 0.027 1.25-38.23 
≥60 3 2.8 3 11 21.98 0.012 1.97-245.2 5.49 0.165 0.50-60.54 
Gender           
Female 39 36 8 30 0.74 0.52 0.29-1.87 0.59 0.318 0.21-1.65 
Ethnic groups           
Chinese 77 71 21 78 1      
Malay 5 4.6 2 7.4 1.44 0.667 0.28-7.49 2.47 0.36 0.36-17.15 
Indian 15 14 2 7.4 0.45 0.344 0.09-2.37 0.39 0.315 0.06-2.47 
Others 11 10 2 7.4 0.65 0.606 0.13-3.36 0.95 0.952 0.17-5.29 
IgG at 
presentation 
          








 0.75 0.059 0.56-1.01 0.78 0.112 0.58-1.06 
Diabetes 
mellitus 
          
Yes 3 2.8 4 15 11.57 0.031 1.25-1077 5.53 0.142 0.56-54.15 
Hypertension           
Yes 10 9.3 5 19 2.22 0.184 0.69-7.17 0.42 0.296 0.08-2.14 
Hyperlipidemia           
Yes 7 6.5 4 15 2.57 0.168 0.67-9.83 1 0.998 0.20-4.87 
Cardiac 
disorder 
          
Yes 2 1.9 3 11 9.83 0.051 0.99-97.23 3.18 0.402 0.21-47.52 
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Dengue Severity Classification and Clinical Outcomes 
 The DHF/DSS classification (WHO 1997) at presentation was not significantly 
associated with ICU admission (ACOR=1.8; 95% CI=0.54-6.08), with sensitivity of about 
19% and specificity of 87%. However, Severe Dengue classification (WHO 2009) at 
presentation was significantly associated with ICU admission (ACOR=8.79; 95% 
CI=2.65-29.16) (Table 16), with sensitivity of 52% and specificity of 94%. By the end of 
the hospitalization, both DHF/DSS and Severe Dengue classifications were observed to be 
significantly associated with ICU admission (WHO 1997: ACOR=2.99; 95% CI=1.15-
7.78) (WHO 2009: ACOR=116.4; 95% CI=8.79-1541) (Table 16). By the end of the 
hospitalization, DHF/DSS classification achieved sensitivity and specificity of 67% and 
78%, respectively, while Severe Dengue classification achieved sensitivity and specificity 
of 89% and 90%, respectively.  
 
 The median days for progression to DHF/DSS and severe dengue for cases was 4 
(25th-75th pctl: 3-5 days) and 3 DPP (25th-75th pctl: 3-5 days), respectively. For the 
controls, the median days for progression to DHF/DSS and severe dengue was 3 (25th-
75th pctl: 2.3-3.8 days) and 2.5 DPP (25th-75th pctl: 1.8-3.3 days). The median length of 
stay (LOS) in hospital was 8 (25th-75th pctl: 6-13.5 days) and 4 days (25th-75th pctl: 3-5 
days) for cases and controls, respectively. The median DPF and DPP to ICU admission 
was 6 (25th-75th pctl: 4-7.5 days) and 3 (25th-75th pctl: 2-4.5 days) days respectively. 
The median LOS in ICU for the cases was 3 days (25th-75th pctl: 2-4 days). Among the 
cases, there were seven deaths (case fatality rate=26%), with median DPF of 7 days (25th-





Table 16. Severity classification and duration of illness of dengue-infected non-ICU 
(controls) and ICU (cases) patients 
DPF- Days Post Fever; DPP- Days Post Presentation; LOS- Length of Stay; COR- Conditional Odds Ratio  
*Adjusted Conditional Odds Ratio (ACOR) was obtained from a multivariate conditional logistic regression 
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ICU Risk Factors at First Presentation in Hospital 
 At first presentation, warning signs from the WHO 2009 classification were not 
observed to be significantly associated with ICU admission. In addition, other signs and 
symptoms such as haemorrhagic manifestation, rash, leucopenia, nausea/vomiting, ache 
and pains, thrombocytopenia and tardycardia were not observed to be significantly 
associated with ICU admission. Hypoproteinemia (ACOR=4.65; 95% CI=1.09-19.74), 
hypotension (ACOR=7.63; 95% CI=1.83-31.79), severe organ involvement 
(ACOR=33.04; 95% CI=3.30-331.3) and hematocrit rise with rapid platelet drop 
(ACOR=8.66; 95% CI=2.46-30.53) were observed to be significantly associated with ICU 
admission (Table 17).  
 
 Pulse rate (ACOR=1.05; 95% CI=1.01-1.09), neutrophil proportion(ACOR=1.11; 
95% CI=1.04-1.17), serum urea (ACOR=1.26; 95% CI=1.02-1.56), creatinine 
(ACOR=1.02; 95% CI=1.01-1.04), aspartate (ACOR=1.01; 95% CI=1.001-1.06) (AST) 
and alanine aminotransferases (ALT),(ACOR=1.01; 95% CI=1.001-1.06) at first 
presentation were positively correlated with ICU admission (Table 17). On the contrary, 
lymphocyte (ACOR=0.90; 95% CI=0.85-0.96) monocyte proportions (ACOR=0.86; 95% 
CI=0.77-0.95), platelet count (ACOR=0.98; 95% CI=0.96-0.99), serum protein 
(ACOR=0.88; 95% CI=0.79-0.98) and albumin (ACOR=0.81; 95% CI=0.70-0.94) at first 
presentation were significantly and negatively correlated with ICU admission (Table 17).  
 
These risk factors of ICU admission at first presentation in hospital were used to 
create a predictive model. The most optimal model derived was a combination of 
neutrophil proportion, ALT and serum urea level with an area under the curve of 0.92 
(Hosmer–Lemeshow Goodness of fit test P=0.52), indicating that the model had good 
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discrimination between non-ICU and ICU patients at first presentation in hospital. A 
prognostic index (P) was created using this model. Using the default cut-off of P = 0.5, the 
model had sensitivity of 58.8%, specificity of 96.3%, positive predictive value of 76.9% 
and negative predictive value of 91.8% (Figure 17). Using a cut-off of P = 0.25 
(maximizing sensitivity and specificity; Figure 17A.), the model had sensitivity of 88.2%, 
specificity of 88.9%, positive predictive value (PPV) of 62.5% and negative predictive 
value (NPV) of 97.3%. The predicted probability of ICU admission at presentation was 











For each individual i, 1x  to 3x  are indicator variables taking on respective values, where 

















Table 17. Clinical and laboratory variables at first presentation of dengue-infected 




















Hypoproteinemia           






Hypotension            








          









          



























































































































































(25%-75%)   
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DPF- Days Post Fever; DPP- Days Post Presentation; LOS- Length of Stay; COR- Conditional Odds Ratio  
*Adjusted Conditional Odds Ratio (ACOR) was obtained from a multivariate conditional logistic regression 




ICU Risk Factors at 24 Hours Prior to ICU Admission 
 Close monitoring of high risk patients in hospital for ICU admission may be 
challenging as clinical conditions can evolve unpredictably. We further explored potential 
risk factors that can provide stratification at 24 hours prior to ICU admission after their 
first presentation in hospital. Pulse rate (COR=1.07; 95% CI=1.002-1.14), white cell count 
(COR=1.59; 95% CI=1.04-2.44), lymphocyte (COR=1.19; 95% CI=1.03-1.38)  and 
monocyte proportions (COR=1.35; 95% CI=1.02-1.78) were observed to be significantly 
higher in ICU dengue patients 24 hour before ICU admission compared with these at first 
presentation (Table 18). On the contrary, blood pressure (COR=0.96; 95% CI=0.92-
0.996) and hematocrit (COR=0.81; 95% CI=0.66-0.99) were observed to be significantly 
lower in ICU dengue patients 24 hour prior to ICU admission compared with that at the 
first presentation (Table 18). The most optimal model derived was a combination of the 
monocyte and lymphocyte proportion, blood pressure and pulse rate, which had an area 
under the curve of 0.94 (Hosmer–Lemeshow Goodness of fit test P=0.96), indicating that 
the model had good predictive potential of whether a high risk dengue-infected patient is 
likely to require ICU admission in the next 24 hour. In addition, this model is more 
accurate than the model comprising of only pulse rate and blood pressure, which are 
known critical factors for ICU admission, and has an AUC of only 0.74. A prognostic 
index (P) was thus created using the model with monocyte and lymphocyte proportion, 
blood pressure and pulse rate. Using the default cut-off of P = 0.5, the model had 
sensitivity of 74.1%, specificity of 88%, positive predictive value of 87% and negative 
predictive value of 75.9% (Figure 17B). Using a cut-off of P = 0.40 (maximizing 
sensitivity and specificity; Figure 17B), the model had sensitivity of 88.9%, specificity of 
86%, PPV of 80% and NPV of 86.4%. The predicted probability of ICU admission in the 















For each individual i, 1x  to 3x  are indicator variables taking on respective values, where 
represents  1x  monocyte proportion (%), 2x blood pressure (mHg), 3x  pulse rate (bpm) and






















Table 18. Significantly associated laboratory variables at 24h prior to ICU admission 





Den-infected ICU at 
24H prior ICU   
(n=23)^ 
COR p-value 95% CI 
Systolic blood pressure 
(25%-75%)   
110 (91.5- 118.5) 90 (80- 101.5) 0.96 0.03 0.92-0.996 
Pulse rate (25%-75%)   95.5 (88.5- 102) 101 (90.5- 117.5) 1.07 0.044 1.002-1.14 
White cell count (25%-
75%)   
3.3 (2.4- 4.2) 4.9 (3- 7.4) 1.59 0.033 1.04-2.44 
Proportion lymphocytes 
(25%-75%)   
16.5 (9.8- 19.9) 23.5 (18.1- 28.6) 1.19 0.020 1.03-1.38 
Proportion monocytes 
(25%-75%)   
7.9 (5.1- 9.9) 12.1 (9.1- 17.9) 1.35 0.033 1.02-1.78 
Serum haematocrit(25%-
75%)   
44.9 (42.8- 47.2) 40.2 (33.6- 43.6) 0.81 0.037 0.66-0.99 
COR- Conditional Odds Ratio 
^ - Four cases were excluded as they were admitted into ICU less than 24 






















Figure 17. Sensitivity and specificity plots of Model at presentation (A.) and Model 










































































Differential Clinical and Laboratory Features of Death Cases at First Presentation 
among the ICU Cases 
 A subgroup analysis was performed among the ICU cases to explore the 
significantly different clinical and laboratory features of death cases at first presentation in 
hospital (Table 19). The median age for death ICU cases (n=7) and non-death ICU (n=20) 
subgroups was 48 (25th-75th pctl: 27-50.5) and 43 (25th-75th pctl: 36.8-54.3) years old, 
respectively. There were about 30% female in both the death and non-death subgroups 
(P=1). Based on the 2009 WHO classification, 100% and 85% had severe dengue in the 
death and non-death subgroups, respectively (P=0.545). The median length of stay in ICU 
was 3 and 3.5 days for the death and non-death subgroups, respectively (P=0.383). The 
median length of stay in hospital was 4 and 9 days for death and non-death subgroups 
(P=0.029). Importantly, the following characteristics at first presentation were observed to 
be significantly different between the death and non-death ICU subgroups: having any 
warning signs (P=0.022), monocyte (P=0.035) and eosinophils proportions (P=0.035), 















Table 19. Significantly different characteristics between deaths and non-deaths 
at first presentation in the subgroup analysis of ICU Dengue-infected patients. 
^- Fisher’s exact test 





















Den-infected ICU  
Non-Death (n=20) 
% 
Den-infected ICU  
Death (n=7) 
% p-value* 
Median LOS in 
hospital (25%-75%) 9 (7-17.25)  4 (3.5-8.5)  0.0285 





Median DPP to death 
(25%-75%) 
0  
7 (7-15.5)   
Any warning sign      
Yes  9 45 7 100 0.022^ 
Proportion monocytes 
(25%-75%) 9.1 (6.55-12.55)  5.4 (3.8-7.15)  0.0348 
Proportion 
eosinophils (25%-75%) 0.1 (0-0.4)  0.5 (0.4-0.9)  0.0351 
Serum AST (25%-75%) 11 (10-17)  19 (16-29)  0.0487 
Serum ALT (25%-75%) 
126 (70.25-263.25)  
939 (442.75-
1577.75)  0.0103 
Serum protein 
(25%-75%) 85.5 (39.25-146.25)  491 (159-653.5)  0.0328 
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6.3. DISCUSSION AND CONCLUSION 
 Dengue infection results in a wide spectrum of clinical severity, from self-limiting 
dengue fever to severe dengue. Timely and appropriate monitoring and clinical 
management, mainly with fluid interventions of dengue patients is critical to reduce 
morbidity and mortality (WHO, 1997, 2009). Some of these patients may also require 
critical clinical management in the intensive care unit (ICU). Healthcare resources such as 
ICU beds and close monitoring may be limited during a large epidemic, making effective 
triage of patients who may require ICU admission more crucial. However, there is 
currently a lack of systematic studies looking at potential early risk factors for ICU 
admission. Simple and vital clinical and laboratory indicators during first presentation at 
hospital or even 24 hours prior to ICU admission may assist clinicians in triaging these 
patients.   
 
 From this matched case-control study, dengue patients who were either between 50 
to 59 years old or with pre-existing diabetes had about five times the risk of ICU 
admission, compared with dengue patients who are less than 30 years old or without 
diabetes, respectively (Table 15). Age group 50 to 59 years old was also implicated in ICU 
admission in a case-control study of dengue fatality (Ong et al., 2007) and the recent 
multi-center mortality cohort study in Singapore (Leo et al., 2011). However, the age 
group at risk of dengue hemorrhagic fever (DHF)observed in a dengue 2 epidemic in our 
other study was those from 30-49 years old (Pang et al., 2012). This suggests that different 
severity outcome measures, either defined as DHF, fatality or the requirement for ICU 
admission, may affect different age groups. Furthermore, age group of 60 years old and 
above was not observed to be a risk factor of ICU admission previously (I. K. Lee et al., 
2012; Lye et al., 2010) which supports the observations in this study. On the contrary, it 
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was observed that the mean age of ICU admission in New Delhi case series was younger 
(39.6 years) (Juneja et al., 2011), which may be due to the lower proportion of dengue 
cases aged greater than 55 years in that study. In addition, in southern Taiwan, dengue 
patients 65 years old or above were reported to have a higher fatality risk compared with 
patients less than 65 years of age (I. K. Lee, Liu, & Yang, 2008). Interestingly, there was 
no significant difference in age between severe cases requiring ICU admission and benign 
casesin a dengue serotype 1 epidemic in New-Caledonia (South Pacific), with mean age of 
47 years in both groups (Bouldouyre et al., 2006). These findings highlighted the potential 
differences in epidemiology of ICU dengue patients in different geographical regions, 
which would be interesting for further evaluation. In general, the risk of ICU admission 
was observed to increase from age 40 years old and above (Table 15). Diabetes was not an 
independent risk factor of ICU admission in this study (even after adjusting for DHF), 
which has also been similarly reported in dengue mortality studies (I. K. Lee et al., 2012; 
Leo et al., 2011; Ong et al., 2007). However, diabetes was shown to be an independent 
risk factor of DHF as an outcome (Figueiredo et al., 2010; Pang et al., 2012), and DHF as 
an outcome was significantly associated with ICU admission in this study. This may 
suggest having diabetes may not predispose a patient to ICU admission or death directly, 
but it may increase the risk of DHF, resulting in ICU admission. However, caution in 
interpretation remains as the sample size of cases is small in this study. 
 
 Based on the WHO classification at presentation, patients who fulfilled the WHO 
2009 severe dengue classification were at a higher risk of ICU admission, eight times 
more than patients classified as non-severe, but not for the WHO 1997 DHF/DSS criteria 
at first presentation(Table 16). This suggests that the WHO 2009 classification for severe 
dengue is more sensitive in identifying clinically more severe patients than the WHO 1997 
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classification for DHF/DSS at first presentation; similar observations have been reported 
in other studies (Gan et al., 2013; Leo et al., 2011; Narvaez et al., 2011). However, the 
application of both WHO 1997 and 2009 classification systems for severe dengue 
conditions only achieved sensitivity of about 19% and 52%, respectively, in differentiating 
patients who required ICU admission at first presentation, although both classification 
systems for classifying severe conditions achieved high specificity of 87% and 94%, 
respectively. In contrast, at the time of final clinical outcome, the WHO 1997 
classification system achieved sensitivity and specificity of about 67% and 78% 
respectively, and the WHO 2009 classification system achieved sensitivity and specificity 
of about 89% and 90% respectively. Our results are comparable to the sensitivity and 
specificity of identifying patients requiring category III care (includes ICU admission) for 
DHF/DSS (39.0% and 75.5%, respectively) and for severe dengue (92.1% and 78.5%, 
respectively) as described by Narvaez F et al. (Narvaez et al., 2011). 
 
 Most warning signs and symptoms at first presentation in this study were not 
observed as risk factors of ICU admission in this study, except for hypoproteinemia, 
hypotension, and hematocrit rise with rapid platelet drop (Table 17). Other studies also 
reported that most warning signs were not able to identify patients progressing into DHF, 
severe dengue, category III care or fatality efficiently (I. K. Lee et al., 2012; Narvaez et 
al., 2011; T. L. Thein, Gan, et al., 2013). Gastrointestinal symptoms were proposed as an 
important warning sign for severe dengue and fatality (Figueiredo et al., 2010; I. K. Lee et 
al., 2012), but it was not associated with ICU admission in this study. Hypoproteinemia 
was observed in most (>80%) of the fatal cases in other studies (Leo et al., 2011), and was 
observed at first presentation of severe patients who required ICU admission (Sam, Omar, 
Teoh, Abd-Jamil, & AbuBakar, 2013) . Similarly, hypotension was observed in 71% of 
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fatal cases (Ong et al., 2007), and was observed to be significantly more in severe cases 
who required ICU admission (Sam et al., 2013). Interestingly, having any warning signs at 
first presentation may be a risk factor for death among ICU cases (Table 19).  
 
 The following laboratory parameters at presentation may be potential indicators of 
ICU admission at first presentation in hospital, and were reported in ICU admission case 
series and/or fatality case-control studies: pulse rate (Ong et al., 2007), neutrophil 
(Bouldouyre et al., 2006), lymphocytes and monocytes proportions, platelet count 
(Chandralekha, Gupta, & Trikha, 2008; I. K. Lee et al., 2012; Ong et al., 2007; Sam et al., 
2013; Schmitz et al., 2011), serum urea, creatinine (Bandyopadhyay et al., 2006; Ong et 
al., 2007; Schmitz et al., 2011), AST, ALT (Bandyopadhyay et al., 2006; Chandralekha et 
al., 2008; Ong et al., 2007; Sam et al., 2013; Schmitz et al., 2011)[5, 10, 15, 20, 22], 
protein (Bouldouyre et al., 2006; Schmitz et al., 2011)[5, 22] and albumin (Bouldouyre et 
al., 2006; Ong et al., 2007; Sam et al., 2013; Schmitz et al., 2011). In our study, a 
prognostic model using a combination of neutrophil proportion, ALT and serum urea level 
provided a sensitivity of 88.2%, specificity of 88.9%, PPV of 62.5% and NPV of 97.3%. 
This is comparable to the models for predicting severity, defined as death using a model 
comprised of creatinine, free bilirubin, amylase and platelets with PPV 66.7% and NPV 
75.5% (Bouldouyre et al., 2006), and the prediction of DHF in adult patients at 
presentation with median DPF of 5 days using a model comprised of clinical bleeding, 
serum urea, serum protein, and lymphocyte proportion with sensitivity 83%, specificity 
84%, PPV 18%, NPV 99% (V. J. Lee et al., 2008; V. J. Lee et al., 2009; T. L. Thein et al., 
2011). Serum urea level was a common variable in these models, which suggests urea 
level in serum may be an important risk factor for severity. Monocyte proportion, AST, 
ALT and serum proteins were also observed to be significantly different between the death 
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and non-death among ICU cases. This suggests that these could be important factors 
involved in the progression of fatality after ICU admission, and should be considered for 
close monitoring during hospitalization. On the contrary, only bandemia (excess of 
immature white blood cells) was highlighted as a significant risk factor at first presentation 
between non-fatal and fatal patients (I. K. Lee et al., 2012) 
 
 Dengue severity is unpredictable during hospitalization. Pulse rate, lymphocyte 
and monocyte proportions, blood pressure, white cell count, and hematocrit were observed 
as risk factors at 24 hours prior to ICU admission, and were reported in ICU admission 
case series and/or fatality case-control studies (Juneja et al., 2011; I. K. Lee et al., 2012; 
Ong et al., 2007). In the fatality study, leukocytosis and platelet count were also shown to 
be significantly different between the first presentation and pre-fatal data (I. K. Lee et al., 
2012). Interestingly, lymphocyte and monocyte proportions of ICU dengue patients at 24 
hours prior to ICU admission was significantly greater compared with that at first 
presentation, but lower compared with non-ICU dengue patients at first presentation. This 
suggests the dynamic differences in immune response between dengue patients who 
required ICU admission and dengue patients who did not require ICU admission were 
already evident even at first presentation, which is about three to five days post fever. In 
addition, this highlighted the fact the immune response changes rapidly over time as a 
patient progresses from first presentation at hospital to 24 hours before ICU admission 
(Hoang et al., 2010). A prognostic model using a combination of monocytes and 
lymphocytes proportion, blood pressure and pulse rate provided a sensitivity of 88.9%, 
specificity of 86%, PPV of 80% and NPV of 86.4%.Some of these significant variables 
were also part of the model used for predicting pediatric DHF which comprise white cell 
count, monocytes proportion, platelet count, and hematocrit with sensitivity of 97% and 
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specificity of 48% (Potts et al., 2010). Furthermore, this model is clinically relevant as 
pulse rate and blood pressure were known critical factors for ICU admission, and the 
predictors were selected in an unbiased manner based on its statistical significance by 
regression techniques. Lastly, this model was observed to be more effective in stratifying 
potential ICU cases requiring ICU intervention in about 24 hours’ time before ICU as 
compared to the predictive model with only pulse rate and blood pressure as significant 
variables. 
 
 There are some limitations in our study that should be taken into consideration 
when interpreting the results. First, the study had a relatively small number of patients 
with ICU admission that may result in low statistical power to detect true association, even 
though Tan Tock Seng Hospital is a major infectious disease center in Singapore, which 
provided care for about 40% of all reported dengue patients in Singapore. As such, the 
power was maximized by using four matched controls to each case. Second, no dengue 
serotype data and BMI/obesity data were available for individual study subjects. In order 
to account for the serotype variable, we used the year of dengue presentation as a 
surrogate for serotype (as describe in methods) as well as a matching factor for our 
selection of controls to minimize confounding effect due to the different predominant 
serotype each year. Third, this model is derived from adult dengue patients presenting to 
hospital at a median of 5 DPF (25th-75thpctl=3-5 days). Hence, the model may be less 
accurate when used for triage of patients outside this period range, or when used at 
community healthcare facilities, where patients may present to clinicians at lesser days 
post fever than in our study. Further validation studies are still required to confirm the 
validity and reliability of this model. Lastly, three parameters in our probability equation 
were laboratory test results, which may not be easily available in resource-poor countries. 
149 
 
However, it is hoped that as the awareness of dengue prevention and clinical management 
is raised with the guidance of the WHO, there will be an increase in laboratory capabilities 
that can help to resolve this challenge gradually. 
 
 Studies to assess risk factors for severity as defined by DHF/DSS and severe 
dengue for effective triage are important. However, information on dengue severity as 
defined by the requirement of ICU admission is also critical, but lacking. This is the first 
systematic study, to our best knowledge, that highlighted the differential 
pathophysiological background of dengue patients at presentation and at 24 hours prior to 
ICU admission. Based on this study, the key demographic and clinical risk factors for 
triage at first presentation that we propose are age group 50 to 59 years old, pre-existing 
diabetes, WHO 2009 classification at first presentation, hypoproteinemia, hypotension and 
hematocrit rise with rapid platelet drop. For laboratory risk factors, two optimal models 
with significantly associated variables were derived and proposed to complement the 
WHO classification system. An optimal model at first presentation comprises neutrophil 
proportion, ALT and serum urea level, and another optimal model for assessing severity 
24 hours prior to ICU admission comprises monocytes and lymphocytes proportions, 
blood pressure and pulse rate. This would be useful to identify dengue patients who may 
require ICU admission early at presentation as well as during hospitalization for closer 
monitoring and clinical management to reduce morbidity and mortality, when validated in 




















CHAPTER 7: THE POTENTIAL PUBLIC HEALTH 
IMPACT OF RISK FACTORS ASSOCIATED WITH ADULT 
DENGUE SEVERITY- THE CLOSING CHAPTER. 
 
7.1. INTRODUCTION 
Dengue caused substantial morbidity and mortality globally, resulting in an alarming 
public health burden (Bhatt et al., 2013; Carrasco et al., 2011; Shepard et al., 2013; P. T. 
Tam et al., 2012; WHO, 2009, 2010a, 2012). Substantial improvements are possible. 
Dengue burden can be reduced through an integrative top-down government and bottom-
up community approach. This strategy involves execution of sustainable prevention 
measures and programmes, and strong recommendation for early diagnosis and prognosis 
to guide interventions and clinical management (WHO, 2009, 2012) at different stages of 
dengue disease: the pre-infection, pre-clinical (post-infection), and clinical stages 
(Ginsburg & Willard, 2009).   
There is no one single risk factor assessed so far that can account for all severe dengue 
disease outcomes, which was also highlighted by Guzman M.G. and Kouri G.P. as a 
“multifactorial and unifying view of the problem”  (Guzman & Kouri, 2008; Kouri, 
Guzman, & Bravo, 1987). Therefore, the integrated approach also involves unravelling of 
risk factors associated with dengue severity from different aspects of dengue diseases, and 
to apply these risk factors in an integrative manner to achieve maximum cost-effectiveness 
in reducing dengue burden. Moreover, it is of paramount importance for the whole 
community (both residents and government), particularly in dengue endemic countries to 
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support prevention measures/programmes, and for the clinicians to recognise the risk 
factors early for early diagnosis, prognosis and interventions to reduce dengue severity. 
Severity is usually defined according to the WHO classifications(WHO, 1997, 2009), but 
this could also be defined by clear and objective clinical criteria such as the requirement of 
intensive care unit admission. Even though it has its own limitations and advantages as a 
measurement of severity, as described in Chapter 1, it remains critically relevant to have 















7.2. APPLICATION OF RISK FACTORS, ITS POTENTIAL 
PUBLIC HEALTH IMPACT, AND IMPLICATIONS FOR 
PATHOGENESIS 
Epidemiological and genetic risk factors as baseline risk 
Susceptible individuals in dengue endemic countries who possessed the 
epidemiological and genetic risk factors identified in Chapter 3 and 4 may be classified as 
the “potentially susceptible group” who are at an elevated risk of complications should 
they get infected with dengue; the genetic factors identified in Chapter 3 would be of 
particular relevance to both children and adult as baseline risk, while the epidemiological 
risk factors identified in Chapter 4 would be of relevance to only adults. This “potentially 
susceptible group” could be educated and guided by clinicians and public health 
professionals about the importance of primary prevention and protective measures such as 
vector control, the use of insect repellent and mosquito nets, and to avoid countries where 
dengue outbreaks are occurring as much as possible. In addition, this “potentially 
susceptible group” may be recommended to have the dengue vaccine when it is made 
available. However, evidence on the effectiveness of personal protective measures for 
dengue prevention is currently lacking, and further evaluation on vaccine safety and 
efficacy for this “potentially susceptible group” is critically required prior to the 
recommendation (Figure 18).  
This “potentially susceptible group” in the endemic countries should also be highly 
encouraged to visit the primary/secondary healthcare for both screening (for 
epidemiological and genetic risk factors) and early diagnosis at less than 72 hour post 
fever, where rapid diagnostic tests such as the viral RNA detection and NS1/IgM/IgG-
based assays would be available and diagnosis can be made usually within 24-hour. 
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However, there is currently an urgent need to raise the awareness and importance of early 
dengue diagnosis in the public primary healthcare settings to maximise these diagnostic 
and prognostic tools. Even in country such as Singapore which has great accessibility and 
availability to medical care, a large proportion of primary care physicians were not as 
active as expected in ordering dengue diagnostic test for patients who fulfilled clinical 
criteria(L. K. Lee et al., 2011). The situation may be worse in the developing countries, 
where a diagnostic test may not be readily available. Fortunately, in a global effort, much 
guidance and research has been gradually put in place on developing and sharing assays 
and raising awareness on early diagnosis of dengue, particularly in dengue endemic 
developing countries (Peeling et al., 2010). With increasingly more active health-seeking 
behaviour of the population towards screening of risk factors and early diagnosis of 
dengue at the primary/secondary healthcare centres, prompt and appropriate 
interventions/clinical management such as antiviral therapy (when made available) and 
hospitalisation for closer monitoring can be applied to ensure the progression to severe 
dengue is prevented. Furthermore, early prescription of antivirals would only be effective 
during early infection to inhibit viral replication, hence, the importance of early diagnosis 











Figure 18. Potential interventions to reduce the public health burden due to dengue 
at different stage of the disease, from pre-infection, pre-clinical (post-infection) to 
clinical stage of the disease. 
(Adapted from Translational Research 154/6, Ginsburg GS and Willard, Genomic and 
personalized medicine: foundations and applications, 277-286, Copyright 2009, with 








Using age range from 30-49, Chinese, female and having diabetes as individual risk 
factors of DHF (Chapter 4) to compute a screening/triage risk score upon first presentation 
to the clinicians of about 2600 laboratory confirmed dengue patients in Singapore, 
sensitivity drops but specificity increases to about 85% as the risk score increases. 
Negative predictive value (NPV) remains relatively high at about 80% as the risk score 
increases (Figure 19a). Similarly, using logistic regression algorithm of these 
epidemiological risk factors listed above to compute the weighted risk score provided 
comparable performance as the discrete risk scoring method (Figure 19b). This suggests 
that using a discrete risk score of 3 or a weighed risk score of 9 and above as a cut-off for 
DHF in a setting with DHF prevalence of about 3% is more reliable for identifying 
patients who are less likely to develop DHF as dengue outcome.  
On applying the top genetic locus at MICB rs3132468 that was associated with DSS 
(Khor et al., 2011) and non-DSS cases (Whitehorn et al., 2013) in Vietnam on a cohort of 
about 1000 Singapore Chinese dengue adult cases to evaluate the prognostic performance 
for DHF, it can only achieve a sensitivity of 17% and specificity of 82%, PPV of 16% and 
NPV of 84%. The low PPV is likely due to the low DHF prevalence rate in Singapore. The 
high specificity but low sensitivity suggests that the MICB genetic locus is also only 
effective to rule out individuals not likely to develop severe dengue, rather than to identify 









Figure 19. Prognostic performance of using discrete (a) and weighted (b) risk scoring 








RNA and protein biomarkers to complement clinical and laboratory risk 
factors as dengue disease progresses from pre-clinical to clinical stage. 
Taking advantage of the dynamic and sensitive transcriptome and proteome 
changes at the pre-clinical stage (post-infection), there would be opportunity at less than 
72 hour post infection for both antiviral therapy and triage of patients who are at high risk 
of developing severe clinical manifestation, and the need for closer monitoring in the 
tertiary hospital, as described in Chapter 5. Similarly, this molecular biomarkers could be 
applied during the early clinical phase of the disease at the tertiary hospital (Figure 18), to 
complement the application of the clinical risk factors to triage adult dengue patients who 
are likely to develop severe outcomes such as the requirement of intensive care unit 
admission, as described in Chapter 6. 
 
Due to the challenges of utilising warning signs as an early prognostic tool on adult 
dengue patients at primary healthcare setting, particularly at less than 72 hour post fever as 
described in Chapter 1 and 5, two molecular prognostic models were built. The model 
with RNA CCL8, VPS13C and protein uPAR has a sensitivity of 82.9%, specificity of 
80.0%, PPV of 80.6% and NPV of 82.4%. The other model with RNA CCL8, VPS13C 
and platelet counts with sensitivity of 80.9% sensitivity, 84.4% specificity, positive 
predictive value of 80.6% and negative predictive value of 82.4% (Chapter 5). These 
molecular prognostic tools would be useful for clinicians to make well-informed decisions 
early at less than 72 hour post fever to guide clinical management, particularly in the 
primary/secondary healthcare centres, after validation with a larger cohort.  
 
As these high risk dengue adult patients are recommended to be hospitalized from 
primary healthcare setting, it would be optimal to have another prognostic capabilities 
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upon presentation at the hospital for dengue patients who are more likely to progress in 
dengue severity and who would require intensive care unit admission (ICU) during 
hospitalization (Chapter 6). The requirement for ICU may be considered as an important 
clinical outcome of severity, and is usually neglected due to the popular usage of the 
WHO classification (WHO, 1997, 2009). Epidemiological risk factors for requiring ICU 
care were age group 50-59 years old and probably patients with diabetes and cardiac 
disorders. One prognostic model was built for ICU triage at first presentation with risk 
factors of significant discriminatory power. The model with neutrophil proportion, ALT 
and serum urea had sensitivity of 88.2%, specificity of 88.9%, PPV of 62.5% and NPV of 
97.3%. Another model was also built for ICU triage 24hr before ICU admission with risk 
factors of significant discrimatory power. This model with monocyte proportion, blood 
pressure, pulse rate (bpm) and lymphocyte had sensitivity of 88.9%, specificity of 76%, 
PPV of 80% and NPV of 86.4%. These models would also be useful to complement the 
use of warning signs for recommendation of closer monitoring during triage at first 
presentation as well as during hospitalisation to guide clinical management and to reduce 
progression of dengue severity of adult patients. Table 20 summaries the results of this 
thesis. 
 
Potential reduction in healthcare cost and burden due to dengue 
In Singapore, about 80% of the notified adult dengue cases were hospitalized from 
2000 to 2005 despite low rates of DHF (1.8–2.8%) (Lye, Chan et al. 2008). Furthermore, 
the usage of the new WHO 2009 classification, particularly with the warning signs may be 
too sensitive and resulted in significant increase in admission and clinical workload, which 
may not be clinically necessary (S. Kalayanarooj, 2011; Leo et al., 2013). As warning 
signs are recommended as criteria for hospitalization, both sensitivity and specificity are 
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important. High specificity is important to optimize the use of scarce hospital resources to 
manage only patients who are at high risk of progressing to severe dengue 
(Srikiatkhachorn et al., 2011). At the same time sensitivity is critical to ensure that dengue 
patients are not being sent home with subsequent progression to DHF or SD. These 
epidemiological, genetic, and molecular risk factors found in this thesis would provide 
additional guidance for clinicians to triage adult dengue patients who are not likely to 
develop severe dengue disease (Chapter 3 and 4), and those who are more likely to require 
close monitoring (Chapter 5 and 6) at early infection (less than 72 hour post fever). These 
risk factors may also augment the previously derived clinical and laboratory risk factors 
which are mostly looking at dengue patients who presented more than 72hour post fever 
(V. J. Lee et al., 2008; V. J. Lee et al., 2009; Leo et al., 2013; T. L. Thein, Gan, et al., 
2013) to ensure that there were tools available to cover a reasonable time period of first 
presentation of these dengue patients for triage. With these, it is hopeful that unnecessary 
hospitalisation can be reduced in tertiary hospitals, but also at the same time, increase the 
chance of early diagnosis and prognosis for appropriate clinical management of those who 
are at higher risk of severe dengue. As a result, there will be much reduced overall 
healthcare cost incurred (Carrasco et al., 2011; L. K. Lee et al., 2013) and dengue burden 
in Singapore if we could accurately triage adult patients who do require close monitoring 
and are likely to develop severe dengue from those patients that can be safely managed as 
outpatients without progression to severe clinical conditions, as reflected hypothetically in 







Table 20.Summary of risk factors as potential early clinical prognosis tools and 
proposed actions. 
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Implications from studies in thesis for dengue pathogenesis  
Risk factors such as MICB, diabetes and older age have been associated with 
impaired immunity. These high risk individuals may have difficulties in mounting an early 
immune response to inhibit viral entry, replication and infection, which manifests as 
elevated viral load and altered blood monocyte and lymphocyte counts, including 
increased in CCL8 (MCP-2), a chemokine that had been previously associated as a 
biomarker for tuberculosis diagnosis (Ruhwald et al., 2008) and outcome of hepatitis C 
virus infection (Hellier et al., 2003), IP-10 (CXCL-10), a pro-inflammatory chemokine 
(Luster, 1998), highly associated as a biomarker to predict severity of inflammatory 
diseases including infectious diseases, immune dysfunction and tumour development (Liu 
et al., 2011). These may then result in adverse clinical outcomes via more complex 
pathways, which remains to be elucidated.  
 
However, many of the factors identified in the thesis do emphasize the role of 
dysfunctional vascular permeability. Plasma leakage has long been recognised as a key 
part of the pathogenesis pathway to DSS, and this thesis adds to the evidence. Firstly, we 
identified the importance of the PLCE1 gene in DSS, a gene thus far implicated in 
nephrotic syndrome; while this may seem to be an unrelated non-communicable disease, 
we note that the key commonality here is leakage of proteins across the vascular 
endothelium. Likewise, diabetes, and to some extent older age also affects vascular 
endothelial function, and provides an alternative non-genetic basis for increased plasma 
leakage. The molecular markers uPAR is an indicator of diabetes, systemic inflammation, 
and active vascular endothelial dysfunction such as segmental glomerulosclerosis (Huang 
et al., 2014). In addition, VPS13C is a vascular protein was previously associated with the 
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pathophysiology of type-2 diabetes (Strawbridge et al., 2011). Therefore, these biomarkers 
potentially reflect a downstream manifestation on the pathway of plasma leakage. As a 
consequence of plasma leakage, altered serum urea levels and subsequent hemodynamic 
changes like low blood pressure and elevated pulse rate necessitate ICU resuscitation, as 
identified in Chapter 6.  
 
In addition, blood coagulation may be hindered by means of fibrinolysis, where a 
fibrin clot, the product of coagulation, is broken. This process is catalysed by the enzyme 
plasmin, which is regulated by tissue plasminogen activator and urokinase (regulated by 
uPAR) that convert plasminogen to the active plasmin, thus allowing fibrinolysis to occur. 
The fibrinolytic system is also closely linked to control of inflammation, and plays a role 
in disease states associated with inflammation. Plasmin, in addition to lysing fibrin clots, 
also cleaves the complement system component C3, and fibrin degradation products have 
some vascular permeability inducing effects. As such, it is hypothesized that the increased 
uPAR level in the blood may be highly associated with the risk of severe bleeding, by 
increasing fibrinolysis, with decreasing platelet count as dengue infection progresses, and 
at the same time, affects the vascular permeability of the endothelium, resulting in 
increased risk of plasma leakage. Future research to prove this hypothesis would be 









Overall limitations of thesis 
Even though a number of potential risk factors and prognostic models had been 
identified and derived in this thesis, further validation with more well-described 
prospective cohorts would be important prior to their application in the clinical setting. 
There are a few limitations that may limit the generalizability of the findings. There is low 
prevalence of severe dengue of adult patients in Singapore, therefore, the PPV and NPV 
may not be applicable in endemic countries with high prevalence of severe dengue among 
adult patients. However, severe dengue is usually more common among the paediatric as 
compared to adult patients. Furthermore, the prevalence of diabetes may vary in different 
endemic countries, and this is mostly likely to affect the PPV and NPV of the risk scoring 
algorithm. Intensive care unit (ICU) admission reflects a more realistic outcome of dengue 
severity compared to the WHO classification of DHF/DSS/Severe Dengue. However, the 
threshold for ICU admission may vary in different hospitals in different countries, and 
hence, an independent study for risk factors of ICU is highly recommended at different 
hospitals. Furthermore, most of these studies were performed in the hospital setting, and 
so to some extent, there may be bias towards selection of patients who had more active 
healthcare-seeking behaviour, or those who had more severe clinical manifestations. There 
may also potentially be non-differential misclassification bias of outcomes and exposures 
due to recall bias or interviewer bias. However, the extent of this bias should be minimal 
as patients were reviewed based on a standardised dengue care path or standardised review 
method of medical records. Last but not least, these prognostic models would only be 
useful if both the medical community and the public understand the importance of early 
dengue diagnosis, which would require the long-term commitment and support from the 
governments as well as the non-profit organisations to drive awareness on these risk 




 In conclusion, this thesis has explored the risk factors of dengue severity, which 
comprised of DSS, DHF (WHO, 1997), the requirement of closer monitoring in hospital 
(WHO, 2009), and ICU admission. In addition, this thesis has taken up the challenge of 
exploring the risk factors from various aspects of adult dengue disease, looking into the 
epidemiological, genetic, molecular and clinical risk factors. Risk factors and models 
derived from each of these aspects for early triage of adult dengue patients would be 
potentially beneficial at every phase of dengue disease, from pre-clinical to clinical, to 
increase the intervention window of reducing the development of severe disease and 
mortality, and ultimately to reduce public health burden due to dengue. They also have 
important implications for prioritising utilisation of dengue vaccines and therapeutics 
should these become available in the near future. Potential future work would include 
prospective intervention studies of these risk factors and models for application in the 
primary and tertiary setting in endemic countries, as well as further basic science and 
clinical research to elucidate the mechanisms behind the risk factors for dengue severity 
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